
<html lang="en"     class="pb-page"  data-request-id="7882ea46-d189-4c28-9edd-a86c3ac0808a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2012.55.issue-17;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm300810x"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="EC144 Is a Potent Inhibitor of the Heat Shock Protein 90" /></meta><meta name="dc.Creator" content="Jiandong  Shi" /></meta><meta name="dc.Creator" content="Ryan  Van de Water" /></meta><meta name="dc.Creator" content="Kevin  Hong" /></meta><meta name="dc.Creator" content="Ryan B.  Lamer" /></meta><meta name="dc.Creator" content="Kenneth W.  Weichert" /></meta><meta name="dc.Creator" content="Cristina M.  Sandoval" /></meta><meta name="dc.Creator" content="Srinivas R.  Kasibhatla" /></meta><meta name="dc.Creator" content="Marcus F.  Boehm" /></meta><meta name="dc.Creator" content="Jianhua  Chao" /></meta><meta name="dc.Creator" content="Karen  Lundgren" /></meta><meta name="dc.Creator" content="Noelito  Timple" /></meta><meta name="dc.Creator" content="Rachel  Lough" /></meta><meta name="dc.Creator" content="Gerardo  Ibanez" /></meta><meta name="dc.Creator" content="Christina  Boykin" /></meta><meta name="dc.Creator" content="Francis J.  Burrows" /></meta><meta name="dc.Creator" content="Marilyn R.  Kehry" /></meta><meta name="dc.Creator" content="Theodore J.  Yun" /></meta><meta name="dc.Creator" content="Erin K.  Harning" /></meta><meta name="dc.Creator" content="Christine  Ambrose" /></meta><meta name="dc.Creator" content="Jeffrey  Thompson" /></meta><meta name="dc.Creator" content="Sarah A.  Bixler" /></meta><meta name="dc.Creator" content="Anthone  Dunah" /></meta><meta name="dc.Creator" content="Pamela  Snodgrass-Belt" /></meta><meta name="dc.Creator" content="Joseph  Arndt" /></meta><meta name="dc.Creator" content="Istvan J.  Enyedy" /></meta><meta name="dc.Creator" content="Ping  Li" /></meta><meta name="dc.Creator" content="Victor S.  Hong" /></meta><meta name="dc.Creator" content="Andres  McKenzie" /></meta><meta name="dc.Creator" content="Marco A.  Biamonte" /></meta><meta name="dc.Description" content="Alkyne 40, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol (EC144), is a second generation inhibitor of heat shock protein..." /></meta><meta name="Description" content="Alkyne 40, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol (EC144), is a second generation inhibitor of heat shock protein..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 31, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm300810x" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm300810x" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm300810x" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm300810x" /></link>
        
    
    

<title>EC144 Is a Potent Inhibitor of the Heat Shock Protein 90 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm300810x" /></meta><meta property="og:title" content="EC144 Is a Potent Inhibitor of the Heat Shock Protein 90" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0014.jpeg" /></meta><meta property="og:description" content="Alkyne 40, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol (EC144), is a second generation inhibitor of heat shock protein 90 (Hsp90) and is substantially more potent in vitro and in vivo than the first generation inhibitor 14 (BIIB021) that completed phase II clinical trials. Alkyne 40 is more potent than 14 in an Hsp90α binding assay (IC50 = 1.1 vs 5.1 nM) as well as in its ability to degrade Her-2 in MCF-7 cells (EC50 = 14 vs 38 nM). In a mouse model of gastric tumors (N87), 40 stops tumor growth at 5 mg/kg and causes partial tumor regressions at 10 mg/kg (po, qd×5). Under the same conditions, 14 stops tumor growth only at 120 mg/kg, and does not induce partial regressions. Thus, alkyne 40 is approximately 20-fold more efficacious than 14 in mice." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm300810x"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm300810x">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm300810x&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm300810x&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm300810x&amp;href=/doi/10.1021/jm300810x" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 7786-7795</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm3008008" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm300846z" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">EC144 Is a Potent Inhibitor of the Heat Shock Protein 90</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiandong++Shi">Jiandong Shi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ryan++Van+de+Water">Ryan Van de Water</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Hong">Kevin Hong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ryan+B.++Lamer">Ryan B. Lamer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth+W.++Weichert">Kenneth W. Weichert</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cristina+M.++Sandoval">Cristina M. Sandoval</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Srinivas+R.++Kasibhatla">Srinivas R. Kasibhatla</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marcus+F.++Boehm">Marcus F. Boehm</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jianhua++Chao">Jianhua Chao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Lundgren">Karen Lundgren</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Noelito++Timple">Noelito Timple</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rachel++Lough">Rachel Lough</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gerardo++Ibanez">Gerardo Ibanez</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christina++Boykin">Christina Boykin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Francis+J.++Burrows">Francis J. Burrows</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marilyn+R.++Kehry">Marilyn R. Kehry</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Theodore+J.++Yun">Theodore J. Yun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Erin+K.++Harning">Erin K. Harning</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christine++Ambrose">Christine Ambrose</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Thompson">Jeffrey Thompson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+A.++Bixler">Sarah A. Bixler</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthone++Dunah">Anthone Dunah</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pamela++Snodgrass-Belt">Pamela Snodgrass-Belt</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph++Arndt">Joseph Arndt</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Istvan+J.++Enyedy">Istvan J. Enyedy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ping++Li">Ping Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Victor+S.++Hong">Victor S. Hong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andres++McKenzie">Andres McKenzie</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marco+A.++Biamonte">Marco A. Biamonte</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Biogen Idec, 5200 Research Place, San Diego, California 92122, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Biogen Idec, 14 Cambridge Center, Cambridge, Massachusetts 02142, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: (858) 999-2360. E-mail: <a href="/cdn-cgi/l/email-protection#1875796a7b77367a71797577766c7d587c7c6c7c36776a7f"><span class="__cf_email__" data-cfemail="4924283b2a26672b20282426273d2c092d2d3d2d67263b2e">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm300810x&amp;href=/doi/10.1021%2Fjm300810x" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 7786–7795</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 31, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 June 2012</li><li><span class="item_label"><b>Published</b> online</span>31 August 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 September 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm300810x" title="DOI URL">https://doi.org/10.1021/jm300810x</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7786%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJiandong%2BShi%252C%2BRyan%2BVan%2Bde%2BWater%252C%2BKevin%2BHong%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D17%26contentID%3Djm300810x%26title%3DEC144%2BIs%2Ba%2BPotent%2BInhibitor%2Bof%2Bthe%2BHeat%2BShock%2BProtein%2B90%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7795%26publicationDate%3DSeptember%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm300810x"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2784</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">38</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm300810x" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;EC144 Is a Potent Inhibitor of the Heat Shock Protein 90&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jiandong&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;Van de Water&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Hong&quot;},{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;B. Lamer&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;W. Weichert&quot;},{&quot;first_name&quot;:&quot;Cristina&quot;,&quot;last_name&quot;:&quot;M. Sandoval&quot;},{&quot;first_name&quot;:&quot;Srinivas&quot;,&quot;last_name&quot;:&quot;R. Kasibhatla&quot;},{&quot;first_name&quot;:&quot;Marcus&quot;,&quot;last_name&quot;:&quot;F. Boehm&quot;},{&quot;first_name&quot;:&quot;Jianhua&quot;,&quot;last_name&quot;:&quot;Chao&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Lundgren&quot;},{&quot;first_name&quot;:&quot;Noelito&quot;,&quot;last_name&quot;:&quot;Timple&quot;},{&quot;first_name&quot;:&quot;Rachel&quot;,&quot;last_name&quot;:&quot;Lough&quot;},{&quot;first_name&quot;:&quot;Gerardo&quot;,&quot;last_name&quot;:&quot;Ibanez&quot;},{&quot;first_name&quot;:&quot;Christina&quot;,&quot;last_name&quot;:&quot;Boykin&quot;},{&quot;first_name&quot;:&quot;Francis&quot;,&quot;last_name&quot;:&quot;J. Burrows&quot;},{&quot;first_name&quot;:&quot;Marilyn&quot;,&quot;last_name&quot;:&quot;R. Kehry&quot;},{&quot;first_name&quot;:&quot;Theodore&quot;,&quot;last_name&quot;:&quot;J. Yun&quot;},{&quot;first_name&quot;:&quot;Erin&quot;,&quot;last_name&quot;:&quot;K. Harning&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;Ambrose&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Thompson&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;A. Bixler&quot;},{&quot;first_name&quot;:&quot;Anthone&quot;,&quot;last_name&quot;:&quot;Dunah&quot;},{&quot;first_name&quot;:&quot;Pamela&quot;,&quot;last_name&quot;:&quot;Snodgrass-Belt&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;Arndt&quot;},{&quot;first_name&quot;:&quot;Istvan&quot;,&quot;last_name&quot;:&quot;J. Enyedy&quot;},{&quot;first_name&quot;:&quot;Ping&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Victor&quot;,&quot;last_name&quot;:&quot;S. Hong&quot;},{&quot;first_name&quot;:&quot;Andres&quot;,&quot;last_name&quot;:&quot;McKenzie&quot;},{&quot;first_name&quot;:&quot;Marco&quot;,&quot;last_name&quot;:&quot;A. Biamonte&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;31&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;7786-7795&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm300810x&quot;},&quot;abstract&quot;:&quot;Alkyne 40, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol (EC144), is a second generation inhibitor of heat shock protein 90 (Hsp90) and is substantially more potent in vitro and in vivo than the first generation inhibitor 14 (BIIB021) that completed phase II clinical trials. Alkyne 40 is more potent than 14 in an Hsp90α binding assay (IC50 = 1.1 vs 5.1 nM) as well as in its ability to degrade Her-2 in MCF-7 cells (EC50 = 14 vs 38 nM). In a mouse model of gastric tumors (N87), 40 stops tumor growth at 5 mg/kg and causes partial tumor regressions at 10 mg/kg (po, qd×5). Under the same conditions, 14 stops tumor growth only at 120 mg/kg, and does not induce partial regressions. Thus, alkyne 40 is approximately 20-fold more efficacious than 14 in mice.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300810x&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300810x" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300810x&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300810x" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300810x&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300810x" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm300810x&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300810x&amp;href=/doi/10.1021/jm300810x" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm300810x" /></input><a href="/doi/pdf/10.1021/jm300810x" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm300810x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm300810x%26sid%3Dliteratum%253Aachs%26pmid%3D22938030%26genre%3Darticle%26aulast%3DShi%26date%3D2012%26atitle%3DEC144%2BIs%2Ba%2BPotent%2BInhibitor%2Bof%2Bthe%2BHeat%2BShock%2BProtein%2B90%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D17%26spage%3D7786%26epage%3D7795%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291650" title="Alcohols">Alcohols</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jmcmar.2012.55.issue-17/production/jmcmar.2012.55.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Alkyne <b>40</b>, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol (EC144), is a second generation inhibitor of heat shock protein 90 (Hsp90) and is substantially more potent in vitro and in vivo than the first generation inhibitor <b>14</b> (BIIB021) that completed phase II clinical trials. Alkyne <b>40</b> is more potent than <b>14</b> in an Hsp90α binding assay (IC<sub>50</sub> = 1.1 vs 5.1 nM) as well as in its ability to degrade Her-2 in MCF-7 cells (EC<sub>50</sub> = 14 vs 38 nM). In a mouse model of gastric tumors (N87), <b>40</b> stops tumor growth at 5 mg/kg and causes partial tumor regressions at 10 mg/kg (po, qd×5). Under the same conditions, <b>14</b> stops tumor growth only at 120 mg/kg, and does not induce partial regressions. Thus, alkyne <b>40</b> is approximately 20-fold more efficacious than <b>14</b> in mice.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76645" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76645" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The rationale for selecting heat shock protein 90 (Hsp90) as a cancer target has been extensively reviewed.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In essence, Hsp90 regulates the folding of nascent and mature proteins, collectively dubbed “client proteins”. Among the over 200 reported Hsp90 client proteins,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> one finds a large proportion of proteins implicated in cell-growth, including well-known oncogenes (Raf-1, Akt, cdk4, Src, Flt-3, hTert, c-Met, etc.) and five proteins targeted by approved cancer drugs: Her-2/neu (trastuzumab), Bcr-Abl (imatinib), the estrogen receptor (tamoxifen), the androgen receptor (bicalutamide), and VEGF, the vascular endothelial growth factor receptor (sunitinib). Inhibition of Hsp90 causes client proteins to adopt aberrant conformations, and these abnormally folded proteins are eliminated via ubiquitination and proteasome degradation. The net result is that Hsp90 inhibitors induce the concomitant degradation of a number of oncogenes and therefore intervene simultaneously on different pathways of cancer progression.</div><div class="NLM_p">In 1998–1999, the first clinical trials with an Hsp90 inhibitor were initiated on the natural product derivative 17-allylamino-17-desmethoxygeldanamycin <b>1</b> (17-AAG, tanespimycin, Cancer Research UK, NCI, Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). 17-AAG was administered intravenously and progressed to phase III studies (Kosan-Bristol Myers Squibb).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Although 17-AAG was poorly water-soluble and difficult to formulate, its hydroquinone version <b>2</b> (IPI-504, retaspimycin, Infinity) could be converted to a water-soluble hydrochloride salt which also advanced to phase III studies.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The derivative 17-desmethoxy-17-<i>N</i>,<i>N</i>-dimethylaminoethylaminogeldanamycin <b>3</b> (17-DMAG, alvespimycin, NCI, Kosan-Bristol Myers Squibb) was also designed to improve the solubility but proved to be more toxic in preclinical species.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The major metabolite of 17-AAG, 17-amino-17-desmethoxygeldanamycin <b>4</b> (17-AG, IPI-493, Infinity), displayed greatly improved oral bioavailability and was advanced as an oral formulation, thus obviating the need for solubility imposed by the intravenous route of administration.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In parallel, 12 fully synthetic small molecules were developed (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>), as either intravenous or oral compounds. The intravenous drugs are <b>5</b> (NVP-AUY922, Novartis, phase II),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a><b>6</b> (AT-13387, Astex, phase II),<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a><b>7</b> (ganetispib, STA-9090, Synta, phase II),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a><b>8</b> (KW-2478, Kyowa Hakko Kirin, phase I/II),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a><b>9</b> (XL-888, Exelixis, phase I),<a onclick="showRef(event, 'cit1a'); return false;" href="javascript:void(0);" class="ref cit1a">(1a)</a><b>10</b> (PU-H71, Memorial Sloan-Kettering Cancer Center, phase I),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and BIIB028 (Biogen Idec, phase I, structure not public). The oral drugs are <b>11</b> (DEBIO-0932/CUDC305, Debiopharm, phase I),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a><b>12</b> (MPC-3100, Myrexis, phase I),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a><b>13a</b> (PF-4929113/SNX-5422, Pfizer, phase I), which is a glycine prodrug of <b>13b</b>,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a><b>14</b> (BIIB021, Biogen Idec, phase II),<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and <b>15</b> (NVP-HSP990, Novartis, phase I).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Hsp90 Inhibitors in Clinical Trials</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As of this writing, the major challenge in the Hsp90 arena is to identify which human cancers best respond to an Hsp90 inhibitor and with which drug combination. Breast cancer is the most studied indication for Hsp90 inhibitors. The rationale is simple: some breast cancers are Her-2 driven, and Her-2 is degraded particularly rapidly upon exposure to Hsp90 inhibitors. Furthermore, Her-2 is the molecular target of the breast cancer drug trastuzumab. In a notable phase II trial, patients with Her-2 positive metastatic breast cancer that were progressing on trastuzumab responded to the combination of 17-AAG and trastuzumab, with a 22% overall response rate.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> This was the first phase II study in which 17-AAG definitely showed responses in solid tumors, as defined by the response evaluation criteria in solid tumors (RECIST). In addition to breast cancer, non-small-cell lung cancer (NSCLC) and multiple myeloma (MM) also appear to be of high interest. In phase II studies in NSCLC patients, retaspimycin and resorcinol <b>7</b> controlled the disease in a subset of patients harboring a mutated/rearranged anaplastic lymphoma kinase (ALK).<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> This is consistent with the fact that ALK is the only Hsp90 client showing equivalent or greater sensitivity than Her-2 to Hsp90 inhibitors.<a onclick="showRef(event, 'cit1a'); return false;" href="javascript:void(0);" class="ref cit1a">(1a)</a> ALK + NSCLC can be treated with the approved ALK inhibitor crizotinib, but resistance appears within 1 year. In vitro, the combination of crizotinib with an Hsp90 inhibitor overcomes the crizotinib resistance.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In a phase I/II study in a MM population, the combination of 17-AAG and bortezomib gave an objective response rate of 27% and was also active in patients that were refractory to bortezomib.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Interestingly, at the preclinical level there is evidence that even low doses of Hsp90 inhibitors can be strongly synergistic with radiation therapy in head and neck squamous cell carcinoma.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> All Hsp90 inhibitors cause fatigue and diarrhea as side effects, and some but not all also produce ocular toxicities, which led to the discontinuation of benzamide <b>13a</b>.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a></div><div class="NLM_p last">In 2005, we selected purine <b>14</b> as clinical candidate because it was the first orally bioavailable Hsp90 inhibitor that consistently demonstrated efficacy in mouse tumor models.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The fact that it could be synthesized in a single step was an additional advantage.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> There was a limitation, however, in that high doses (60–120 mg kg<sup>–1</sup> day<sup>–1</sup>) were required for efficacy in mouse. In human, even though the doses of <b>14</b> may be lower, treating patients still requires 100 mg twice daily or 450 mg thrice weekly, as proposed in a phase II study conducted in combination with exemestane (Aromasin, 25 mg daily) for hormone receptor positive metastatic breast cancer (HR + mBC). While running clinical trials with <b>14</b>, we sought a second generation oral Hsp90 inhibitor that would be more efficacious than <b>14</b> to allow for lower daily or weekly dosing. We now report the chemistry that led to a series of deazapurine analogues, some of which showed efficacy in mouse tumor models at 5 mg/kg and represent an improvement of over 1 logarithm over the first generation inhibitors.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2 Assays</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78684" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78684" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">HSP90 exists as two isoforms: HSP90α is an inducible form overexpressed in cancer cells, while HSP90β is the constitutive form. Both HSP90α and HSP90β are found in the cytoplasm. There are also two paralogues: Grp94, localized in the endoplasmic reticulum lumen, and TRAP1, confined to mitochondria. The binding assays were performed on HSP90α as described previously.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">The effect of HSP90 inhibitors on breast cancer MCF-7 cells was evaluated by measuring the degradation of the HSP90 client Her-2. Her-2, being a cell-surface receptor, can be conveniently monitored with extracellular-directed fluorescent antibodies and flow cytometry.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p last">For in vivo work, and unless otherwise noted, <b>40</b> was suspended in an aqueous solution containing 0.5 wt % carboxymethylcellulose (CMC) and 0.1 wt % Tween 80. The suspension was sonicated for 30 min at room temperature and homogenized for 30 s using a homogenizer set at 4000 rpm. Alternatively, <b>40</b> was dissolved in 0.1 N HCl, and the two formulations gave comparable results. Pharmacokinetic parameters were determined by analyzing extracted plasma and tissue samples by LC/MS/MS and by using noncompartmental methods with WinNonlin, version 5 (Pharsight).</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3 Design and Synthesis of the Pyrrolo[2,3-<i>d</i>]pyrimidine Scaffold</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22011" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22011" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The optimization of <b>14</b> was challenging, as all attempts to modify the substituents Ra–Rf (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>) typically led to a drastic decrease in potency. Similarly, replacement of X or Y by a carbon atom also led to a loss in potency. We therefore hypothesized that each of these positions was in close contact with the protein. Yet it seemed logical to expect that at least one part of the molecule would face the solvent and that modifications of the solvent-exposed area of the molecule would be the most tolerable. We felt that the solvent-exposed area may be used to our advantage to improve the drug properties and to possibly gain potency by making new interactions at the rim of the binding pocket. Since the substituents Ra–Rf, as well as the atoms X and Y, were clearly failing at reaching the solvent-exposed area, we deduced that the solvent-exposed area must have been pointing in another direction. By elimination, we surmised that the solvent was facing the direction of the N7 lone pair, and this initial hypothesis was later validated by an X-ray structure (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Modifications of <b>16</b> in positions Ra–Rf led to a decrease in potency, suggesting that the solvent exposed area of the molecule was pointing in the same direction as the N7 lone pair of purine <b>14</b>.</p></p></figure><figure id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. The X-ray structure of <b>14</b> in complex with Hsp90 shows that N7 faces a solvent exposed area (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QDD">3QDD</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to substitute the molecule along the desired vector, it was necessary to replace N7 with a carbon atom. To this effect, we prepared pyrrolo[2,3-<i>d</i>]pyrimidines (=deazapurines) based on scaffold <b>17</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>) where the iodo group would enable a range of cross-couplings. The synthesis started with 2,6-diaminopyrimidin-4-ol <b>18</b> (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). The next four steps relied on existing procedures<a onclick="showRef(event, 'ref26 ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28 ref29 ref30">(26-30)</a> that were modified to increase the yield of <b>23</b> and to obviate the need for chromatographic purifications. Thus, treatment of <b>18</b> with aqueous chloroacetaldehyde provided the pyrrolo[2,3-<i>d</i>]pyrimidine <b>19</b> (42%). By performing this cyclization in the presence of <i>N</i>,<i>N</i>-dimethylacetamide (DMA) as opposed to DMF,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> the desired product precipitated out as a 1:1 DMA complex, which facilitated its production on kilogram scale. The DMA was then easily removed by recrystallization from MeOH (95%). Protection of the amino group with PivCl gave amide <b>21</b> (93%).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Deoxychlorination<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> was best achieved with a POCl<sub>3</sub>/BnNEt<sub>3</sub>Cl system to give <b>22</b> (70%), and a subsequent iodination with <i>N</i>-iodosuccinimide (NIS)<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a> yielded <b>23</b> regioselectively (81%). It is noteworthy that the pivaloyl group was necessary for both the deoxychlorination and the iodination to proceed smoothly. Attempts at replacing the pivaloyl group with an acetyl or octanoyl group resulted in a complex mixture of products upon sequential treatment with POCl<sub>3</sub> and NIS. However, cleaving the pivaloyl group proved to be a difficult operation. After extensive experimentation, we found that the pivaloyl group could be efficiently removed if <b>23</b> was first alkylated with the commercially available chloromethylpyridine <b>24</b> (80%) and then treated with ZnCl<sub>2</sub> in refluxing EtOH, thus yielding the key intermediate <b>27</b> (85%). Interestingly, this deprotection procedure was successful only if <b>23</b> was alkylated with <b>24</b> prior to treatment with ZnCl<sub>2</sub>. Alkylation of <b>23</b> with the isomeric chloromethylpyridine <b>28</b> gave substrate <b>29</b>, which failed to undergo the ZnCl<sub>2</sub>-mediated deprotection. Similarly, alkylation of <b>23</b> with benzyl bromide gave substrate <b>31</b> that was equally unreactive toward ZnCl<sub>2</sub>. To rationalize these results, we suggest that the pyridine nitrogen of <b>25</b> is actively involved in the transition state, possibly by offering an additional coordination site for the Zn atom as shown in the putative intermediate <b>26</b>. The entire sequence <b>18</b> → <b>27</b> could be performed without any chromatographic purification on kilogram scale.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preferred Synthesis of Pyrrolo[2,3-<i>d</i>]pyrimidine <b>27</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an alternative route (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>), pyrrolo[2,3-<i>d</i>]pyrimidine <b>33</b> was temporarily silylated with <i>N</i>,<i>O</i>-bis(trimethylsilyl)acetamide (BSA), reacted with NIS, and desilylated with water to give iodide <b>34</b> in a single pot.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Iodide <b>34</b> was poorly soluble in organic solvents, which precluded further purification. Iodide <b>34</b> could nonetheless be alkylated to give <b>27</b>. For SAR purposes, compound <b>33</b> was also directly alkylated to give pyrrolopyrimdine <b>35</b>, devoid of any substituent at C5.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Alternative Synthesis to Pyrrolo[2,3-<i>d</i>]pyrimidine <b>27</b> and Synthesis of <b>35</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">4 Optimization of Potency</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43278" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43278" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Having devised two efficient syntheses of iodide <b>27</b>, we submitted it to Pd cross-couplings (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>). A Suzuki coupling with PhB(OH)<sub>2</sub> gave the 5-phenyl adduct <b>36</b>, while Sonogashira couplings with TMS acetylene, propargylic alcohol, homopropargylic alcohol, or with 2-methylpent-4-yn-2-ol<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> gave derivatives <b>37</b>–<b>40</b>. Hydrogenation of propargylic alcohol <b>38</b> with Raney nickel gave propanol <b>41</b>. The reactions leading to <b>37</b>–<b>41</b> were not optimized. All compounds were prepared in greater than 95% purity as determined by analytical HPLC at 254 nm.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0013.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) PhB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 2 M K<sub>2</sub>CO<sub>3</sub>, 80 °C (20%); (b) HC≡C–SiMe<sub>3</sub>, Et<sub>3</sub>N, CuI, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 50 °C (25–50%), then TBAF, THF, rt (25%); (c) alkyne, Et<sub>3</sub>N, CuI, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 50 °C (25–50%), or alkyne, Et<sub>3</sub>N, CuI, 10% Pd/C, PPh<sub>3</sub>, H<sub>2</sub>O, DMA or DMSO, 75 °C (40–75%); (d) Raney Ni, H<sub>2</sub> (4.5 atm), MeOH, rt (32%).</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Hsp90 Inhibitors: Binding to Hsp90α and Effect on the Degradation of Her-2 in MCF-7 Cells</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">inhibitor</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">binding Hsp90α IC<sub>50</sub> [nM]</th><th class="colsep0 rowsep0" align="center">Her-2 EC<sub>50</sub> [nM]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">17-AAG</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">12 ± 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b> (resorcinol)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><0.4</td><td class="colsep0 rowsep0" align="left">7 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13b</b> (benzamide)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">19 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b> (purine)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5.1 ± 2.0</td><td class="colsep0 rowsep0" align="left">38 ± 13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">98 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">6.0 ± 2.8</td><td class="colsep0 rowsep0" align="left">250 ± 14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">C≡CH</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.6</td><td class="colsep0 rowsep0" align="left">26 (<i>n</i> = 1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">C≡C–CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">0.7 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">15 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">C≡C–(CH<sub>2</sub>)<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">2.0 ± 1.3</td><td class="colsep0 rowsep0" align="left">9 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">C≡C–CH<sub>2</sub>–CMe<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">1.1 ± 0.5</td><td class="colsep0 rowsep0" align="left">14 ± 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>– CH<sub>2</sub>–CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">3.9 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">32 ± 5</td></tr></tbody></table></div></div><div class="NLM_p">In a biochemical assay, compounds <b>35</b>–<b>41</b> all bound to Hsp90α with IC<sub>50</sub> < 10 nM (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Next, their ability to induce the degradation of Her-2 in MCF-7 breast cancer cells was examined (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The first-generation clinical candidate <b>14</b> degraded Her-2 with EC<sub>50</sub> = 38 nM. In the same assay, the unsubstituted pyrrolo[2,3-<i>d</i>]pyrimidine <b>35</b> (EC<sub>50</sub> = 100 nM) was almost as active as <b>14</b>. More importantly, substituents at the C5 position were tolerated. Compared to <b>35</b>, a phenyl substituent (<b>36</b>, 250 nM) only led to a 2.5-fold decrease in potency, while a terminal alkyne group (<b>37</b>, 26 nM) improved the potency 4-fold. The propargyl alcohol <b>38</b> (15 nM) and the homopropargylic alcohols <b>39</b> (9 nM) and <b>40</b> (EC144, 14 nM) were the most potent compounds and were approximately 3-fold more potent in vitro than the first-generation clinical candidate <b>14</b>. Reduction of the propargylic alcohol <b>38</b> to the propanol <b>41</b> (32 nM) was tolerated.</div><div class="NLM_p">Thus, compounds <b>38</b>–<b>40</b> were the most potent ones in vitro. This article focuses on compound <b>40</b>, since it later proved to have the best combination of pharmacokinetic properties and efficacy in murine cancer models.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">A crystal structure of <b>40</b> in complex with Hsp90 revealed a favorable hydrophobic interaction between the C≡C fragment of the inhibitor and the adjacent side chains of Met-98 and Leu-107 (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> There were no other obvious additional interactions. The distance between the OH group and the Lys-58 amino group was too large (4.3 Å) for a hydrogen bond, although the solution structure may differ from the crystal structure, possibly granting the side chain of Lys-58 enough flexibility to form a hydrogen bond in solution.</div><figure id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray structure of alcohol <b>40</b> in complex with Hsp90α (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3NMQ">3NMQ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">5 Selectivity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64418" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64418" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The tertiary alcohol <b>40</b> binds to Hsp90α with <i>K</i><sub>i</sub> = 0.2 nM and is selective against the Hsp90 paralogues TRAP1 (<i>K</i><sub>i</sub> = 255 nM) and Grp94 (<i>K</i><sub>i</sub> = 61 nM).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Alcohol <b>40</b> has no inhibitory activity (IC<sub>50</sub> > 10 μM) against a panel of 285 human kinases.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> When incubated with N87 (gastric) or BT474 (breast) tumor cell lines, <b>40</b> displays the characteristic signature of Hsp90 inhibitors: degradation of the client proteins (Her-2, EGFR, IGFR, ERK, Akt, Rb, cyclin D, cdk6), up-regulation of Hsp70, and no effect on p85 PI3K, which is not a Hsp90 client (data not shown for cell cultures, see <a class="ref internalNav" href="#sec7" aria-label="section 7">section 7</a> for in vivo data).</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">6 In Vitro ADMET and in Vivo PK</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17411" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17411" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Alcohol <b>40</b> satisfies the “rule of five” by virtue of its two hydrogen-bond donors, four hydrogen bond acceptors, a molecular weight of 414, and a cLogP of 2.8. Alcohol <b>40</b> is highly permeable in CACO-2 cells (34.7 × 10<sup>–6</sup> cm/s, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) and is not actively effluxed (efflux ratio (B → A)/(A → B) = 1.1). The lack of efflux is similar to what was observed with the first-generation purine <b>14</b> (efflux ratio = 1.5) and contrasts with the behavior of resorcinol <b>5</b> (efflux ratio = 15) and benzamide <b>13b</b> (efflux ratio = 35). Alcohol <b>40</b> is 94–97% protein bound depending on the species and in this respect is similar to resorcinol <b>5</b> (94–96%) and benzamide <b>13b</b> (90–94%). Alcohol <b>40</b> is metabolized by microsomes at medium–high rates; the intrinsic hepatic clearance is 119 mL min<sup>–1</sup> kg<sup>–1</sup> in human microsomes, which is higher than for resorcinol <b>5</b> (39 mL min<sup>–1</sup> kg<sup>–1</sup>) and benzamide <b>13b</b> (54 mL min<sup>–1</sup> kg<sup>–1</sup>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro ADME Parameters of Selected Hsp90 Inhibitors<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">CACO-2 permeability [×10<sup>–6</sup> cm/s]</th><th class="rowsep1 colsep0" colspan="3" align="center">protein binding, fraction unbound [%]</th><th class="rowsep1 colsep0" colspan="3" align="center">microsomal intrinsic hepatic clearance [mL min<sup>–1</sup> kg<sup>–1</sup>]</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><i>P</i><sub>app</sub>(A → B)</th><th class="colsep0 rowsep0" align="center">ratio (B → A)/(A → B)</th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b> (resorcinol)</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="left">443</td><td class="colsep0 rowsep0" align="left">219</td><td class="colsep0 rowsep0" align="left">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13b</b> (benzamide)</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">6.0</td><td class="colsep0 rowsep0" align="left">9.6</td><td class="colsep0 rowsep0" align="left">6.8</td><td class="colsep0 rowsep0" align="left">301</td><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="left">54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b> (purine)</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11.4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">34.7</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">5.8</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">727</td><td class="colsep0 rowsep0" align="left">276</td><td class="colsep0 rowsep0" align="left">119</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>a</sup><p class="last">Errors on the protein binding are in the ±0.2–0.9 range.</p></div></div></div><div class="NLM_p">In mice, the maximum tolerated dose (MTD) of alkyne <b>40</b> for a <i>single</i> oral administration is 30 mg/kg. Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> reports the mouse pharmacokinetic data for a single oral dose of <b>40</b>, compared with the data for other known Hsp90 inhibitors. At 25 mg/kg, the plasma exposure of <b>40</b> is 4419 ng·h/mL. In contrast, the first-generation inhibitor <b>14</b> required a dose of 100 mg/kg to give a comparable exposure. This may be more evident by looking at the AUC/dose ratio which, if expressed in (ng·h/mL)/(mg/kg), gives 48 for purine <b>14</b> and 177 for alcohol <b>40</b>. Alcohol <b>40</b> is cleared with a <i>T</i><sub>1/2</sub> of 1.5 h, which is somewhat longer than for purine <b>14</b> (0.8 h) but shorter than for benzamide <b>13</b> (2.9 h) and resorcinol <b>5</b> (6.6 h).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Pharmacokinetic Data for Selected Hsp90 Inhibitors in CD-1 Mouse after a Single Oral or Intravenous Administration<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">ROA</th><th class="colsep0 rowsep0" align="center">dose [mg/kg]</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max,Co</sub>[ng/mL]</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> [h]</th><th class="colsep0 rowsep0" align="center">AUC [ng·h/mL]</th><th class="colsep0 rowsep0" align="center">AUC/dose[(ng·h/mL)/(mg/kg)]</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> [h]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b> (resorcinol)</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">2180</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2409</td><td class="colsep0 rowsep0" align="left">481</td><td class="colsep0 rowsep0" align="left">6.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b> (benzamide)</td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">1724</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">8517</td><td class="colsep0 rowsep0" align="left">341</td><td class="colsep0 rowsep0" align="left">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b> (purine)</td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">10000</td><td class="colsep0 rowsep0" align="left">0.083</td><td class="colsep0 rowsep0" align="left">4800</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">1556</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">4419</td><td class="colsep0 rowsep0" align="left">177</td><td class="colsep0 rowsep0" align="left">1.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>a</sup><p class="last">Benzamide <b>13</b> was administered as its prodrug <b>13a</b>, and the PK parameters refer to its active metabolite <b>13b</b>.</p></div></div></div><div class="NLM_p">A tissue-distribution study (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>) indicates that <b>40</b> distributes well to the brain, spleen, and lymph nodes. Alcohol <b>40</b> crosses the blood-brain barrier (brain/plasma = 2.2), which is consistent with the fact that it is not an efflux substrate.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Data for <b>40</b> in DBA1 Mouse after a Single po Administration of 5 mg/kg</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">tissue</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub>[ng/mL]</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> [h]</th><th class="colsep0 rowsep0" align="center">AUC<sub>inf</sub>[ng·h/mL]</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> [h]</th><th class="colsep0 rowsep0" align="center">tissue/plasma (AUC ratio)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="left">835</td><td class="colsep0 rowsep0" align="left">0.083</td><td class="colsep0 rowsep0" align="left">2118</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">brain</td><td class="colsep0 rowsep0" align="left">1446</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">4713</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lymph nodes</td><td class="colsep0 rowsep0" align="left">2144</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">5186</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">spleen</td><td class="colsep0 rowsep0" align="left">1887</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">8159</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">3.9</td></tr></tbody></table></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">7 Applications to Oncology</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86025" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86025" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hsp90 inhibitors have been reported to be retained in tumors. Alkyne <b>40</b> was administered in a single dose of 6 or 12 mg/kg to mice bearing xenografts of N87 gastric tumors (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Tumors were collected 1, 6, and 24 h after dosing and analyzed. At the 6 and 24 h time-points, the concentration of alkyne <b>40</b> was highest in the tumors and decreased in the order tumors > spleen > brain > serum, indicating that tumors retain alkyne <b>40</b> better than other tissues as time progresses (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Retention of alkyne <b>40</b> in tumors. Mice bearing N87 xenografts were administered a single dose of 6 or 12 mg/kg alkyne <b>40</b>. The concentration of alkyne <b>40</b> was measured in the serum, tumors, brain, and spleen at 1, 6, and 24 h postdose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The pharmacodynamic profile of alkyne <b>40</b> was evaluated by treating mice bearing breast-cancer BT474 tumors with a single oral dose of 4 or 8 mg/kg (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Alkyne <b>40</b> induces the typical signature of Hsp90 inhibitors: degradation of the Hsp90 clients Her-2, pHer-2, pAKT, pRAf, pERK, cdk6, pRb, up-regulation of Hsp70 and Hsp27, and no effect on PI3K, which is not an Hsp90 client. Of note, the pharmacodynamic effect of <b>40</b> is long lasting. Since cells require 24–48 h to resynthesize the client proteins, even a relatively brief exposure to <b>40</b> (plasma <i>T</i><sub>1/2</sub> = 1.2 h) results in a protracted pharmacodynamic response that lasts >24 h. A similar effect was reported for purine <b>14</b> and has been colloquially called a “hit-and-run effect”.<a onclick="showRef(event, 'cit1c'); return false;" href="javascript:void(0);" class="ref cit1c">(1c)</a> In addition, as mentioned above, <b>40</b> is retained in tumors for longer than in the plasma.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmacodynamic effect of alkyne <b>40</b>. Mice bearing BT474 xenografts were treated with a single oral dose of 4 or 8 mg/kg alkyne <b>40</b>. Tumors were collected for Western blot analysis at 6, 24, and 48 h postdose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a N87 gastric tumor xenograft model, <b>40</b> caused tumor stasis when dosed 5 days per week at 5 mg/kg and induced partial tumor regressions at 10 mg/kg (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). This is a significant increase in potency when compared to <b>14</b>, which was not quite as effective, even at 120 mg/kg, and which did not cause partial regressions. The increase in potency of <b>40</b> was accompanied by a commensurate increase in toxicity, and the MTD of <b>40</b> on a 5 days per week schedule was 10 mg kg<sup>–1</sup> day<sup>–1</sup>. Above the MTD, weight loss and diarrhea were observed, as is typical of all Hsp90 inhibitors. The fact that the toxicity increases proportionally with the efficacy was seen with every Hsp90 inhibitor we tested, irrespective of its chemical class, suggesting that the toxicity is consistently mediated by Hsp90 (on-target).</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibition of tumor growth in the N87 gastric tumor model. Athymic mice bearing established N87 gastric tumor xenografts were treated with vehicle control, purine <b>14</b>, or alcohol <b>40</b> orally qd×5 for 4 weeks.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Tumors were measured using Vernier calipers on the indicated days, and tumor volumes are reported as mean volume ± SEM tumor for groups of eight mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Alcohol <b>40</b> was also tested in a PGP overexpressing adrenocortical carcinoma model (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) and was active at 8 mg/kg. Purine <b>14</b> was less potent but still inhibited tumor growth at 120 mg/kg. In contrast, 17-AAG, which is a known PGP substrate,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> did not slow tumor progression at its MTD (60 mg/kg, iv). Thus, this PGP-overexpressing tumor responded much better to <b>40</b> than to the PGP substrate 17-AAG.</div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Inhibition of tumor growth in the PGP overexpressing NCI295 adrenal carcinoma. Athymic mice bearing established NCI295 carcinoma were treated with vehicle control, purine <b>14</b> (120 mg/kg, po), alcohol <b>40</b> (8 mg/kg, po), or 17-AAG (60 mg/kg, ip), qd×5 for 4 weeks. Tumors were measured using Vernier calipers on the indicated days, and tumor volumes are reported as the mean volume ± SEM tumor for groups of seven mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">8 Applications to Immunology</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76683" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76683" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The applications of <b>40</b> to inflammatory and autoimmune conditions are reported in a separate publication, where alcohol <b>40</b> is shown to block inflammatory and immune processes in vitro and in vivo.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Alcohol <b>40</b> inhibited TNF-α release by LPS administration in an LPS shock model. Furthermore, <b>40</b> also suppressed disease development in T cell driven rodent collagen-induced arthritis models.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">9 Applications to Neurology</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25816" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25816" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inhibition of Hsp90 has been shown to lead to the degradation of aberrant forms of p-tau,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> which aggregate to form neurofibrillary tangles. Such tangles are a hallmark of Alzheimer’s disease (AD).<a onclick="showRef(event, 'ref38 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40 ref41">(38-41)</a> Since <b>40</b> distributes well across the BBB (brain/plasma ratio of 2.2), we examined if <b>40</b> could reach pharmacologically relevant concentrations in the brain by monitoring the up-regulation of brain Hsp70. Up-regulation of Hsp70 is the pharmacodynamic response expected of Hsp90 inhibitors. Groups of four B6D2F1 female mice were administered a single oral dose of vehicle alone or compound <b>40</b> at several dose levels (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). The animals were humanely sacrificed 24 h later, and Hsp70 levels in whole brain homogenates were analyzed by ELISA. The level of Hsp70 was determined to be significantly higher in the animals dosed with 30 mg/kg or higher compared to vehicle treatment alone. This indicates that at 30 mg/kg the amount of <b>40</b> that crossed into the brain was sufficient to robustly inhibit brain Hsp90. Hence, alcohol <b>40</b> appears to be a good tool compound to examine the effect of Hsp90 inhibition in the brain after a single acute dose. It should be noted, however, that a dose of 30 mg/kg is 3 times higher than what would be tolerated upon a repeated daily dosing, suggesting that neurological effects may not be detectable at therapeutically relevant doses and that <b>40</b> may be ill-suited for neurological indications that would require repeated daily dosing.</div><figure id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Pharmacodynamic effect of <b>40</b> on Hsp70 levels in the brain, following administration of a single oral dose in B6D2F1 female mice. HSP70 levels in brain homogenates were determined by ELISA and analyzed for statistical significance using unpaired two-tailed <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">10 Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47445" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47445" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In summary, the second-generation Hsp90 inhibitor <b>40</b> is an orally available compound that is substantially more potent than the first generation clinical inhibitor <b>14</b>. Compound <b>40</b> binds Hsp90α with <i>K</i><sub>i</sub> = 0.2 nM (vs 1.7 nM for the first-generation purine <b>14</b>). In MCF-7 cells, <b>40</b> induces Her-2 degradation with EC<sub>50</sub> = 14 ± 5 nM and is 3 times more potent than <b>14</b> (EC<sub>50</sub> = 38 ± 13 nM for <b>14</b>). In mouse, the plasma exposure upon a single oral dose of 25 mg/kg is 4419 ng·h/mL, while <b>14</b> is required to be dosed at 100 mg/kg to give a comparable exposure. Compound <b>40</b> is not a PGP substrate and is not actively effluxed by CACO-2 cells. In an N87 gastric tumor model, compound <b>40</b> completely blocks tumor growth at 5 mg/kg upon oral daily dosing (po, qd×5) and causes partial tumor regressions at 10 mg/kg. This is an improvement of over 20-fold with respect to <b>14</b>, which completely blocks tumor growth only at 120 mg/kg (po, qd×5) and does not induce regressions. Compound <b>40</b> is also active at 8 mg/kg in a NCI295 adrenocortical carcinoma that overexpresses PGP and against which the PGP substrate 17-AAG is inactive at 60 mg/kg.</div><div class="NLM_p last">We also investigated applications of <b>40</b> that would extend beyond the scope of oncology. We reported in a separate publication that <b>40</b> halts disease progression in rodent models of arthritis.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> As for possible neurological indications, <b>40</b> is brain permeable (brain/plasma AUC ratio of 2.2), and a single oral dose of 30 mg/kg inhibits Hsp90 in the brains of mice, as witnessed by the up-regulation of brain Hsp70. The effect was statistically significant at 30 mg/kg but not at 10 mg/kg. Since the MTD for repeated daily dosing is 10 mg/kg, we conclude that <b>40</b> may not be well-suited to treat neurological indications. However, compound <b>40</b> remains of interest for severe inflammatory conditions and has a strong potential for the treatment of cancer.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18"><a href="/doi/suppl/10.1021/jm300810x">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Preparation of iodide <b>27</b> and of Hsp90 inhibitors <b>35</b>–<b>41</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300810x/suppl_file/jm300810x_si_001.pdf">jm300810x_si_001.pdf (730.65 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm300810x" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84155" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84155" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marco A. Biamonte</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#15787467767a3b777c74787a7b617055717161713b7a6772"><span class="__cf_email__" data-cfemail="5d303c2f3e32733f343c30323329381d3939293973322f3a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiandong Shi</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan Van de Water</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Hong</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan B. Lamer</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth W. Weichert</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cristina M. Sandoval</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Srinivas R. Kasibhatla</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcus F. Boehm</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianhua Chao</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Lundgren</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Noelito Timple</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rachel Lough</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gerardo Ibanez</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christina Boykin</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francis J. Burrows</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marilyn R. Kehry</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Theodore J. Yun</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erin K. Harning</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine Ambrose</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Thompson</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah A. Bixler</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthone Dunah</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pamela Snodgrass-Belt</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph Arndt</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Istvan J. Enyedy</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ping Li</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victor S. Hong</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andres McKenzie</span> - <span class="hlFld-Affiliation affiliation">Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1037e2108-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51123" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51123" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank the following persons for their contribution to the in vitro and in vivo pharmacokinetic data: Reggie Angeles, Cheryl Black, Robin Caputo, Min Chang, Lawrence Gan, Julia Kaplan, Samina Khan, Eric Sands, Dong Wei, Chichih Wu, and Liyu Yang.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i20" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i20"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i21" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i21"> Abbreviations Used</h2><tr><td class="NLM_term">17-AG</td><td class="NLM_def"><p class="first last">17-amino-17-desmethoxygeldanamycin</p></td></tr><tr><td class="NLM_term">17-AAG</td><td class="NLM_def"><p class="first last">17-allylamino-17-desmethoxygeldanamycin</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">total area under the drug concentration–time curve</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>O</i>-bis(trimethylsilyl)acetamide</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum plasma drug concentration during a dosing interval</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">total clearance of drug in plasma</p></td></tr><tr><td class="NLM_term">CMC</td><td class="NLM_def"><p class="first last">carboxymethylcellulose</p></td></tr><tr><td class="NLM_term">17-DMAG</td><td class="NLM_def"><p class="first last">17-desmethoxy-17-<i>N</i>,<i>N</i>-dimethylaminoethylaminodesmethoxygeldanamycin</p></td></tr><tr><td class="NLM_term">HR+ mBC</td><td class="NLM_def"><p class="first last">hormone receptor positive metastatic breast cancer</p></td></tr><tr><td class="NLM_term">HSP</td><td class="NLM_def"><p class="first last">heat shock protein</p></td></tr><tr><td class="NLM_term">MM</td><td class="NLM_def"><p class="first last">multiple myeloma</p></td></tr><tr><td class="NLM_term">MTD</td><td class="NLM_def"><p class="first last">maximum tolerated dose</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">PGP</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">qd×5</td><td class="NLM_def"><p class="first last">daily dosing 5 days on (Monday–Friday) and 2 days off (Saturday–Sunday) (Latin: quaque die = daily)</p></td></tr><tr><td class="NLM_term">RECIST</td><td class="NLM_def"><p class="first last">response evaluation criteria in solid tumors</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time after dosing when at maximum plasma drug concentration</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 41 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Hsp90 molecular chaperone inhibitors: are we there yet?</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">64</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1078-0432.CCR-11-1000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=22215907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=64-76&author=L.+Neckersauthor=P.+Workman&title=Hsp90+molecular+chaperone+inhibitors%3A+are+we+there+yet%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?</span></div><div class="casAuthors">Neckers, Len; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-76</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Heat shock protein (Hsp) 90 is an ATP-dependent mol. chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-assocd. kinases and transcription factors, and it is essential for oncogenic transformation.  Originally viewed with skepticism, Hsp90 inhibitors are now being actively pursued by the pharmaceutical industry, with 17 agents having entered clin. trials.  Investigators established Hsp90's druggability using the natural products geldanamycin and radicicol, which mimic the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause potent and selective blockade of ATP binding/hydrolysis, inhibit chaperone function, deplete oncogenic clients, and show antitumor activity.  Preclin. data obtained with these natural products have heightened interest in Hsp90 as a drug target, and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has shown clin. activity (as defined by Response Evaluation Criteria in Solid Tumors) in HER2+ breast cancer.  Many optimized synthetic, small-mol. Hsp90 inhibitors from diverse chemotypes are now in clin. trials.  Here, we review the discovery and development of Hsp90 inhibitors and assess their potential.  There has been significant learning from studies of the basic biol. of Hsp90, as well as translational drug development involving this chaperone, enhanced by the use of Hsp90 inhibitors as chem. probes.  Success will likely lie in treating cancers that are addicted to particular driver oncogene products (e.g., HER2, ALK, EGFR, and BRAF) that are sensitive Hsp90 clients, as well as malignancies (esp. multiple myeloma) in which buffering of proteotoxic stress is crit. for survival.  We discuss approaches for enhancing the effectiveness of Hsp90 inhibitors and highlight new chaperone and stress-response pathway targets, including HSF1 and Hsp70.  Clin Cancer Res; 18(1); 64-76.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfICmNu1IWFbVg90H21EOLACvtfcHk0lhSXbvhCuMkKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D&md5=f67c3c11b5847e3866c91af2a16a63b8</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1000%26sid%3Dliteratum%253Aachs%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DHsp90%2520molecular%2520chaperone%2520inhibitors%253A%2520are%2520we%2520there%2520yet%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D64%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Massey, A. J.</span><span> </span><span class="NLM_article-title">ATPases as drug targets: insights from heat shock proteins 70 and 90</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7280</span><span class="NLM_x">–</span> <span class="NLM_lpage">7286</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100342z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosVGgsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7280-7286&author=A.+J.+Massey&title=ATPases+as+drug+targets%3A+insights+from+heat+shock+proteins+70+and+90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">ATPases as Drug Targets: Insights from Heat Shock Proteins 70 and 90</span></div><div class="casAuthors">Massey, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7280-7286</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouskN9BSeSLLVg90H21EOLACvtfcHk0lhSXbvhCuMkKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosVGgsrY%253D&md5=1fb082e98a0e666b2276cb7dc1e38c2a</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1021%2Fjm100342z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100342z%26sid%3Dliteratum%253Aachs%26aulast%3DMassey%26aufirst%3DA.%2BJ.%26atitle%3DATPases%2520as%2520drug%2520targets%253A%2520insights%2520from%2520heat%2520shock%2520proteins%252070%2520and%252090%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7280%26epage%3D7286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Biamonte, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van De Water, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perret, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannevin, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W.-C.</span><span> </span><span class="NLM_article-title">Heat shock protein 90: Inhibitors in clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9004708" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3-17&author=M.+A.+Biamonteauthor=R.+Van+De+Waterauthor=D.+Perretauthor=J.+W.+Arndtauthor=R.+H.+Scannevinauthor=W.-C.+Lee&title=Heat+shock+protein+90%3A+Inhibitors+in+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90: Inhibitors in Clinical Trials</span></div><div class="casAuthors">Biamonte, Marco A.; Van de Water, Ryan; Arndt, Joseph W.; Scannevin, Robert H.; Perret, Daniel; Lee, Wen-Cherng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-17</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  HSP90 is the 90 kDa member of the family and exists as two isoforms: HSP90 is an inducible form overexpressed in cancer cells, while HSP90 is the constitutive form.  Since inhibition of HSP90 can lead to the degrdn. of a large no. of oncogenic proteins, HSP90 has become a target of interest for oncol.  A major advantage of HSP90 inhibitors is that they simultaneously attack several pathways necessary for cancer development, reducing the likelihood of the tumor acquiring resistance to any single therapeutic pathway.  It has also been proposed that HSP90 occurs in an activated form in cancer cells, whereas in normal somatic cells only the latent form is found.  This has given rise to the hypothesis that HSP90 inhibitors could be designed to selectively target the activated form and thus more specifically target cancer cells, but this assertion has been challenged.  Cancer cells seem to have a higher HSP90 activity than normal cells, and oncogenes are more dependent on HSP90 than house-keeping proteins.  In cell cultures, HSP90 inhibitors kill tumor cells at concns. much lower than those required to kill normal cells.  In mice, efficacy can be obsd. at nontoxic doses, and in humans, the first signs of clin. benefit are emerging.  It remains to be verified, however, if HSP90 inhibitors will truly provide a sufficient safety margin in the clinic.  Nononcol. indications may also emerge; besides cancer, the prevalent conditions mentioned in the literature with respect to HSP90 are Parkinson's disease, Alzheimer's disease, and fungal infections.  For the time being, however, the focus is oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYseMVVt55b7Vg90H21EOLACvtfcHk0lhEG7S_jegIcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ&md5=14eee1036fc22e45da13b49cc93ed845</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1021%2Fjm9004708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004708%26sid%3Dliteratum%253Aachs%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DVan%2BDe%2BWater%26aufirst%3DR.%26aulast%3DPerret%26aufirst%3DD.%26aulast%3DArndt%26aufirst%3DJ.%2BW.%26aulast%3DScannevin%26aufirst%3DR.%2BH.%26aulast%3DLee%26aufirst%3DW.-C.%26atitle%3DHeat%2520shock%2520protein%252090%253A%2520Inhibitors%2520in%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span>HSP90 Interactors. <a href="http://www.picard.ch/downloads/Hsp90interactors.pdf" class="extLink">http://www.picard.ch/downloads/Hsp90interactors.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=HSP90+Interactors.+http%3A%2F%2Fwww.picard.ch%2Fdownloads%2FHsp90interactors.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Schnur, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallaschun, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dee, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzzi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiOrio, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacci, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, M. P.</span><span> </span><span class="NLM_article-title">erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure–activity relationships</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">3813</span><span class="NLM_x">–</span> <span class="NLM_lpage">3820</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00019a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=3813-3820&author=R.+C.+Schnurauthor=M.+L.+Cormanauthor=R.+J.+Gallaschunauthor=B.+A.+Cooperauthor=M.+F.+Deeauthor=J.+L.+Dotyauthor=M.+L.+Muzziauthor=C.+I.+DiOrioauthor=E.+G.+Barbacciauthor=P.+E.+Millerauthor=V.+A.+Pollackauthor=D.+M.+Savageauthor=D.+E.+Sloanauthor=L.+R.+Pustilnikauthor=J.+D.+Moyerauthor=M.+P.+Moyer&title=erbB-2+oncogene+inhibition+by+geldanamycin+derivatives%3A+synthesis%2C+mechanism+of+action%2C+and+structure%E2%80%93activity+relationships"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm00019a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00019a011%26sid%3Dliteratum%253Aachs%26aulast%3DSchnur%26aufirst%3DR.%2BC.%26aulast%3DCorman%26aufirst%3DM.%2BL.%26aulast%3DGallaschun%26aufirst%3DR.%2BJ.%26aulast%3DCooper%26aufirst%3DB.%2BA.%26aulast%3DDee%26aufirst%3DM.%2BF.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DMuzzi%26aufirst%3DM.%2BL.%26aulast%3DDiOrio%26aufirst%3DC.%2BI.%26aulast%3DBarbacci%26aufirst%3DE.%2BG.%26aulast%3DMiller%26aufirst%3DP.%2BE.%26aulast%3DPollack%26aufirst%3DV.%2BA.%26aulast%3DSavage%26aufirst%3DD.%2BM.%26aulast%3DSloan%26aufirst%3DD.%2BE.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26atitle%3DerbB-2%2520oncogene%2520inhibition%2520by%2520geldanamycin%2520derivatives%253A%2520synthesis%252C%2520mechanism%2520of%2520action%252C%2520and%2520structure%25E2%2580%2593activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D3813%26epage%3D3820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Ge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dembski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georges, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grenier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pak, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sydor, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbits, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palombella, V. J.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of HSP90</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4606</span><span class="NLM_x">–</span> <span class="NLM_lpage">4615</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0603116" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4606-4615&author=J.+Geauthor=E.+Normantauthor=J.+R.+Porterauthor=J.+A.+Aliauthor=M.+S.+Dembskiauthor=Y.+Gaoauthor=A.+T.+Georgesauthor=L.+Grenierauthor=R.+H.+Pakauthor=J.+Pattersonauthor=J.+R.+Sydorauthor=T.+T.+Tibbitsauthor=J.+K.+Tongauthor=J.+Adamsauthor=V.+J.+Palombella&title=Design%2C+synthesis%2C+and+biological+evaluation+of+hydroquinone+derivatives+of+17-amino-17-demethoxygeldanamycin+as+potent%2C+water-soluble+inhibitors+of+HSP90"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm0603116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603116%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DDembski%26aufirst%3DM.%2BS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGeorges%26aufirst%3DA.%2BT.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DPak%26aufirst%3DR.%2BH.%26aulast%3DPatterson%26aufirst%3DJ.%26aulast%3DSydor%26aufirst%3DJ.%2BR.%26aulast%3DTibbits%26aufirst%3DT.%2BT.%26aulast%3DTong%26aufirst%3DJ.%2BK.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520hydroquinone%2520derivatives%2520of%252017-amino-17-demethoxygeldanamycin%2520as%2520potent%252C%2520water-soluble%2520inhibitors%2520of%2520HSP90%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4606%26epage%3D4615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Glaze, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormick, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaraj, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyubimov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egorin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomaszewski, J. E.</span><span> </span><span class="NLM_article-title">Dose range-finding toxicity studies of 17-DMAG</span> <span class="citation_source-journal">Proc. Am. Assoc. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">162</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=162-162&author=E.+R.+Glazeauthor=A.+C.+Smithauthor=D.+W.+Johnsonauthor=D.+L.+McCormickauthor=A.+B.+Brownauthor=B.+S.+Levinauthor=R.+Krishnarajauthor=A.+Lyubimovauthor=M.+J.+Egorinauthor=J.+E.+Tomaszewski&title=Dose+range-finding+toxicity+studies+of+17-DMAG"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGlaze%26aufirst%3DE.%2BR.%26aulast%3DSmith%26aufirst%3DA.%2BC.%26aulast%3DJohnson%26aufirst%3DD.%2BW.%26aulast%3DMcCormick%26aufirst%3DD.%2BL.%26aulast%3DBrown%26aufirst%3DA.%2BB.%26aulast%3DLevin%26aufirst%3DB.%2BS.%26aulast%3DKrishnaraj%26aufirst%3DR.%26aulast%3DLyubimov%26aufirst%3DA.%26aulast%3DEgorin%26aufirst%3DM.%2BJ.%26aulast%3DTomaszewski%26aufirst%3DJ.%2BE.%26atitle%3DDose%2520range-finding%2520toxicity%2520studies%2520of%252017-DMAG%26jtitle%3DProc.%2520Am.%2520Assoc.%2520Cancer%2520Res.%26date%3D2003%26volume%3D44%26spage%3D162%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Eiseman, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagatutta, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamburger, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covey, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egorin, M. J.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1007%2Fs00280-004-0865-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=15338192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWjt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2005&pages=21-32&author=J.+L.+Eisemanauthor=J.+Lanauthor=T.+F.+Lagatuttaauthor=D.+R.+Hamburgerauthor=E.+Josephauthor=J.+M.+Coveyauthor=M.+J.+Egorin&title=Pharmacokinetics+and+pharmacodynamics+of+17-demethoxy+17-%5B%5B%282-dimethylamino%29ethyl%5Damino%5Dgeldanamycin+%2817DMAG%2C+NSC+707545%29+in+C.B-17+SCID+mice+bearing+MDA-MB-231+human+breast+cancer+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts</span></div><div class="casAuthors">Eiseman, Julie L.; Lan, Jing; Lagattuta, Theodore F.; Hamburger, Deborah R.; Joseph, Erin; Covey, Joseph M.; Egorin, Merrill J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-32</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Purpose: 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) is a water-sol. analog of 17-(allylamino)-17-demethoxygeldanamycin (17AAG), a compd. currently in clin. trials.  These preclin. studies: (1) characterized 17DMAG concns. in plasma, normal tissues, and tumor after i.v. delivery to mice; and (2) correlated tumor and normal tissue 17DMAG concns. with alterations in heat shock protein 90 (HSP90) and selected HSP90-chaperoned proteins.  Methods: At specified times after i.v. administration of 75 mg/kg 17DMAG, SCID mice bearing s.c.  MDA-MB-231 human breast xenografts were killed and plasma and tissues were retained. 17DMAG concns. were detd. by HPLC.  Raf-1, heat shock protein 70 (HSP70), and HSP90 in tissues were detd. by Western blotting.  Results: Peak plasma 17DMAG concn. was 15.4±1.4 μg/mL.  The area under the plasma 17DMAG concn. vs. time curve was 1072 μg/mL min, corresponding to a total body clearance of 70 mL/kg/min.  Peak 17DMAG concns. in liver (118.8±5.7 μg/g), kidney (122.9±10.6 μg/g), heart (81.3±8.1 μg/g), and lung (110.6±25.4 μg/g) occurred at 5-10 min, while peak concns. in spleen (70.6±9.6 μg/g) and tumor (9.0±1.0 μg/g) occurred at 30-45 min.  At 48 h, 17DMAG was detectable in tumor but not in any normal tissue.  Raf-1 in tumors of 17DMAG-treated mice killed at 4, 7, 24 and 48 h was about 20 lower than in tumors from vehicle-treated mice.  HSP90 and HSP70 in tumors of 17DMAG-treated animals were significantly lower than in tumors of control animals at 4, 7, and 24 h.  Hepatic Raf-1 was decreased by more than 60 at all times after 17DMAG treatment; however, hepatic HSP90 was not affected.  HSP70 was undetectable in livers of vehicle-treated mice or mice killed at 2 or 4 h after 17DMAG treatment, but was detected in livers at 7, 24 and 48 h. 17DMAG did not affect renal Raf-1.  In contrast, renal HSP70 and HSP90 were decreased by more than 50 at 2 and 4 h after 17DMAG treatment.  Renal HSP70 increased approx. twofold above that in kidneys from vehicle-treated control mice at 7 and 24 h, while HSP90 relative protein concn. was no different from that in controls.  Conclusions: Plasma pharmacokinetics of 17DMAG in tumor-bearing mice were similar to those previously reported in nontumor-bearing mice. 17DMAG was distributed widely to tissues but was retained for longer in tumors than normal tissues.  Raf-1, HSP90, and HSP70 were altered to different degrees in tumors, livers, and kidneys of 17DMAG-treated animals.  These data illustrate the complex nature of the biol. responses to 17DMAG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGmcN-fv9ZSbVg90H21EOLACvtfcHk0liB_h8uj9B8Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWjt77J&md5=9b7cf6c82811bf0b8e93dcb52d713ba0</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1007%2Fs00280-004-0865-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-004-0865-3%26sid%3Dliteratum%253Aachs%26aulast%3DEiseman%26aufirst%3DJ.%2BL.%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DLagatutta%26aufirst%3DT.%2BF.%26aulast%3DHamburger%26aufirst%3DD.%2BR.%26aulast%3DJoseph%26aufirst%3DE.%26aulast%3DCovey%26aufirst%3DJ.%2BM.%26aulast%3DEgorin%26aufirst%3DM.%2BJ.%26atitle%3DPharmacokinetics%2520and%2520pharmacodynamics%2520of%252017-demethoxy%252017-%255B%255B%25282-dimethylamino%2529ethyl%255Damino%255Dgeldanamycin%2520%252817DMAG%252C%2520NSC%2520707545%2529%2520in%2520C.B-17%2520SCID%2520mice%2520bearing%2520MDA-MB-231%2520human%2520breast%2520cancer%2520xenografts%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2005%26volume%3D55%26spage%3D21%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span>IPI-493, a Potent, Orally Bioavailable Hsp90 Inhibitor of the Ansamycin Class. <a href="http://infi.com/pipeline-archives/IPI-493%20EORTC%202008.pdf" class="extLink">http://infi.com/pipeline-archives/IPI-493%20EORTC%202008.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=IPI-493%2C+a+Potent%2C+Orally+Bioavailable+Hsp90+Inhibitor+of+the+Ansamycin+Class.+http%3A%2F%2Finfi.com%2Fpipeline-archives%2FIPI-493%2520EORTC%25202008.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Brough, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barril, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgognoni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cansfield, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K.-M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, N. G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drysdale, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northfield, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodromou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roughley, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surgenor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walmsley, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, L.</span><span> </span><span class="NLM_article-title">4,5-Diarylisoxazole HSP90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">196</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701018h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=196-218&author=P.+A.+Broughauthor=W.+Aherneauthor=X.+Barrilauthor=J.+Borgognoniauthor=K.+Boxallauthor=J.+E.+Cansfieldauthor=K.-M.+J.+Cheungauthor=I.+Collinsauthor=N.+G.+M.+Daviesauthor=M.+J.+Drysdaleauthor=B.+Dymockauthor=S.+A.+Ecclesauthor=H.+Finchauthor=A.+Finkauthor=A.+Hayesauthor=R.+Howesauthor=R.+E.+Hubbardauthor=K.+Jamesauthor=A.+M.+Jordanauthor=A.+Lockieauthor=V.+Martinsauthor=A.+Masseyauthor=T.+P.+Matthewsauthor=E.+McDonaldauthor=C.+J.+Northfieldauthor=L.+H.+Pearlauthor=C.+Prodromouauthor=S.+Rayauthor=F.+I.+Raynaudauthor=S.+D.+Roughleyauthor=S.+Y.+Sharpauthor=A.+Surgenorauthor=D.+L.+Walmsleyauthor=P.+Webbauthor=M.+Woodauthor=P.+Workmanauthor=L.+Wright&title=4%2C5-Diarylisoxazole+HSP90+chaperone+inhibitors%3A+potential+therapeutic+agents+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm701018h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701018h%26sid%3Dliteratum%253Aachs%26aulast%3DBrough%26aufirst%3DP.%2BA.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DBorgognoni%26aufirst%3DJ.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DCansfield%26aufirst%3DJ.%2BE.%26aulast%3DCheung%26aufirst%3DK.-M.%2BJ.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DDavies%26aufirst%3DN.%2BG.%2BM.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFinch%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DLockie%26aufirst%3DA.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DNorthfield%26aufirst%3DC.%2BJ.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWalmsley%26aufirst%3DD.%2BL.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DL.%26atitle%3D4%252C5-Diarylisoxazole%2520HSP90%2520chaperone%2520inhibitors%253A%2520potential%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D196%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Woodhead, A. J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angove, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosme, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figueroa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederickson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parra, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trewartha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vimkovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolford, A. J.</span><span> </span><span class="NLM_article-title">Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-yl-methyl)-1,3-dihydroisondol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5956</span><span class="NLM_x">–</span> <span class="NLM_lpage">5969</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100060b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5956-5969&author=A.+J+Woodheadauthor=H.+Angoveauthor=M.+G.+Carrauthor=G.+Chessariauthor=M.+Congreveauthor=J.+E.+Coyleauthor=J.+Cosmeauthor=B.+Grahamauthor=P.+J.+Dayauthor=R.+Downhamauthor=L.+Fazalauthor=R.+Feltellauthor=E.+Figueroaauthor=M.+Fredericksonauthor=J.+Lewisauthor=R.+McMenaminauthor=C.+W.+Murrayauthor=M.+A.+O%E2%80%99Brienauthor=L.+Parraauthor=S.+Patelauthor=T.+Phillipsauthor=D.+C.+Reesauthor=S.+Richauthor=D.-M.+Smithauthor=G.+Trewarthaauthor=M.+Vimkovicauthor=B.+Williamsauthor=A.+J.+Woolford&title=Discovery+of+%282%2C4-dihydroxy-5-isopropylphenyl%29-%5B5-%284-methylpiperazin-1-yl-methyl%29-1%2C3-dihydroisondol-2-yl%5Dmethanone+%28AT13387%29%2C+a+novel+inhibitor+of+the+molecular+chaperone+Hsp90+by+fragment+based+drug+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm100060b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100060b%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhead%26aufirst%3DA.%2BJ%26aulast%3DAngove%26aufirst%3DH.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DCosme%26aufirst%3DJ.%26aulast%3DGraham%26aufirst%3DB.%26aulast%3DDay%26aufirst%3DP.%2BJ.%26aulast%3DDownham%26aufirst%3DR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DFeltell%26aufirst%3DR.%26aulast%3DFigueroa%26aufirst%3DE.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DParra%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DT.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.-M.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DVimkovic%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520of%2520%25282%252C4-dihydroxy-5-isopropylphenyl%2529-%255B5-%25284-methylpiperazin-1-yl-methyl%2529-1%252C3-dihydroisondol-2-yl%255Dmethanone%2520%2528AT13387%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520the%2520molecular%2520chaperone%2520Hsp90%2520by%2520fragment%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5956%26epage%3D5969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Ying, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatsuta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acquaviva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsoum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, K.</span><span> </span><span class="NLM_article-title">Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1535-7163.MCT-11-0755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=22144665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=475-484&author=W.+Yingauthor=Z.+Duauthor=L.+Sunauthor=K.+P.+Foleyauthor=D.+A.+Proiaauthor=R.+K.+Blackmanauthor=D.+Zhouauthor=T.+Inoueauthor=N.+Tatsutaauthor=J.+Sangauthor=S.+Yeauthor=J.+Acquavivaauthor=L.+S.+Ogawaauthor=Y.+Wadaauthor=J.+Barsoumauthor=K.+Koya&title=Ganetespib%2C+a+unique+triazolone-containing+Hsp90+inhibitor%2C+exhibits+potent+antitumor+activity+and+a+superior+safety+profile+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy</span></div><div class="casAuthors">Ying, Weiwen; Du, Zhenjian; Sun, Lijun; Foley, Kevin P.; Proia, David A.; Blackman, Ronald K.; Zhou, Dan; Inoue, Takayo; Tatsuta, Noriaki; Sang, Jim; Ye, Shuxia; Acquaviva, Jamie; Ogawa, Luisa Shin; Wada, Yumiko; Barsoum, James; Koya, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">475-484</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted inhibition of the mol. chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an attractive strategy for the development of novel cancer therapeutics.  Ganetespib (formerly known as STA-9090) is a unique resorcinolic triazolone inhibitor of Hsp90 that is currently in clin. trials for a no. of human cancers.  In the present study, we showed that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematol. tumor cell lines, including those that express mutated kinases that confer resistance to small-mol. tyrosine kinase inhibitors.  Ganetespib treatment rapidly induced the degrdn. of known Hsp90 client proteins, displayed superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), and exhibited sustained activity even with short exposure times.  In vivo, ganetespib showed potent antitumor efficacy in solid and hematol. xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions.  Notably, evaluation of the microregional activity of ganetespib in tumor xenografts showed that ganetespib was efficiently distributed throughout tumor tissue, including hypoxic regions >150 μm from the microvasculature, to inhibit proliferation and induce apoptosis.  Importantly, ganetespib showed no evidence of cardiac or liver toxicity.  Taken together, this preclin. activity profile indicates that ganetespib may have broad application for a variety of human malignancies, and with select mechanistic and safety advantages over other first- and second-generation Hsp90 inhibitors.  Mol Cancer Ther; 11(2); 475-84.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhzG1TPr4lbVg90H21EOLACvtfcHk0liPCNnbNXZ1jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D&md5=269d41b30e5add9b9503cb43a98b0157</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0755%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DN.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DOgawa%26aufirst%3DL.%2BS.%26aulast%3DWada%26aufirst%3DY.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DKoya%26aufirst%3DK.%26atitle%3DGanetespib%252C%2520a%2520unique%2520triazolone-containing%2520Hsp90%2520inhibitor%252C%2520exhibits%2520potent%2520antitumor%2520activity%2520and%2520a%2520superior%2520safety%2520profile%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D475%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Nakashima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagaya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seike, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiotsu, Y.</span><span> </span><span class="NLM_article-title">New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2792</span><span class="NLM_x">–</span> <span class="NLM_lpage">2802</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1078-0432.CCR-09-3112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=20406843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvF2hsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2792-2802&author=T.+Nakashimaauthor=T.+Ishiiauthor=H.+Tagayaauthor=T.+Seikeauthor=H.+Nakagawaauthor=Y.+Kandaauthor=S.+Akinagaauthor=S.+Sogaauthor=Y.+Shiotsu&title=New+molecular+and+biological+mechanism+of+antitumor+activities+of+KW-2478%2C+a+novel+nonansamycin+heat+shock+protein+90+inhibitor%2C+in+multiple+myeloma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells</span></div><div class="casAuthors">Nakashima, Takayuki; Ishii, Toshihiko; Tagaya, Hisashi; Seike, Toshihiro; Nakagawa, Hiroshi; Kanda, Yutaka; Akinaga, Shiro; Soga, Shiro; Shiotsu, Yukimasa</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2792-2802</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The heat shock protein 90 (Hsp90) plays an important role in chaperoning oncogenic client proteins in multiple myeloma (MM) cells, and several Hsp90 inhibitors have shown antitumor activities both in vitro and in vivo.  However the precise mechanism of action of Hsp90 inhibitor in MM has not been fully elucidated.  Exptl. Design: The authors evaluated the antitumor activities of KW-2478, a nonansamycin Hsp90 inhibitor, in MM cells with various chromosomal translocations of Ig heavy chain (IgH) loci both in vitro and in vivo.  RESULTS: The authors' studies revealed that exposure of KW-2478 to MM cells resulted in growth inhibition and apoptosis, which were assocd. with degrdn. of well-known client proteins as well as a decrease in IgH translocation products (FGFR3, c-Maf, and cyclin D1), and FGFR3 was shown to be a new client protein of Hsp90 chaperon complex.  In addn., KW-2478 depleted the Hsp90 client Cdk9, a transcriptional kinase, and the phosphorylated 4E-BP1, a translational inhibitor.  Both inhibitory effects of KW-2478 on such transcriptional and translational pathways were shown to reduce c-Maf and cyclin D1 expression.  In NCI-H929 s.c. inoculated model, KW-2478 showed a significant suppression of tumor growth and induced the degrdn. of client proteins in tumors.  Furthermore, in a novel orthotopic MM model of i.v. inoculated OPM-2/green fluorescent protein, KW-2478 showed a significant redn. of both serum M protein and MM tumor burden in the bone marrow.  CONCLUSIONS: These results suggest that targeting such diverse pathways by KW-2478 could be a promising strategy for the treatment of MM with various cytogenetic abnormalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozKElc2AcPx7Vg90H21EOLACvtfcHk0liPCNnbNXZ1jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvF2hsr8%253D&md5=dfe115d5696acc0a9ae62c94c24a42ec</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-3112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-3112%26sid%3Dliteratum%253Aachs%26aulast%3DNakashima%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DTagaya%26aufirst%3DH.%26aulast%3DSeike%26aufirst%3DT.%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DSoga%26aufirst%3DS.%26aulast%3DShiotsu%26aufirst%3DY.%26atitle%3DNew%2520molecular%2520and%2520biological%2520mechanism%2520of%2520antitumor%2520activities%2520of%2520KW-2478%252C%2520a%2520novel%2520nonansamycin%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%2520in%2520multiple%2520myeloma%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D2792%26epage%3D2802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Immormino, R. M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gewirth, D. T.</span><span> </span><span class="NLM_article-title">Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4953</span><span class="NLM_x">–</span> <span class="NLM_lpage">4960</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060297x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4953-4960&author=R.+M+Immorminoauthor=Y.+Kangauthor=G.+Chiosisauthor=D.+T.+Gewirth&title=Structural+and+quantum+chemical+studies+of+8-aryl-sulfanyl+adenine+class+Hsp90+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1021%2Fjm060297x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060297x%26sid%3Dliteratum%253Aachs%26aulast%3DImmormino%26aufirst%3DR.%2BM%26aulast%3DKang%26aufirst%3DY.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26atitle%3DStructural%2520and%2520quantum%2520chemical%2520studies%2520of%25208-aryl-sulfanyl%2520adenine%2520class%2520Hsp90%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4953%26epage%3D4960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Caldas-Lopes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerchietti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robles, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moulick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taldone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Stanchina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varticovski, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">8368</span><span class="NLM_x">–</span> <span class="NLM_lpage">8373</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=8368-8373&author=E.+Caldas-Lopesauthor=L.+Cerchiettiauthor=J.+H.+Ahnauthor=C.+C.+Clementauthor=A.+I.+Roblesauthor=A.+Rodinaauthor=K.+Moulickauthor=T.+Taldoneauthor=A.+Gozmanauthor=Y.+Guoauthor=N.+Wuauthor=E.+de+Stanchinaauthor=J.+Whiteauthor=S.+S.+Grossauthor=Y.+Maauthor=L.+Varticovskiauthor=A.+Melnickauthor=G.+Chiosis&title=Hsp90+inhibitor+PU-H71%2C+a+multimodal+inhibitor+of+malignancy%2C+induces+complete+responses+in+triple-negative+breast+cancer+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaldas-Lopes%26aufirst%3DE.%26aulast%3DCerchietti%26aufirst%3DL.%26aulast%3DAhn%26aufirst%3DJ.%2BH.%26aulast%3DClement%26aufirst%3DC.%2BC.%26aulast%3DRobles%26aufirst%3DA.%2BI.%26aulast%3DRodina%26aufirst%3DA.%26aulast%3DMoulick%26aufirst%3DK.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DGozman%26aufirst%3DA.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DN.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DGross%26aufirst%3DS.%2BS.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DVarticovski%26aufirst%3DL.%26aulast%3DMelnick%26aufirst%3DA.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DHsp90%2520inhibitor%2520PU-H71%252C%2520a%2520multimodal%2520inhibitor%2520of%2520malignancy%252C%2520induces%2520complete%2520responses%2520in%2520triple-negative%2520breast%2520cancer%2520models%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D8368%26epage%3D8373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Rocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">4046</span><span class="NLM_x">–</span> <span class="NLM_lpage">4057</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1078-0432.CCR-09-0152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=19509149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntlOisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=4046-4057&author=R.+Baoauthor=C.-J.+Laiauthor=H.+Quauthor=D.+Wangauthor=L.+Yinauthor=B.+Zifcakauthor=R.+Atoyanauthor=J.+Wangauthor=M.+Samsonauthor=J.+Forresterauthor=S.+Della+Roccaauthor=G.-X.+Xuauthor=X.+Taoauthor=H.-X.+Zhaiauthor=X.+Caiauthor=C.+Qian&title=CUDC-305%2C+a+novel+synthetic+HSP90+inhibitor+with+unique+pharmacologic+properties+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy</span></div><div class="casAuthors">Bao, Rudi; Lai, Cheng-Jung; Qu, Hui; Wang, Dagong; Yin, Ling; Zifcak, Brian; Atoyan, Ruzanna; Wang, Jing; Samson, Maria; Forrester, Jeffrey; Della Rocca, Steven; Xu, Guang-Xin; Tao, Xu; Zhai, Hai-Xiao; Cai, Xiong; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4046-4057</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class.  Here, we report its unique pharmacol. properties and antitumor activities in a variety of tumor types.  The potency of the compd. was analyzed by fluorescence polarization competition binding assay.  Its antiproliferative activities were assessed in 40 human cancer cell lines.  Its pharmacol. properties and antitumor activities were evaluated in a variety of tumor xenograft models.  CUDC-305 shows high affinity for HSP90α/β (IC50, ∼100 nmol/L) and HSP90 complex derived from cancer cells (IC50, 48.8 nmol/L).  It displays potent antiproliferative activity against a broad range of cancer cell lines (mean IC50, 220 nmol/L).  CUDC-305 exhibits high oral bioavailability (96.0%) and selective retention in tumor (half-life, 20.4 h) compared with normal tissues.  Furthermore, CUDC-305 can cross blood-brain barrier and reach therapeutic levels in brain tissue.  CUDC-305 exhibits dose-dependent antitumor activity in an s.c. xenograft model of U87MG glioblastoma and significantly prolongs animal survival in U87MG orthotopic model.  CUDC-305 also displays potent antitumor activity in animal models of erlotinib-resistant non-small cell lung cancer and induces tumor regression in animal models of MDA-MB-468 breast cancer and MV4-11 acute myelogenous leukemia.  Correlating with its efficacy in these various tumor models, CUDC-305 robustly inhibits multiple signaling pathways, including PI3K/AKT and RAF/MEK/ERK, and induces apoptosis.  In combination studies, CUDC-305 enhances the antitumor activity of std.-of-care agents in breast and colorectal tumor models.  CUDC-305 is a promising drug candidate for the treatment of a variety of cancers, including brain malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyxsZpWkM4MrVg90H21EOLACvtfcHk0lhQ7Thgr55RXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntlOisL4%253D&md5=b872c7658a2fc98f263f7e6a23cb58f6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0152%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DR.%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DDella%2BRocca%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DG.-X.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-305%252C%2520a%2520novel%2520synthetic%2520HSP90%2520inhibitor%2520with%2520unique%2520pharmacologic%2520properties%2520for%2520cancer%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D4046%26epage%3D4057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span>Evaluation of the Pharmacokinetics and Efficacy of a Novel Pro-Drug of the HSP90 Inhibitor. <a href="http://www.myriadpharma.com/images/stories/product-pipeline/mpc-3100/AACR%202011/aacr-2011-abst3237-mpc-3100-prodrug-mpc-0767.pdf" class="extLink">http://www.myriadpharma.com/images/stories/product-pipeline/mpc-3100/AACR%202011/aacr-2011-abst3237-mpc-3100-prodrug-mpc-0767.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Evaluation+of+the+Pharmacokinetics+and+Efficacy+of+a+Novel+Pro-Drug+of+the+HSP90+Inhibitor.+http%3A%2F%2Fwww.myriadpharma.com%2Fimages%2Fstories%2Fproduct-pipeline%2Fmpc-3100%2FAACR%25202011%2Faacr-2011-abst3237-mpc-3100-prodrug-mpc-0767.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Fadden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steed, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barabasz, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Partridge, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubois, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freed, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silinski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barta, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ommen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spangenberg, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaves, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenks, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pronk, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verleysen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haystead, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. E.</span><span> </span><span class="NLM_article-title">Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">686</span><span class="NLM_x">–</span> <span class="NLM_lpage">694</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1016%2Fj.chembiol.2010.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=20659681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptleitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=686-694&author=P.+Faddenauthor=K.+H.+Huangauthor=J.+M.+Vealauthor=P.+M.+Steedauthor=A.+F.+Barabaszauthor=B.+Foleyauthor=M.+Huauthor=J.+M.+Partridgeauthor=J.+Riceauthor=A.+Scottauthor=L.+G.+Duboisauthor=T.+A.+Freedauthor=M.+A.+Silinskiauthor=T.+E.+Bartaauthor=P.+F.+Hughesauthor=A.+Ommenauthor=W.+Maauthor=E.+D.+Smithauthor=A.+W.+Spangenbergauthor=J.+Eavesauthor=G.+J.+Hansonauthor=L.+Hinkleyauthor=M.+Jenksauthor=M.+Lewisauthor=J.+Ottoauthor=G.+J.+Pronkauthor=K.+Verleysenauthor=T.+A.+Haysteadauthor=S.+E.+Hall&title=Application+of+chemoproteomics+to+drug+discovery%3A+identification+of+a+clinical+candidate+targeting+hsp90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Chemoproteomics to Drug Discovery: Identification of a Clinical Candidate Targeting Hsp90</span></div><div class="casAuthors">Fadden, Patrick; Huang, Kenneth H.; Veal, James M.; Steed, Paul M.; Barabasz, Amy F.; Foley, Briana; Hu, Mei; Partridge, Jeffrey M.; Rice, John; Scott, Anisa; Dubois, Laura G.; Freed, Tiffany A.; Rehder Silinski, Melanie A.; Barta, Thomas E.; Hughes, Philip F.; Ommen, Andy; Ma, Wei; Smith, Emilie D.; Woodward Spangenberg, Angela; Eaves, Jeron; Hanson, Gunnar J.; Hinkley, Lindsay; Jenks, Matthew; Lewis, Meredith; Otto, James; Pronk, Gijsbertus J.; Verleysen, Katleen; Haystead, Timothy A.; Hall, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">686-694</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: A chemoproteomics-based drug discovery strategy is presented that utilizes a highly parallel screening platform, encompassing more than 1000 targets, with a focused chem. library prior to target selection.  This chemoproteomics-based process enables a data-driven selection of both the biol. target and chem. hit after the screen is complete.  The methodol. has been exemplified for the purine binding proteome (proteins utilizing ATP, NAD, FAD).  Screening of an 8000 member library yielded over 1500 unique protein-ligand interactions, which included novel hits for the oncol. target Hsp90.  The approach, which also provides broad target selectivity information, was used to drive the identification of a potent and orally active Hsp90 inhibitor, SNX-5422, which is currently in phase 1 clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfemxEaaJVH7Vg90H21EOLACvtfcHk0lhQ7Thgr55RXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptleitL4%253D&md5=68486178a6847516af3fb5417a9b1911</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DFadden%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DK.%2BH.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DSteed%26aufirst%3DP.%2BM.%26aulast%3DBarabasz%26aufirst%3DA.%2BF.%26aulast%3DFoley%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DPartridge%26aufirst%3DJ.%2BM.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DA.%26aulast%3DDubois%26aufirst%3DL.%2BG.%26aulast%3DFreed%26aufirst%3DT.%2BA.%26aulast%3DSilinski%26aufirst%3DM.%2BA.%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DHughes%26aufirst%3DP.%2BF.%26aulast%3DOmmen%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DE.%2BD.%26aulast%3DSpangenberg%26aufirst%3DA.%2BW.%26aulast%3DEaves%26aufirst%3DJ.%26aulast%3DHanson%26aufirst%3DG.%2BJ.%26aulast%3DHinkley%26aufirst%3DL.%26aulast%3DJenks%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DJ.%26aulast%3DPronk%26aufirst%3DG.%2BJ.%26aulast%3DVerleysen%26aufirst%3DK.%26aulast%3DHaystead%26aufirst%3DT.%2BA.%26aulast%3DHall%26aufirst%3DS.%2BE.%26atitle%3DApplication%2520of%2520chemoproteomics%2520to%2520drug%2520discovery%253A%2520identification%2520of%2520a%2520clinical%2520candidate%2520targeting%2520hsp90%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D686%26epage%3D694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Kasibhatla, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biamonte, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busch, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karjian, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensintaffar, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lough, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brekken, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundgren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grecko, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timony, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ran, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansfield, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulm, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M. F.</span><span> </span><span class="NLM_article-title">Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2767</span><span class="NLM_x">–</span> <span class="NLM_lpage">2778</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050752%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2767-2778&author=S.+R.+Kasibhatlaauthor=K.+Hongauthor=M.+A.+Biamonteauthor=D.+J.+Buschauthor=P.+L.+Karjianauthor=J.+L.+Sensintaffarauthor=A.+Kamalauthor=R.+E.+Loughauthor=J.+Brekkenauthor=K.+Lundgrenauthor=R.+Greckoauthor=G.+A.+Timonyauthor=Y.+Ranauthor=R.+Mansfieldauthor=L.+C.+Fritzauthor=E.+Ulmauthor=F.+J.+Burrowsauthor=M.+F.+Boehm&title=Rationally+designed+high-affinity+2-amino-6-halopurine+heat+shock+protein+90+inhibitors+that+exhibit+potent+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm050752%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050752%252B%26sid%3Dliteratum%253Aachs%26aulast%3DKasibhatla%26aufirst%3DS.%2BR.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DBusch%26aufirst%3DD.%2BJ.%26aulast%3DKarjian%26aufirst%3DP.%2BL.%26aulast%3DSensintaffar%26aufirst%3DJ.%2BL.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DLough%26aufirst%3DR.%2BE.%26aulast%3DBrekken%26aufirst%3DJ.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DGrecko%26aufirst%3DR.%26aulast%3DTimony%26aufirst%3DG.%2BA.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DMansfield%26aufirst%3DR.%26aulast%3DFritz%26aufirst%3DL.%2BC.%26aulast%3DUlm%26aufirst%3DE.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26atitle%3DRationally%2520designed%2520high-affinity%25202-amino-6-halopurine%2520heat%2520shock%2520protein%252090%2520inhibitors%2520that%2520exhibit%2520potent%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2767%26epage%3D2778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Menezes, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taverna, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duhl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machajewski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryer, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z.</span><span> </span><span class="NLM_article-title">The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1535-7163.MCT-11-0667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=22246440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=730-739&author=D.+L.+Menezesauthor=P.+Tavernaauthor=M.+R.+Jensenauthor=T.+Abramsauthor=D.+Stuartauthor=G.+K.+Yuauthor=D.+Duhlauthor=T.+Machajewskiauthor=W.+R.+Sellersauthor=N.+K.+Pryerauthor=Z.+Gao&title=The+novel+oral+Hsp90+inhibitor+NVP-HSP990+exhibits+potent+and+broad-spectrum+antitumor+activities+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo</span></div><div class="casAuthors">Menezes, Daniel L.; Taverna, Pietro; Jensen, Michael R.; Abrams, Tinya; Stuart, Darrin; Yu, Guoying Karen; Duhl, David; Machajewski, Timothy; Sellers, William R.; Pryer, Nancy K.; Gao, Zhenhai</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A novel oral Hsp90 inhibitor, NVP-HSP990, has been developed and characterized in vitro and in vivo.  In vitro, NVP-HSP990 exhibits single digit nanomolar IC50 values on three of the Hsp90 isoforms (Hsp90α, Hsp90β, and GRP94) and 320 nanomolar IC50 value on the fourth (TRAP-1), with selectivity against unrelated enzymes, receptors, and kinases.  In c-Met amplified GTL-16 gastric tumor cells, NVP-HSP990 dissocd. the Hsp90-p23 complex, depleted client protein c-Met, and induced Hsp70.  NVP-HSP990 potently inhibited the growth of human cell lines and primary patient samples from a variety of tumor types.  In vivo, NVP-HSP990 exhibits drug-like pharmaceutical and pharmacol. properties with high oral bioavailability.  In the GTL-16 xenograft model, a single oral administration of 15 mg/kg of NVP-HSP990 induced sustained downregulation of c-Met and upregulation of Hsp70.  In repeat dosing studies, NVP-HSP990 treatment resulted in tumor growth inhibition of GTL-16 and other human tumor xenograft models driven by well-defined oncogenic Hsp90 client proteins.  On the basis of its pharmacol. profile and broad-spectrum antitumor activities, clin. trials have been initiated to evaluate NVP-HSP990 in advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4xi_VsuoE5rVg90H21EOLACvtfcHk0lifm01x2Nxhdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKisLs%253D&md5=34994c38583b9d59d01f7a8bb8354809</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0667%26sid%3Dliteratum%253Aachs%26aulast%3DMenezes%26aufirst%3DD.%2BL.%26aulast%3DTaverna%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DStuart%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DG.%2BK.%26aulast%3DDuhl%26aufirst%3DD.%26aulast%3DMachajewski%26aufirst%3DT.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DPryer%26aufirst%3DN.%2BK.%26aulast%3DGao%26aufirst%3DZ.%26atitle%3DThe%2520novel%2520oral%2520Hsp90%2520inhibitor%2520NVP-HSP990%2520exhibits%2520potent%2520and%2520broad-spectrum%2520antitumor%2520activities%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">For another series, also from Novartis, see the following: </p></div><span class="NLM_contrib-group">Massey, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepfer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chene, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drysdale, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfaar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radimerski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruetz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweitzer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, M. R.</span><span> </span><span class="NLM_article-title">Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">906</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1535-7163.MCT-10-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=20371713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktlCqt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=906-919&author=A.+J.+Masseyauthor=J.+Schoepferauthor=P.+A.+Broughauthor=J.+Brueggenauthor=P.+Cheneauthor=M.+J.+Drysdaleauthor=U.+Pfaarauthor=T.+Radimerskiauthor=S.+Ruetzauthor=A.+Schweitzerauthor=M.+Woodauthor=C.+Garcia-Echeverriaauthor=M.+R.+Jensen&title=Preclinical+antitumor+activity+of+the+orally+available+heat+shock+protein+90+inhibitor+NVP-BEP800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800</span></div><div class="casAuthors">Massey, Andrew J.; Schoepfer, Joseph; Brough, Paul A.; Brueggen, Josef; Chene, Patrick; Drysdale, Martin J.; Pfaar, Ulrike; Radimerski, Thomas; Ruetz, Stephan; Schweitzer, Alain; Wood, Mike; Garcia-Echeverria, Carlos; Jensen, Michael Rugaard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">906-919</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a ubiquitously expressed mol. chaperone with ATPase activity involved in the conformational maturation and stability of key signaling mols. involved in cell proliferation, survival, and transformation.  Through its ability to modulate multiple pathways involved in oncogenesis, Hsp90 has generated considerable interest as a therapeutic target.  NVP-BEP800 is a novel, fully synthetic, orally bioavailable inhibitor that binds to the NH2-terminal ATP-binding pocket of Hsp90.  NVP-BEP800 showed activity against a panel of human tumor cell lines and primary human xenografts in vitro at nanomolar concns.  In A375 melanoma and BT-474 breast cancer cell lines, NVP-BEP800 induced client protein degrdn. (including ErbB2, B-RafV600E, Raf-1, and Akt) and Hsp70 induction.  Oral administration of NVP-BEP800 was well tolerated and induced robust antitumor responses in tumor xenograft models, including regression in the BT-474 breast cancer model.  In these tumor models, NVP-BEP800 modulated Hsp90 client proteins and downstream signaling pathways at doses causing antitumor activity.  NVP-BEP800 showed in vivo activity in a variety of dosing regimens covering daily to weekly schedules, potentially providing a high degree of flexibility in dose and schedule within the clin. setting.  Overall, given the mechanism of action, preclin. activity profile, tolerability, and pharmaceutical properties, NVP-BEP800 is an exciting new oral Hsp90 inhibitor warranting further development.  Mol Cancer Ther; 9(4); 906-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWkCBDzOlzZ7Vg90H21EOLACvtfcHk0lifm01x2Nxhdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktlCqt7s%253D&md5=8b52241a44d2fdd2a38aa7edaa99101c</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0055%26sid%3Dliteratum%253Aachs%26aulast%3DMassey%26aufirst%3DA.%2BJ.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DBrough%26aufirst%3DP.%2BA.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DPfaar%26aufirst%3DU.%26aulast%3DRadimerski%26aufirst%3DT.%26aulast%3DRuetz%26aufirst%3DS.%26aulast%3DSchweitzer%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520the%2520orally%2520available%2520heat%2520shock%2520protein%252090%2520inhibitor%2520NVP-BEP800%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D906%26epage%3D919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopeck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moynahan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannan, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C.</span><span> </span><span class="NLM_article-title">Hsp90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with Her-2 positive metastatic breast cancer progressing on trastuzumab</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5132</span><span class="NLM_x">–</span> <span class="NLM_lpage">5139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1078-0432.CCR-11-0072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=21558407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=5132-5139&author=S.+Modiauthor=A.+Stopeckauthor=A.+Lindenauthor=D.+Solitauthor=S.+Chandarlapatyauthor=N.+Rosenauthor=G.+D%E2%80%99Andreaauthor=M.+Dicklerauthor=M.+E.+Moynahanauthor=S.+Sugarmanauthor=W.+Maauthor=S.+Patilauthor=L.+Nortonauthor=A.+L.+Hannanauthor=C.+Hudis&title=Hsp90+inhibition+is+effective+in+breast+cancer%3A+a+phase+II+trial+of+tanespimycin+%2817-AAG%29+plus+trastuzumab+in+patients+with+Her-2+positive+metastatic+breast+cancer+progressing+on+trastuzumab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab</span></div><div class="casAuthors">Modi, Shanu; Stopeck, Alison; Linden, Hannah; Solit, David; Chandarlapaty, Sarat; Rosen, Neal; D'Andrea, Gabriella; Dickler, Maura; Moynahan, Mary E.; Sugarman, Steven; Ma, Weining; Patil, Sujata; Norton, Larry; Hannah, Alison L.; Hudis, Clifford</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5132-5139</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: HSP90 is a chaperone protein required for the stability of a variety of client proteins. 17-Demethoxygeldanamycin (17-AAG) is a natural product that binds to HSP90 and inhibits its activity, thereby inducing the degrdn. of these clients.  In preclin. studies, HER2 is one of the most sensitive known client proteins of 17-AAG.  On the basis of these data and activity in a phase I study, we conducted a phase II study of 17-AAG (tanespimycin) with trastuzumab in advanced trastuzumab-refractory HER2-pos. breast cancer.  Exptl. Design: We enrolled patients with metastatic HER2+ breast cancer whose disease had previously progressed on trastuzumab.  All patients received weekly treatment with tanespimycin at 450 mg/m2 i.v. and trastuzumab at a conventional dose.  Therapy was continued until disease progression.  The primary endpoint was response rate by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.  RESULTS: Thirty-one patients were enrolled with a median age of 53 years and a median Karnofsky performance status (KPS) of 90%.  The most common toxicities, largely grade 1, were diarrhea, fatigue, nausea, and headache.  The overall response rate was 22%, the clin. benefit rate [complete response + partial response + stable disease] was 59%, the median progression-free survival was 6 mo (95% CI: 4-9), and the median overall survival was 17 mo (95% CI: 16-28).  CONCLUSIONS: This is the first phase II study to definitively show RECIST-defined responses for 17-AAG in solid tumors.  Tanespimycin plus trastuzumab has significant anticancer activity in patients with HER2-pos., metastatic breast cancer previously progressing on trastuzumab.  Further research exploring this therapeutic interaction and the activity of HSP90 inhibitors is clearly warranted.  Clin Cancer Res; 17(15); 5132-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFgVCzhN1fHLVg90H21EOLACvtfcHk0lifm01x2Nxhdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbw%253D&md5=07d9e8e06caad7cd7abe03f9e9f7375a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0072%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DS.%26aulast%3DStopeck%26aufirst%3DA.%26aulast%3DLinden%26aufirst%3DA.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DDickler%26aufirst%3DM.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DHannan%26aufirst%3DA.%2BL.%26aulast%3DHudis%26aufirst%3DC.%26atitle%3DHsp90%2520inhibition%2520is%2520effective%2520in%2520breast%2520cancer%253A%2520a%2520phase%2520II%2520trial%2520of%2520tanespimycin%2520%252817-AAG%2529%2520plus%2520trastuzumab%2520in%2520patients%2520with%2520Her-2%2520positive%2520metastatic%2520breast%2520cancer%2520progressing%2520on%2520trastuzumab%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D5132%26epage%3D5139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Wong, K. K.; Koczywas, M.; Goldman, J. W.; Paschold, E. H.; Horn, L.; Lufkin, J. M.; Kepros, J.; Teofilici, F.; Shapiro, G.; Socinski, M. A.</span><span> </span><span class="NLM_article-title">An Open-Label Phase II Study of the Hsp90 Inhibitor Ganetespib. (STA-9090) as Monotherapy in Patients with Advanced NSCLC</span>. Presented at the ASCO Annual Meeting,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://www.syntapharma.com/Documents/Ganetespib_Phase%202%20NSCLC_Shapiro_ASCO%202011.pdf" class="extLink">http://www.syntapharma.com/Documents/Ganetespib_Phase%202%20NSCLC_Shapiro_ASCO%202011.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=K.+K.+Wong&author=M.+Koczywas&author=J.+W.+Goldman&author=E.+H.+Paschold&author=L.+Horn&author=J.+M.+Lufkin&author=J.+Kepros&author=F.+Teofilici&author=G.+Shapiro&author=M.+A.+Socinski&title=An+Open-Label+Phase+II+Study+of+the+Hsp90+Inhibitor+Ganetespib.+%28STA-9090%29+as+Monotherapy+in+Patients+with+Advanced+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DAn%2520Open-Label%2520Phase%2520II%2520Study%2520of%2520the%2520Hsp90%2520Inhibitor%2520Ganetespib.%2520%2528STA-9090%2529%2520as%2520Monotherapy%2520in%2520Patients%2520with%2520Advanced%2520NSCLC%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gettinger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senzer, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilenbaum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafeez, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayzel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borger, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natale, R.</span><span> </span><span class="NLM_article-title">Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">4953</span><span class="NLM_x">–</span> <span class="NLM_lpage">4960</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1200%2FJCO.2010.30.8338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=20940188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFCntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=4953-4960&author=L.+V.+Sequistauthor=S.+Gettingerauthor=N.+N.+Senzerauthor=R.+G.+Martinsauthor=P.+A.+J%C3%A4nneauthor=R.+Lilenbaumauthor=J.+E.+Grayauthor=A.+J.+Iafrateauthor=R.+Katayamaauthor=N.+Hafeezauthor=J.+Sweeneyauthor=J.+R.+Walkerauthor=C.+Fritzauthor=R.+W.+Rossauthor=D.+Grayzelauthor=J.+A.+Engelmanauthor=D.+R.+Borgerauthor=G.+Paezauthor=R.+Natale&title=Activity+of+IPI-504%2C+a+novel+heat-shock+protein+90+inhibitor%2C+in+patients+with+molecularly+defined+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Gettinger, Scott; Senzer, Neil N.; Martins, Renato G.; Janne, Pasi A.; Lilenbaum, Rogerio; Gray, Jhanelle E.; Iafrate, A. John; Katayama, Ryohei; Hafeez, Nafeeza; Sweeney, Jennifer; Walker, John R.; Fritz, Christian; Ross, Robert W.; Grayzel, David; Engelman, Jeffrey A.; Borger, Darrell R.; Paez, Guillermo; Natale, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4953-4960</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: IPI-504 is a novel, water-sol., potent inhibitor of heat-shock protein 90 (Hsp90).  Its potential anticancer activity has been validated in preclin. in vitro and in vivo models.  We studied the activity of IPI-504 after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced, molecularly defined non-small-cell lung cancer (NSCLC).  Patients and Methods: Patients with advanced NSCLC, prior treatment with EGFR TKIs, and tumor tissue available for mol. genotyping were enrolled in this prospective, nonrandomized, multicenter, phase II study of IPI-504 monotherapy.  The primary outcome was objective response rate (ORR).  Secondary aims included safety, progression-free survival (PFS), and anal. of activity by mol. subtypes.  Results: Seventy-six patients were enrolled between Dec. 2007 and May 2009 from 10 United States cancer centers.  An ORR of 7% (five of 76) was obsd. in the overall study population, 10% (four of 40) in patients who were EGFR wild-type, and 4% (one of 28) in those with EGFR mutations.  Although both EGFR groups were below the target ORR of 20%, among the three patients with an ALK gene rearrangement, two had partial responses and the third had prolonged stable disease (7.2 mo, 24% redn. in tumor size).  The most common adverse events included grades 1 and 2 fatigue, nausea, and diarrhea.  Grade 3 or higher liver function abnormalities were obsd. in nine patients (11.8%).  Conclusion: IPI-504 has clin. activity in patients with NSCLC, particularly among patients with ALK rearrangements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyleDQqYi1qLVg90H21EOLACvtfcHk0lhDG5oh_Dq33A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFCntA%253D%253D&md5=accaddc9ab9e334d40d513a70fbcd9ed</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.30.8338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.30.8338%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DGettinger%26aufirst%3DS.%26aulast%3DSenzer%26aufirst%3DN.%2BN.%26aulast%3DMartins%26aufirst%3DR.%2BG.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DLilenbaum%26aufirst%3DR.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DHafeez%26aufirst%3DN.%26aulast%3DSweeney%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DFritz%26aufirst%3DC.%26aulast%3DRoss%26aufirst%3DR.%2BW.%26aulast%3DGrayzel%26aufirst%3DD.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DBorger%26aufirst%3DD.%2BR.%26aulast%3DPaez%26aufirst%3DG.%26aulast%3DNatale%26aufirst%3DR.%26atitle%3DActivity%2520of%2520IPI-504%252C%2520a%2520novel%2520heat-shock%2520protein%252090%2520inhibitor%252C%2520in%2520patients%2520with%2520molecularly%2520defined%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D4953%26epage%3D4960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">7535</span><span class="NLM_x">–</span> <span class="NLM_lpage">7540</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebiauthor=V.+M.+Riveraauthor=W.+C.+Shakespeareauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Therapeutic+strategies+to+overcome+crizotinib+resistance+in+non-small+cell+lung+cancers+harboring+the+fusion+oncogene+EML4-ALK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520strategies%2520to%2520overcome%2520crizotinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancers%2520harboring%2520the%2520fusion%2520oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D7535%26epage%3D7540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Richardson, P G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanan-Khan, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonial, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">153</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="NLM_x">–</span> <span class="NLM_lpage">740</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1111%2Fj.1365-2141.2011.08664.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=21534941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslajtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2011&pages=729-740&author=P+G.+Richardsonauthor=A.+A.+Chanan-Khanauthor=S.+Lonialauthor=A.+Y.+Krishnanauthor=M.+P.+Carrollauthor=M.+Alsinaauthor=M.+Albitarauthor=D.+Bermanauthor=M.+Messinaauthor=K.+C.+Anderson&title=Tanespimycin+and+bortezomib+combination+treatment+in+patients+with+relapsed+or+relapsed+and+refractory+multiple+myeloma%3A+results+of+a+phase+1%2F2+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study</span></div><div class="casAuthors">Richardson, Paul G.; Chanan-Khan, Asher A.; Lonial, Sagar; Krishnan, Amrita Y.; Carroll, Michael P.; Alsina, Melissa; Albitar, Maher; Berman, David; Messina, Marianne; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">729-740</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">This open-label, dose escalation, multicentre phase 1/2 trial was undertaken to det. the safety and tolerability of the heat shock protein 90 (HSP90) inhibitor tanespimycin (100-340 mg/m2) + bortezomib (0.7-1.3 mg/m2) given on days 1, 4, 8 and 11 in each 21-d cycle.  Phase 2 expansion occurred at the highest tested dose of tanespimycin at 340 mg/m2 and bortezomib at 1.3 mg/m2.  Seventy-two patients (median age, 60 years) with relapsed or relapsed and refractory multiple myeloma (MM) were enrolled; 63 patients (89%) completed the study.  Tanespimycin in combination with bortezomib was well tolerated; few patients experienced significant neutropenia, constipation and anorexia (<10%), and no patients developed severe peripheral neuropathy.  Among 67 efficacy-evaluable patients, there were 2 (3%) complete responses and 8 (12%) partial responses, for an objective response rate (ORR) of 27%, including 8 (12%) minimal responses.  Response rates were highest among bortezomib-naive patients and proved durable in all patient subgroups, including those with bortezomib-refractory disease.  Pharmacodynamic analyses indicated that tanespimycin plus bortezomib effectively inhibited the proteasome, as evidenced by decreased 20S proteasome activity, and inhibited HSP90, as reflected by increased HSP70 expression.  The results of this study support addnl. studies of this combination approach in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw1MlwVkziIrVg90H21EOLACvtfcHk0lgQEzUVd3XYwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslajtrY%253D&md5=c1d4ac3b4758b8830cf2b192979e3961</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2011.08664.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2011.08664.x%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP%2BG.%26aulast%3DChanan-Khan%26aufirst%3DA.%2BA.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DKrishnan%26aufirst%3DA.%2BY.%26aulast%3DCarroll%26aufirst%3DM.%2BP.%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DBerman%26aufirst%3DD.%26aulast%3DMessina%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DTanespimycin%2520and%2520bortezomib%2520combination%2520treatment%2520in%2520patients%2520with%2520relapsed%2520or%2520relapsed%2520and%2520refractory%2520multiple%2520myeloma%253A%2520results%2520of%2520a%2520phase%25201%252F2%2520study%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2011%26volume%3D153%26spage%3D729%26epage%3D740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laubach, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonial, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanan-Khan, A. A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1111%2Fj.1365-2141.2010.08360.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=21219297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtVOntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2011&pages=367-379&author=P.+G.+Richardsonauthor=C.+S.+Mitsiadesauthor=J.+P.+Laubachauthor=S.+Lonialauthor=A.+A+Chanan-Khanauthor=K.+C.+Anderson&title=Inhibition+of+heat+shock+protein+90+%28HSP90%29+as+a+therapeutic+strategy+for+the+treatment+of+myeloma+and+other+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers</span></div><div class="casAuthors">Richardson, Paul G.; Mitsiades, Constantine S.; Laubach, Jacob P.; Lonial, Sagar; Chanan-Khan, Asher A.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">367-379</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Heat shock protein 90 (HSP90) is a mol. chaperone that is induced in response to cellular stress and stabilizes client proteins involved in cell cycle control and proliferative/anti-apoptotic signalling.  HSP90 is overexpressed in a range of cancers, and may contribute to tumor cell survival by stabilizing aberrant signalling proteins and by interfering with apoptosis.  Tanespimycin, an HSP90 inhibitor, reduces tumor cell survival in vitro.  In multiple myeloma (MM), HSP90 inhibition affects multiple client proteins that contribute to tumor cell survival, including the IGF1 receptor and the IL-6 receptor, and elements of the PI3/Akt, STAT3, and MAPK signalling pathways.  HSP90 inhibition also abrogates the protective effect of bone marrow stromal cells and inhibits angiogenesis and osteoclastogenesis.  Tanespimycin acts synergistically with the proteasome inhibitor bortezomib in MM cells and tumor explants, possibly reducing their ability to resist bortezomib-induced stress to the endoplasmic reticulum.  The combination of tanespimycin and bortezomib has demonstrated significant and durable responses with acceptable toxicity in a phase I/II study in patients with relapsed and relapsed/refractory MM.  HSP90 inhibition is a promising strategy in MM esp. in combination with bortezomib; addnl. studies will further evaluate optimal dosings of candidate drugs and schedules, as well as confirm efficacy in comparative phase III trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9tsEVNXnwwrVg90H21EOLACvtfcHk0lgQEzUVd3XYwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtVOntr4%253D&md5=2ec48571564edbf6ec2bcab69baf01a2</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2010.08360.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2010.08360.x%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DChanan-Khan%26aufirst%3DA.%2BA%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DInhibition%2520of%2520heat%2520shock%2520protein%252090%2520%2528HSP90%2529%2520as%2520a%2520therapeutic%2520strategy%2520for%2520the%2520treatment%2520of%2520myeloma%2520and%2520other%2520cancers%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2011%26volume%3D152%26spage%3D367%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Yin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundgren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shores, C. G.</span><span> </span><span class="NLM_article-title">BIIB021, a novel Hsp90 inhibitor, sensitized head and neck squamous cell carcinoma to radiotherapy</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">1216</span><span class="NLM_x">–</span> <span class="NLM_lpage">1225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=19662650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFCr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=1216-1225&author=Z.+Yinauthor=H.+Zhangauthor=K.+Lundgrenauthor=L.+Wilsonauthor=F.+Burrowsauthor=C.+G.+Shores&title=BIIB021%2C+a+novel+Hsp90+inhibitor%2C+sensitized+head+and+neck+squamous+cell+carcinoma+to+radiotherapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy</span></div><div class="casAuthors">Yin, Xiaoying; Zhang, Hong; Lundgren, Karen; Wilson, Lynn; Burrows, Francis; Shores, Carol G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1216-1225</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a mol. chaperone that promotes the conformational maturation of numerous client proteins, many of which play crit. roles in tumor cell growth and survival.  The ansamycin-based Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) is currently in Phase III clin. testing.  However, 17-AAG is difficult to formulate and assocd. with dose-limited toxicity issues.  A fully synthetic and bioavailable Hsp90 inhibitor, BIIB021, was evaluated for antitumor activity in a variety of head and neck squamous cell carcinoma (HNSCC) cell lines and HNSCC xenograft models, either as a single agent or in combination with fractionated radiation and the results were compared with that of 17-AAG.  BIIB021 showed strong antitumor activity, comparable with, and in certain instances, superior to 17-AAG.  BIIB021 enhanced the in vitro radiosensitivity of HNSCCA cell lines with a corresponding redn. in the expression of key radioresponsive proteins, increased apoptotic cells and enhance G2 arrest.  In xenograft studies, BIIB021 exhibited a strong antitumor effect outperforming 17-AAG, either as a single agent and or in combination with radiation, thereby improved the efficacy of radiation.  These results suggest that this synthetic and bioavailable Hsp90 inhibitor affects multiple pathways involved in tumor development and progression in the HNSCC setting and may represent a better strategy for the treatment of HNSCC patients, either as a monotherapy or a radiosensitizer.  Furthermore, it also demonstrates the benefits of using preclin. models of chemosensitization to radiotherapy to explore clin. relevant radiation dosing schemes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOA3e86hmal7Vg90H21EOLACvtfcHk0lgQEzUVd3XYwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFCr&md5=e06436d60f7a79e43d68ec1064d1f6fd</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DL.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DShores%26aufirst%3DC.%2BG.%26atitle%3DBIIB021%252C%2520a%2520novel%2520Hsp90%2520inhibitor%252C%2520sensitized%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%2520to%2520radiotherapy%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2010%26volume%3D126%26spage%3D1216%26epage%3D1225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Infante, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brega, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Hoff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, R.</span><span> </span><span class="NLM_article-title">Phase 1 dose escalation study of the oral heat shock protein 90 (Hsp90) inhibitor PF-04929113/SNX-5422 (PF-113) and its associated ocular toxicity</span> <span class="citation_source-journal">EJC Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1016%2FS1359-6349%2810%2972082-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=119&author=J.+Infanteauthor=G.+Weissauthor=S.+Jonesauthor=R.+Tibesauthor=J.+Bendellauthor=N.+Bregaauthor=V.+Tortiauthor=D.+Von+Hoffauthor=H.+Burrisauthor=R.+Ramanathan&title=Phase+1+dose+escalation+study+of+the+oral+heat+shock+protein+90+%28Hsp90%29+inhibitor+PF-04929113%2FSNX-5422+%28PF-113%29+and+its+associated+ocular+toxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS1359-6349%2810%2972082-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6349%252810%252972082-6%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DTibes%26aufirst%3DR.%26aulast%3DBendell%26aufirst%3DJ.%26aulast%3DBrega%26aufirst%3DN.%26aulast%3DTorti%26aufirst%3DV.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26aulast%3DBurris%26aufirst%3DH.%26aulast%3DRamanathan%26aufirst%3DR.%26atitle%3DPhase%25201%2520dose%2520escalation%2520study%2520of%2520the%2520oral%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitor%2520PF-04929113%252FSNX-5422%2520%2528PF-113%2529%2520and%2520its%2520associated%2520ocular%2520toxicity%26jtitle%3DEJC%2520Suppl.%26date%3D2010%26volume%3D8%26spage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, K. H.; Eaves, J.; Veal, J.; Barta, T.; Lifeng, G.; Hinkley, L.; Hanson, G.</span><span> </span><span class="NLM_article-title">Tetrahydroindolone and Tetrahydroindazolone Derivatives</span>, WO 2006/091963,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=K.+H.+Huang&author=J.+Eaves&author=J.+Veal&author=T.+Barta&author=G.+Lifeng&author=L.+Hinkley&author=G.+Hanson&title=Tetrahydroindolone+and+Tetrahydroindazolone+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DK.%2BH.%26atitle%3DTetrahydroindolone%2520and%2520Tetrahydroindazolone%2520Derivatives%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Huang, K. H.; Eaves, J.; Veal, J.; Hall, S. E.; Barta, T. E.; Hanson, G. J.</span><span> </span><span class="NLM_article-title">Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives</span>. US 2007/0207984,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=K.+H.+Huang&author=J.+Eaves&author=J.+Veal&author=S.+E.+Hall&author=T.+E.+Barta&author=G.+J.+Hanson&title=Cyclohexylamino+Benzene%2C+Pyridine%2C+and+Pyridazine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DK.%2BH.%26atitle%3DCyclohexylamino%2520Benzene%252C%2520Pyridine%252C%2520and%2520Pyridazine%2520Derivatives%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Lundgren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brekken, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huser, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timple, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busch, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neely, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensintaffar, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenzie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannevin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, F. J.</span><span> </span><span class="NLM_article-title">BIIB021, an orally available, fully synthetic small molecule inhibitor of the heat shock protein HSP90</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">921</span><span class="NLM_x">–</span> <span class="NLM_lpage">929</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1535-7163.MCT-08-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=19372565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1amt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=921-929&author=K.+Lundgrenauthor=H.+Zhangauthor=J.+Brekkenauthor=N.+Huserauthor=R.+E.+Powellauthor=N.+Timpleauthor=D.+J.+Buschauthor=L.+Neelyauthor=J.+L.+Sensintaffarauthor=Y.-C.+Yangauthor=A.+McKenzieauthor=J.+Friedmanauthor=R.+Scannevinauthor=A.+Kamalauthor=K.+Hongauthor=S.+R.+Kasibhatlaauthor=M.+F.+Boehmauthor=F.+J.+Burrows&title=BIIB021%2C+an+orally+available%2C+fully+synthetic+small+molecule+inhibitor+of+the+heat+shock+protein+HSP90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90</span></div><div class="casAuthors">Lundgren, Karen; Zhang, Hong; Brekken, John; Huser, Nanni; Powell, Rachel E.; Timple, Noel; Busch, David J.; Neely, Laura; Sensintaffar, John L.; Yang, Yong-ching; McKenzie, Andres; Friedman, Jessica; Scannevin, Robert; Kamal, Adeela; Hong, Kevin; Kasibhatla, Srinivas R.; Boehm, Marcus F.; Burrows, Francis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">921-929</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inhibition of heat shock protein 90 (Hsp90) results in the degrdn. of oncoproteins that drive malignant progression, inducing cell death, making Hsp90 a target of substantial interest for cancer therapy.  BIIB021 is a novel, fully synthetic inhibitor of Hsp90 that binds competitively with geldanamycin in the ATP-binding pocket of Hsp90.  In tumor cells, BIIB021 induced the degrdn. of Hsp90 client proteins including HER-2, AKT, and Raf-1 and up-regulated expression of the heat shock proteins Hsp70 and Hsp27.  BIIB021 treatment resulted in growth inhibition and cell death in cell lines from a variety of tumor types at nanomolar concns.  Oral administration of BIIB021 led to the degrdn. of Hsp90 client proteins measured in tumor tissue and resulted in the inhibition of tumor growth in several human tumor xenograft models.  Studies to investigate the antitumor effects of BIIB021 showed activity on both daily and intermittent dosing schedules, providing dose schedule flexibility for clin. studies.  Assays measuring the HER-2 protein in tumor tissue and the HER-2 extracellular domain in plasma were used to show interdiction of the Hsp90 pathway and utility as potential biomarkers in clin. trials for BIIB021.  Together, these data show that BIIB021 is a promising new oral inhibitor of Hsp90 with antitumor activity in preclin. models.[Mol Cancer Ther 2009;8(4):921-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSbI2RYG4aF7Vg90H21EOLACvtfcHk0lhuqOKsyXfLuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1amt74%253D&md5=271e2311ab807bc74b2ac66b81e514e1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0758%26sid%3Dliteratum%253Aachs%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBrekken%26aufirst%3DJ.%26aulast%3DHuser%26aufirst%3DN.%26aulast%3DPowell%26aufirst%3DR.%2BE.%26aulast%3DTimple%26aufirst%3DN.%26aulast%3DBusch%26aufirst%3DD.%2BJ.%26aulast%3DNeely%26aufirst%3DL.%26aulast%3DSensintaffar%26aufirst%3DJ.%2BL.%26aulast%3DYang%26aufirst%3DY.-C.%26aulast%3DMcKenzie%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DJ.%26aulast%3DScannevin%26aufirst%3DR.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DKasibhatla%26aufirst%3DS.%2BR.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26atitle%3DBIIB021%252C%2520an%2520orally%2520available%252C%2520fully%2520synthetic%2520small%2520molecule%2520inhibitor%2520of%2520the%2520heat%2520shock%2520protein%2520HSP90%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D921%26epage%3D929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Miller, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravikumar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suh, J.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerwin, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertus, J. D.</span><span> </span><span class="NLM_article-title">Structure-based and characterization of novel platforms for ricin and shiga toxin inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm010186s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=90-98&author=D.+J.+Millerauthor=K.+Ravikumarauthor=H.+Shenauthor=J.-K.+Suhauthor=S.+M.+Kerwinauthor=J.+D.+Robertus&title=Structure-based+and+characterization+of+novel+platforms+for+ricin+and+shiga+toxin+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm010186s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010186s%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DD.%2BJ.%26aulast%3DRavikumar%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSuh%26aufirst%3DJ.-K.%26aulast%3DKerwin%26aufirst%3DS.%2BM.%26aulast%3DRobertus%26aufirst%3DJ.%2BD.%26atitle%3DStructure-based%2520and%2520characterization%2520of%2520novel%2520platforms%2520for%2520ricin%2520and%2520shiga%2520toxin%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D90%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Taylor, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhnt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinzel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grindey, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barredo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jannatipour, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, R. G.</span><span> </span><span class="NLM_article-title">A dideazatetrahydrofolate analog lacking a chiral center at C-6: <i>N</i>-[4-[2-(2-amino-3,4-dihydro-4-oxo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-5yl)ethyl[benzoyl]-<span class="smallcaps smallerCapital">l</span>-glutamic acid is an inhibitor of thymidylate synthase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">4450</span><span class="NLM_x">–</span> <span class="NLM_lpage">4454</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00101a023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=4450-4454&author=E.+C.+Taylorauthor=D.+Kuhntauthor=C.+Shihauthor=S.+M.+Rinzelauthor=G.+B.+Grindeyauthor=J.+Barredoauthor=M.+Jannatipourauthor=R.+G.+Moran&title=A+dideazatetrahydrofolate+analog+lacking+a+chiral+center+at+C-6%3A+N-%5B4-%5B2-%282-amino-3%2C4-dihydro-4-oxo-7H-pyrrolo%5B2%2C3-d%5Dpyrimidin-5yl%29ethyl%5Bbenzoyl%5D-l-glutamic+acid+is+an+inhibitor+of+thymidylate+synthase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm00101a023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00101a023%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DE.%2BC.%26aulast%3DKuhnt%26aufirst%3DD.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DRinzel%26aufirst%3DS.%2BM.%26aulast%3DGrindey%26aufirst%3DG.%2BB.%26aulast%3DBarredo%26aufirst%3DJ.%26aulast%3DJannatipour%26aufirst%3DM.%26aulast%3DMoran%26aufirst%3DR.%2BG.%26atitle%3DA%2520dideazatetrahydrofolate%2520analog%2520lacking%2520a%2520chiral%2520center%2520at%2520C-6%253A%2520N-%255B4-%255B2-%25282-amino-3%252C4-dihydro-4-oxo-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-5yl%2529ethyl%255Bbenzoyl%255D-l-glutamic%2520acid%2520is%2520an%2520inhibitor%2520of%2520thymidylate%2520synthase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D4450%26epage%3D4454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisliuk, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haile, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobrero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuire, J. J.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological activities of classical <i>N</i>-{4-[2-(2-amino-4-ethylpyrrolo[2,3-<i>d</i>]pyrimidin-5-yl)ethyl]benzoyl}-<span class="smallcaps smallerCapital">l</span>-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase as potential antitumor agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0203534" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=591-600&author=A.+Gangjeeauthor=J.+Yuauthor=R.+L.+Kisliukauthor=W.+H.+Haileauthor=G.+Sobreroauthor=J.+J.+McGuire&title=Design%2C+synthesis%2C+and+biological+activities+of+classical+N-%7B4-%5B2-%282-amino-4-ethylpyrrolo%5B2%2C3-d%5Dpyrimidin-5-yl%29ethyl%5Dbenzoyl%7D-l-glutamic+acid+and+its+6-methyl+derivative+as+potential+dual+inhibitors+of+thymidylate+synthase+and+dihydrofolate+reductase+as+potential+antitumor+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0203534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0203534%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26aulast%3DHaile%26aufirst%3DW.%2BH.%26aulast%3DSobrero%26aufirst%3DG.%26aulast%3DMcGuire%26aufirst%3DJ.%2BJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520activities%2520of%2520classical%2520N-%257B4-%255B2-%25282-amino-4-ethylpyrrolo%255B2%252C3-d%255Dpyrimidin-5-yl%2529ethyl%255Dbenzoyl%257D-l-glutamic%2520acid%2520and%2520its%25206-methyl%2520derivative%2520as%2520potential%2520dual%2520inhibitors%2520of%2520thymidylate%2520synthase%2520and%2520dihydrofolate%2520reductase%2520as%2520potential%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D591%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Shih, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gossett, L. S.</span><span> </span><span class="NLM_article-title">The synthesis of <i>N</i>-{2-amino-4-substituted [(pyrrolo[2,3-<i>d</i>]pyrimidin-5-yl)ethyl]benzoyl}-<span class="smallcaps smallerCapital">l</span>-glutamic acids as antineoplastic agents</span> <span class="citation_source-journal">Heterocycles</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">825</span><span class="NLM_x">–</span> <span class="NLM_lpage">841</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1993&pages=825-841&author=C.+Shihauthor=L.+S.+Gossett&title=The+synthesis+of+N-%7B2-amino-4-substituted+%5B%28pyrrolo%5B2%2C3-d%5Dpyrimidin-5-yl%29ethyl%5Dbenzoyl%7D-l-glutamic+acids+as+antineoplastic+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShih%26aufirst%3DC.%26aulast%3DGossett%26aufirst%3DL.%2BS.%26atitle%3DThe%2520synthesis%2520of%2520N-%257B2-amino-4-substituted%2520%255B%2528pyrrolo%255B2%252C3-d%255Dpyrimidin-5-yl%2529ethyl%255Dbenzoyl%257D-l-glutamic%2520acids%2520as%2520antineoplastic%2520agents%26jtitle%3DHeterocycles%26date%3D1993%26volume%3D35%26spage%3D825%26epage%3D841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Seela, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span> </span><span class="NLM_article-title">Regioselective syntheses of 7-halogenated 7-deazapurine nucleosides related to 2-amino-7-deaza-2′-deoxyadenosine and 7-deaza-2′-deoxyisoguanosine</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_fpage">1203</span><span class="NLM_x">–</span> <span class="NLM_lpage">1210</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1055%2Fs-2004-822382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltFCqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=1203-1210&author=F.+Seelaauthor=X.+Peng&title=Regioselective+syntheses+of+7-halogenated+7-deazapurine+nucleosides+related+to+2-amino-7-deaza-2%E2%80%B2-deoxyadenosine+and+7-deaza-2%E2%80%B2-deoxyisoguanosine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective syntheses of 7-halogenated 7-deazapurine nucleosides related to 2-amino-7-deaza-2'-deoxyadenosine and 7-deaza-2'-deoxyisoguanosine</span></div><div class="casAuthors">Seela, Frank; Peng, Xiaohua</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1203-1210</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">The syntheses of 7-halogenated derivs. of 2-amino-7-deaza-2'-deoxyadenosine as well as 7-bromo and 7-chloro-7-deaza-2'-deoxyisoguanosines are described.  Nucleobase anion glycosylation was employed for the convergent nucleoside synthesis.  The regioselective 7-halogenation was performed either on the nucleoside precursor or on the nucleobase.  Two bromo substituents were introduced in the 7- and 8-position when the unprotected 2-amino nucleoside 9 was used.  Conformational anal. of the sugar moiety of nucleosides was performed on the basis of vicinal 1H, 1H NMR coupling consts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2GYJJcH-6ibVg90H21EOLACvtfcHk0ljqdQDh9Q-MNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltFCqsLs%253D&md5=0441eb21091a9e2c0e9565c3d944ea30</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1055%2Fs-2004-822382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2004-822382%26sid%3Dliteratum%253Aachs%26aulast%3DSeela%26aufirst%3DF.%26aulast%3DPeng%26aufirst%3DX.%26atitle%3DRegioselective%2520syntheses%2520of%25207-halogenated%25207-deazapurine%2520nucleosides%2520related%2520to%25202-amino-7-deaza-2%25E2%2580%25B2-deoxyadenosine%2520and%25207-deaza-2%25E2%2580%25B2-deoxyisoguanosine%26jtitle%3DSynthesis%26date%3D2004%26spage%3D1203%26epage%3D1210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Barnett, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobierski, M. E.</span><span> </span><span class="NLM_article-title">A convenient method for regioselective C-5 halogenation of 4(3<i>H</i>)-oxo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidines</span> <span class="citation_source-journal">J. Heterocycl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1181</span><span class="NLM_x">–</span> <span class="NLM_lpage">1183</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1994&pages=1181-1183&author=C.+J.+Barnettauthor=M.+E.+Kobierski&title=A+convenient+method+for+regioselective+C-5+halogenation+of+4%283H%29-oxo-7H-pyrrolo%5B2%2C3-d%5Dpyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarnett%26aufirst%3DC.%2BJ.%26aulast%3DKobierski%26aufirst%3DM.%2BE.%26atitle%3DA%2520convenient%2520method%2520for%2520regioselective%2520C-5%2520halogenation%2520of%25204%25283H%2529-oxo-7H-pyrrolo%255B2%252C3-d%255Dpyrimidines%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1994%26volume%3D31%26spage%3D1181%26epage%3D1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Tu, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huebener, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dettner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francke, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McErlean, C. S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitching, W.</span><span> </span><span class="NLM_article-title">Synthesis and stereochemistry of insect derived spiroacetals with branched carbon skeletons</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1956</span><span class="NLM_x">–</span> <span class="NLM_lpage">1978</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1055%2Fs-2000-8232" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=1956-1978&author=Y.+Q.+Tuauthor=A.+Huebenerauthor=H.+Zhangauthor=C.+J.+Mooreauthor=M.+T.+Fletcherauthor=P.+Hayesauthor=K.+Dettnerauthor=W.+Franckeauthor=C.+S.+P.+McErleanauthor=W.+Kitching&title=Synthesis+and+stereochemistry+of+insect+derived+spiroacetals+with+branched+carbon+skeletons"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1055%2Fs-2000-8232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2000-8232%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DY.%2BQ.%26aulast%3DHuebener%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMoore%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DM.%2BT.%26aulast%3DHayes%26aufirst%3DP.%26aulast%3DDettner%26aufirst%3DK.%26aulast%3DFrancke%26aufirst%3DW.%26aulast%3DMcErlean%26aufirst%3DC.%2BS.%2BP.%26aulast%3DKitching%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520stereochemistry%2520of%2520insect%2520derived%2520spiroacetals%2520with%2520branched%2520carbon%2520skeletons%26jtitle%3DSynthesis%26date%3D2000%26volume%3D13%26spage%3D1956%26epage%3D1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="note"><p class="first last">The sterically bulky <i>gem</i>-dimethyl group of <b>40</b> was designed to maximize the metabolic stability of <b>40</b> by simultaneously hindering any potential phase I metabolism at the adjacent propargylic position and any potential phase II metabolism of the OH group. This may be a reason for the improved pharmacokinetic properties.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Yun, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harning, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giza, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabah, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchetti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biamonte, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundgren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kehry, M. R.</span><span> </span><span class="NLM_article-title">EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">186</span><span class="NLM_x">, </span> <span class="NLM_fpage">563</span><span class="NLM_x">–</span> <span class="NLM_lpage">575</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2011&pages=563-575&author=T.+J.+Yunauthor=E.+K.+Harningauthor=K.+Gizaauthor=D.+Rabahauthor=P.+Liauthor=J.+W.+Arndtauthor=D.+Luchettiauthor=M.+A.+Biamonteauthor=J.+Shiauthor=K.+Lundgrenauthor=A.+Manningauthor=M.+R.+Kehry&title=EC144%2C+a+synthetic+inhibitor+of+heat+shock+protein+90%2C+blocks+innate+and+adaptive+immune+responses+in+models+of+inflammation+and+autoimmunity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DT.%2BJ.%26aulast%3DHarning%26aufirst%3DE.%2BK.%26aulast%3DGiza%26aufirst%3DK.%26aulast%3DRabah%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DArndt%26aufirst%3DJ.%2BW.%26aulast%3DLuchetti%26aufirst%3DD.%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DManning%26aufirst%3DA.%26aulast%3DKehry%26aufirst%3DM.%2BR.%26atitle%3DEC144%252C%2520a%2520synthetic%2520inhibitor%2520of%2520heat%2520shock%2520protein%252090%252C%2520blocks%2520innate%2520and%2520adaptive%2520immune%2520responses%2520in%2520models%2520of%2520inflammation%2520and%2520autoimmunity%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D186%26spage%3D563%26epage%3D575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="note"><p class="first last">Compounds <b>14</b> and <b>40</b> were dosed in 0.1 N HCl for the xenograft models.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blower, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadée, W.</span><span> </span><span class="NLM_article-title">Chemogenomic analysis indentifies geldanamycins as substrated and inhibitors of ABCB1</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1702</span><span class="NLM_x">–</span> <span class="NLM_lpage">1712</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=1702-1712&author=Y.+Huangauthor=P.+E.+Blowerauthor=R.+Liuauthor=Z.+Daiauthor=A.+N.+Phamauthor=H.+Moonauthor=J.+Fangauthor=W.+Sad%C3%A9e&title=Chemogenomic+analysis+indentifies+geldanamycins+as+substrated+and+inhibitors+of+ABCB1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DBlower%26aufirst%3DP.%2BE.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DDai%26aufirst%3DZ.%26aulast%3DPham%26aufirst%3DA.%2BN.%26aulast%3DMoon%26aufirst%3DH.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DSad%25C3%25A9e%26aufirst%3DW.%26atitle%3DChemogenomic%2520analysis%2520indentifies%2520geldanamycins%2520as%2520substrated%2520and%2520inhibitors%2520of%2520ABCB1%26jtitle%3DPharm.%2520Res.%26date%3D2007%26volume%3D9%26spage%3D1702%26epage%3D1712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neely, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timple, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, F.</span><span> </span><span class="NLM_article-title">BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">1226</span><span class="NLM_x">–</span> <span class="NLM_lpage">1234</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2009&pages=1226-1234&author=H.+Zhangauthor=L.+Neelyauthor=Y.-C.+Yangauthor=N.+Timpleauthor=F.+Burrows&title=BIIB021%2C+a+synthetic+Hsp90+inhibitor%2C+has+broad+application+against+tumors+with+acquired+multidrug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DNeely%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DY.-C.%26aulast%3DTimple%26aufirst%3DN.%26aulast%3DBurrows%26aufirst%3DF.%26atitle%3DBIIB021%252C%2520a%2520synthetic%2520Hsp90%2520inhibitor%252C%2520has%2520broad%2520application%2520against%2520tumors%2520with%2520acquired%2520multidrug%2520resistance%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2009%26volume%3D126%26spage%3D1226%26epage%3D1234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Luo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Heat shock protein 90: translation from cancer to Alzheimer’s disease treatment?</span> <span class="citation_source-journal">BMC Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">S7</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=S7&issue=Suppl.+2&author=W.+Luoauthor=A.+Rodinaauthor=G.+Chiosis&title=Heat+shock+protein+90%3A+translation+from+cancer+to+Alzheimer%E2%80%99s+disease+treatment%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DRodina%26aufirst%3DA.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DHeat%2520shock%2520protein%252090%253A%2520translation%2520from%2520cancer%2520to%2520Alzheimer%25E2%2580%2599s%2520disease%2520treatment%253F%26jtitle%3DBMC%2520Neurosci.%26date%3D2008%26volume%3D9%26issue%3DSuppl.%25202%26spage%3DS7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Luo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dou, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chip, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moulick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greengard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">9511</span><span class="NLM_x">–</span> <span class="NLM_lpage">9516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1073%2Fpnas.0701055104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=17517623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtlGqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=9511-9516&author=W.+Luoauthor=F.+Douauthor=A.+Rodinaauthor=S.+Chipauthor=J.+Kimauthor=Q.+Zhaoauthor=K.+Moulickauthor=J.+Aguirreauthor=N.+Wuauthor=P.+Greengardauthor=G.+Chiosis&title=Roles+of+heat-shock+protein+90+in+maintaining+and+facilitating+the+neurodegenerative+phenotype+in+tauopathies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies</span></div><div class="casAuthors">Luo, Wenjie; Dou, Fei; Rodina, Anna; Chip, Sophorn; Kim, Joungnam; Zhao, Qi; Moulick, Kamalika; Aguirre, Julia; Wu, Nian; Greengard, Paul; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9511-9516</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Neurodegeneration, a result of multiple dysregulatory events, is a lengthy multistep process manifested by accrual of mutant variants and abnormal expression, posttranslational modification, and processing of certain proteins.  Accumulation of these dysregulated processes requires a mechanism that maintains their functional stability and allows the evolution of the neurodegenerative phenotype.  In malignant cells, the capacity to buffer transformation has been attributed to heat-shock protein 90 (Hsp90).  Although normal proteins seem to require limited assistance from the chaperone, their aberrant counterparts seem to be highly dependent on Hsp90.  Whereas enhanced Hsp90 affinity for mutated or functionally deregulated client proteins has been obsd. for several oncoproteins, it is unknown whether Hsp90 plays a similar role for neuronal proteins and thus maintains and facilitates the transformed phenotype in neurodegenerative diseases.  Tauopathies are neurodegenerative diseases characterized by aberrant phosphorylation and/or expression of Tau protein, leading to a time-dependent accumulation of Tau aggregates and subsequent neuronal death.  Here, we show that the stability of p35, a neuronal protein that activates cyclin-dependent protein kinase 5 through complex formation leading to aberrant Tau phosphorylation, and that of mutant but not WT Tau protein is maintained in tauopathies by Hsp90.  Inhibition of Hsp90 in cellular and mouse models of tauopathies leads to a redn. of the pathogenic activity of these proteins and results in elimination of aggregated Tau.  The results identify important roles played by Hsp90 in maintaining and facilitating the degenerative phenotype in these diseases and provide a common principle governing cancer and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcCkJP_DiSK7Vg90H21EOLACvtfcHk0ljsfRkQK8A0rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtlGqsr4%253D&md5=232a72b98067db9340561258ebb6fcb8</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0701055104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0701055104%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DDou%26aufirst%3DF.%26aulast%3DRodina%26aufirst%3DA.%26aulast%3DChip%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DMoulick%26aufirst%3DK.%26aulast%3DAguirre%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DN.%26aulast%3DGreengard%26aufirst%3DP.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DRoles%2520of%2520heat-shock%2520protein%252090%2520in%2520maintaining%2520and%2520facilitating%2520the%2520neurodegenerative%2520phenotype%2520in%2520tauopathies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D9511%26epage%3D9516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Dickey, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunmore, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrucelli, L.</span><span> </span><span class="NLM_article-title">HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=753-755&author=C.+A.+Dickeyauthor=J.+Dunmoreauthor=B.+Luauthor=J.-W.+Wangauthor=W.+C.+Leeauthor=A.+Kamalauthor=F.+Burrowsauthor=C.+Eckmanauthor=M.+Huttonauthor=L.+Petrucelli&title=HSP+induction+mediates+selective+clearance+of+tau+phosphorylated+at+proline-directed+Ser%2FThr+sites+but+not+KXGS+%28MARK%29+sites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDickey%26aufirst%3DC.%2BA.%26aulast%3DDunmore%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DJ.-W.%26aulast%3DLee%26aufirst%3DW.%2BC.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DEckman%26aufirst%3DC.%26aulast%3DHutton%26aufirst%3DM.%26aulast%3DPetrucelli%26aufirst%3DL.%26atitle%3DHSP%2520induction%2520mediates%2520selective%2520clearance%2520of%2520tau%2520phosphorylated%2520at%2520proline-directed%2520Ser%252FThr%2520sites%2520but%2520not%2520KXGS%2520%2528MARK%2529%2520sites%26jtitle%3DFASEB%2520J.%26date%3D2006%26volume%3D20%26spage%3D753%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Dickey, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckman, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrucelli, L.</span><span> </span><span class="NLM_article-title">Development of a high throughput drug screening assay for the detection of changes in tau levels—proof of concept with HSP90 inhibitors</span> <span class="citation_source-journal">Curr. Alzheimer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.2174%2F1567205053585927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=15974923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltVant7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=231-238&author=C.+A.+Dickeyauthor=J.+Eriksenauthor=A.+Kamalauthor=F.+Burrowsauthor=S.+Kasibhatlaauthor=C.+B.+Eckmanauthor=M.+Huttonauthor=L.+Petrucelli&title=Development+of+a+high+throughput+drug+screening+assay+for+the+detection+of+changes+in+tau+levels%E2%80%94proof+of+concept+with+HSP90+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a high throughput drug screening assay for the detection of changes in Tau levels - proof of concept with HSP90 inhibitors</span></div><div class="casAuthors">Dickey, Chad A.; Eriksen, Jason; Kamal, Adeela; Burrows, Francis; Kasibhatla, Srinivas; Eckman, Christopher B.; Hutton, Mike; Petrucelli, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">231-238</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Therapeutic development for Alzheimer's disease has largely focused on the removal of beta amyloid because of its suggested role in the primary agent in initiating the disease process.  However, with the recent discovery of mutations that result as pathol. buildup of tau in the absence of amyloid pathol., tau is beginning to be recognized as a potential target for drug discovery.  We have developed a high-throughput drug screening method that allows for direct intracellular quantitation of tau protein species, enabling the fast, reliable detection of these changes.  We have identified a family of small, blood brain barrier penetrant heat shock protein 90 inhibitors that significantly reduce tau protein levels in vitro.  Western blot anal. demonstrated a clear inverse correlation between the tau levels and the increase in HSP27, HSP40 and HSP90.  Modifications to this assay will further allow the specific anal. of pathol. relevant species.  Using this assay, we have demonstrated that a class of HSP90 inhibitors is able to significantly lower intracellular tau levels most likely through induction of a heat shock response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8QafNfAabPLVg90H21EOLACvtfcHk0ljsfRkQK8A0rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltVant7g%253D&md5=419ce21f9d5c342c266a58fbd804d7a8</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2174%2F1567205053585927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567205053585927%26sid%3Dliteratum%253Aachs%26aulast%3DDickey%26aufirst%3DC.%2BA.%26aulast%3DEriksen%26aufirst%3DJ.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DEckman%26aufirst%3DC.%2BB.%26aulast%3DHutton%26aufirst%3DM.%26aulast%3DPetrucelli%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520a%2520high%2520throughput%2520drug%2520screening%2520assay%2520for%2520the%2520detection%2520of%2520changes%2520in%2520tau%2520levels%25E2%2580%2594proof%2520of%2520concept%2520with%2520HSP90%2520inhibitors%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2005%26volume%3D2%26spage%3D231%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Salminen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojala, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaarniranta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiltunen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soininen, H.</span><span> </span><span class="NLM_article-title">Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer’s disease</span> <span class="citation_source-journal">Prog. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1016%2Fj.pneurobio.2010.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=21056617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A280%3ADC%252BC3M7mvFSitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2011&pages=99-110&author=A.+Salminenauthor=J.+Ojalaauthor=K.+Kaarnirantaauthor=M.+Hiltunenauthor=H.+Soininen&title=Hsp90+regulates+tau+pathology+through+co-chaperone+complexes+in+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease</span></div><div class="casAuthors">Salminen Antero; Ojala Johanna; Kaarniranta Kai; Hiltunen Mikko; Soininen Hilkka</div><div class="citationInfo"><span class="NLM_cas:title">Progress in neurobiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-110</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's disease is a tauopathy which involves the deposition of microtubule-associated tau proteins into neurofibrillary tangles.  Post-translational modifications, in particular site-specific phosphorylations, affect the conformation of tau protein which is an intrinsically disordered protein.  These structural changes significantly increase the affinity of tau protein for certain molecular chaperones.  Hsp90 is a major cellular chaperone which assembles large complexes with a variety of co-chaperones.  The main function of Hsp90 complexes is to maintain protein quality control and assist in protein degradation via proteasomal and autophagic-lysosomal pathways.  Tau protein is a client protein for these Hsp90 complexes.  If the tau protein is in an abnormal or modified form, then it can trigger the recruitment of CHIP protein, a co-chaperone with E3 activity, to the complex which induces the ubiquitination of tau protein and activates its downstream degradation processes.  Large immunophilins, FKBP51 and FKBP52 are also co-chaperones of Hsp90-tau complexes.  These proteins contain peptidylprolyl cis/trans isomerase activity which catalyzes phosphorylation-dependent rotation in pSer/Thr-Pro peptide bond.  The proline switch in the tau conformation triggers dephosphorylation of Ser/Thr residues phosphorylated, e.g. by two well-known tau kinases Cdk5 and GSK-3β.  Binding of PP5 protein phosphatase to Hsp90 complex, can also dephosphorylate tau protein.  Subsequently, dephosphorylated tau protein can be shuttled back to the microtubules.  It seems that high-affinity binding of abnormal tau to Hsp90 complexes may have some counteracting effects on the aggregation process, since Hsp90 inhibitors can ameliorate the aggregation process in several neurodegenerative diseases.  We will review the role of Hsp90 chaperone network in the regulation of tau biology and pathology in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIGys_IlOfaRe4jJGKT5N0fW6udTcc2ebpvevYPie1Rbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7mvFSitw%253D%253D&md5=92c5535c5b5bc12c8c0807ea338310d4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2010.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2010.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DSalminen%26aufirst%3DA.%26aulast%3DOjala%26aufirst%3DJ.%26aulast%3DKaarniranta%26aufirst%3DK.%26aulast%3DHiltunen%26aufirst%3DM.%26aulast%3DSoininen%26aufirst%3DH.%26atitle%3DHsp90%2520regulates%2520tau%2520pathology%2520through%2520co-chaperone%2520complexes%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DProg.%2520Neurobiol.%26date%3D2011%26volume%3D93%26spage%3D99%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5a','cit5b'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24a','cit24b'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':[],'ref34':['cit34'],'ref35':[],'ref36':['cit36a','cit36b'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 38 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Young K. Cheun, Arnold S. Groehler, IV, <span class="NLM_string-name hlFld-ContribAuthor">Orlando D. Schärer</span>. </span><span class="cited-content_cbyCitation_article-title">New Synthetic Analogs of Nitrogen Mustard DNA Interstrand Cross-Links and Their Use to Study Lesion Bypass by DNA Polymerases. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2021,</strong> <em>34 </em>
                                    (7)
                                     , 1790-1799. <a href="https://doi.org/10.1021/acs.chemrestox.1c00123" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.1c00123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.1c00123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.1c00123%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DNew%252BSynthetic%252BAnalogs%252Bof%252BNitrogen%252BMustard%252BDNA%252BInterstrand%252BCross-Links%252Band%252BTheir%252BUse%252Bto%252BStudy%252BLesion%252BBypass%252Bby%252BDNA%252BPolymerases%26aulast%3DCheun%26aufirst%3DYoung%2BK.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01042021%26date%3D16062021%26volume%3D34%26issue%3D7%26spage%3D1790%26epage%3D1799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chihoko Yoshimura, Satoru Nagatoishi, Daisuke Kuroda, Yasuo Kodama, Takao Uno, Makoto Kitade, Khoontee Chong-Takata, Hiromi Oshiumi, Hiromi Muraoka, Satoshi Yamashita, Yuichi Kawai, Shuichi Ohkubo, <span class="NLM_string-name hlFld-ContribAuthor">Kouhei Tsumoto</span>. </span><span class="cited-content_cbyCitation_article-title">Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2669-2677. <a href="https://doi.org/10.1021/acs.jmedchem.0c01715" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01715</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01715%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThermodynamic%252BDissection%252Bof%252BPotency%252Band%252BSelectivity%252Bof%252BCytosolic%252BHsp90%252BInhibitors%26aulast%3DYoshimura%26aufirst%3DChihoko%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29102020%26date%3D23022021%26volume%3D64%26issue%3D5%26spage%3D2669%26epage%3D2677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Tanaji T. Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Acetylene Group, Friend or Foe in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (11)
                                     , 5625-5663. <a href="https://doi.org/10.1021/acs.jmedchem.9b01617" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01617</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01617%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAcetylene%252BGroup%25252C%252BFriend%252Bor%252BFoe%252Bin%252BMedicinal%252BChemistry%26aulast%3DTalele%26aufirst%3DTanaji%2BT.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D29092019%26date%3D19022020%26date%3D07022020%26volume%3D63%26issue%3D11%26spage%3D5625%26epage%3D5663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Son Tung Ngo, Khanh B. Vu, Le Minh Bui, <span class="NLM_string-name hlFld-ContribAuthor">Van V. Vu</span>. </span><span class="cited-content_cbyCitation_article-title">Effective Estimation of Ligand-Binding Affinity Using Biased Sampling Method. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (2)
                                     , 3887-3893. <a href="https://doi.org/10.1021/acsomega.8b03258" title="DOI URL">https://doi.org/10.1021/acsomega.8b03258</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b03258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b03258%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DEffective%252BEstimation%252Bof%252BLigand-Binding%252BAffinity%252BUsing%252BBiased%252BSampling%252BMethod%26aulast%3DNgo%26aufirst%3DSon%2BTung%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D14122018%26date%3D08022019%26volume%3D4%26issue%3D2%26spage%3D3887%26epage%3D3893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ken Yamada, Yusuke Abe, Hirotaka Murase, Yuta Ida, Shinya Hagihara, <span class="NLM_string-name hlFld-ContribAuthor">Fumi Nagatsugi</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Properties of 2′-OMe-RNAs Modified with Cross-Linkable 7-Deazaguanosine Derivatives. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (16)
                                     , 8851-8862. <a href="https://doi.org/10.1021/acs.joc.8b01002" title="DOI URL">https://doi.org/10.1021/acs.joc.8b01002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b01002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b01002%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Band%252BProperties%252Bof%252B2%2525E2%252580%2525B2-OMe-RNAs%252BModified%252Bwith%252BCross-Linkable%252B7-Deazaguanosine%252BDerivatives%26aulast%3DYamada%26aufirst%3DKen%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D20042018%26date%3D27072018%26date%3D17072018%26volume%3D83%26issue%3D16%26spage%3D8851%26epage%3D8862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Tanaji T. Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (6)
                                     , 2166-2210. <a href="https://doi.org/10.1021/acs.jmedchem.7b00315" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00315</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00315%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNatural-Products-Inspired%252BUse%252Bof%252Bthe%252Bgem-Dimethyl%252BGroup%252Bin%252BMedicinal%252BChemistry%26aulast%3DTalele%26aufirst%3DTanaji%2BT.%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D27022017%26date%3D08092017%26date%3D29082017%26volume%3D61%26issue%3D6%26spage%3D2166%26epage%3D2210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fen  Jiang</span>, <span class="hlFld-ContribAuthor ">Hui-Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Yu-Hui  Jin</span>, <span class="hlFld-ContribAuthor ">Qiong  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhi-Hui  Wang</span>, <span class="hlFld-ContribAuthor ">Jian-Min  Jia</span>, <span class="hlFld-ContribAuthor ">Fang  Liu</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Qi-Chao  Bao</span>, <span class="hlFld-ContribAuthor ">Dong-Dong  Li</span>, <span class="hlFld-ContribAuthor ">Qi-Dong  You</span>, and <span class="hlFld-ContribAuthor ">Xiao-Li  Xu</span>  . </span><span class="cited-content_cbyCitation_article-title">Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (23)
                                     , 10498-10519. <a href="https://doi.org/10.1021/acs.jmedchem.6b00912" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00912</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00912%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BTetrahydropyrido%25255B4%25252C3-d%25255Dpyrimidines%252Bas%252BPotent%252BInhibitors%252Bof%252BChaperone%252BHeat%252BShock%252BProtein%252B90%26aulast%3DJiang%26aufirst%3DFen%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D17062016%26date%3D22112016%26date%3D08122016%26date%3D09112016%26volume%3D59%26issue%3D23%26spage%3D10498%26epage%3D10519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laurens M.  De Coen</span>, <span class="hlFld-ContribAuthor ">Thomas S. A.  Heugebaert</span>, <span class="hlFld-ContribAuthor ">Daniel  García</span>, and <span class="hlFld-ContribAuthor ">Christian V.  Stevens</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthetic Entries to and Biological Activity of Pyrrolopyrimidines. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2016,</strong> <em>116 </em>
                                    (1)
                                     , 80-139. <a href="https://doi.org/10.1021/acs.chemrev.5b00483" title="DOI URL">https://doi.org/10.1021/acs.chemrev.5b00483</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.5b00483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.5b00483%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DSynthetic%252BEntries%252Bto%252Band%252BBiological%252BActivity%252Bof%252BPyrrolopyrimidines%26aulast%3DDe%2BCoen%26aufirst%3DLaurens%2BM.%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D14082015%26date%3D23122015%26date%3D13012016%26volume%3D116%26issue%3D1%26spage%3D80%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Xianglin    Shi </span><span class="hlFld-ContribAuthor "> William F.    Kiesman </span><span class="hlFld-ContribAuthor "> Donald G.    Walker </span>. </span><span class="cited-content_cbyCitation_article-title">Development of Hsp90 Inhibitors for the Treatment of HER-2 Positive Solid Cancers. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 69-100. <a href="https://doi.org/10.1021/bk-2016-1239.ch003" title="DOI URL">https://doi.org/10.1021/bk-2016-1239.ch003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2016-1239.ch003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2016-1239.ch003%26sid%3Dliteratum%253Aachs%26atitle%3DDevelopment%252Bof%252BHsp90%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BHER-2%252BPositive%252BSolid%252BCancers%26aulast%3DShi%26aufirst%3DXianglin%26date%3D2016%26date%3D2016%26spage%3D69%26epage%3D100%26atitle%3DComprehensive%252BAccounts%252Bof%252BPharmaceutical%252BResearch%252Band%252BDevelopment%25253A%252BFrom%252BDiscovery%252Bto%252BLate-Stage%252BProcess%252BDevelopment%252BVolume%252B1%26aulast%3DAbdel-Magid%26aufirst%3DAhmed%2BF.%26date%3D2016%26date%3D2016%26volume%3D1239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian E.  Nordin</span>, <span class="hlFld-ContribAuthor ">Yongsheng  Liu</span>, <span class="hlFld-ContribAuthor ">Arwin  Aban</span>, <span class="hlFld-ContribAuthor ">Heidi E.  Brown</span>, <span class="hlFld-ContribAuthor ">Jiangyue  Wu</span>, <span class="hlFld-ContribAuthor ">Anna K.  Hainley</span>, <span class="hlFld-ContribAuthor ">Jonathan S.  Rosenblum</span>, <span class="hlFld-ContribAuthor ">Tyzoon K.  Nomanbhoy</span>, and <span class="hlFld-ContribAuthor ">John W.  Kozarich</span>  . </span><span class="cited-content_cbyCitation_article-title">ATP Acyl Phosphate Reactivity Reveals Native Conformations of Hsp90 Paralogs and Inhibitor Target Engagement. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2015,</strong> <em>54 </em>
                                    (19)
                                     , 3024-3036. <a href="https://doi.org/10.1021/acs.biochem.5b00148" title="DOI URL">https://doi.org/10.1021/acs.biochem.5b00148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.5b00148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.5b00148%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DATP%252BAcyl%252BPhosphate%252BReactivity%252BReveals%252BNative%252BConformations%252Bof%252BHsp90%252BParalogs%252Band%252BInhibitor%252BTarget%252BEngagement%26aulast%3DNordin%26aufirst%3DBrian%2BE.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D12022015%26date%3D23042015%26date%3D08052015%26date%3D19052015%26date%3D23042015%26volume%3D54%26issue%3D19%26spage%3D3024%26epage%3D3036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tony  Taldone</span>, <span class="hlFld-ContribAuthor ">Pallav D.  Patel</span>, <span class="hlFld-ContribAuthor ">Maulik  Patel</span>, <span class="hlFld-ContribAuthor ">Hardik J.  Patel</span>, <span class="hlFld-ContribAuthor ">Christopher E.  Evans</span>, <span class="hlFld-ContribAuthor ">Anna  Rodina</span>, <span class="hlFld-ContribAuthor ">Stefan  Ochiana</span>, <span class="hlFld-ContribAuthor ">Smit K.  Shah</span>, <span class="hlFld-ContribAuthor ">Mohammad  Uddin</span>, <span class="hlFld-ContribAuthor ">Daniel  Gewirth</span>, and <span class="hlFld-ContribAuthor ">Gabriela  Chiosis</span>  . </span><span class="cited-content_cbyCitation_article-title">Experimental and Structural Testing Module to Analyze Paralogue-Specificity and Affinity in the Hsp90 Inhibitors Series. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (17)
                                     , 6803-6818. <a href="https://doi.org/10.1021/jm400619b" title="DOI URL">https://doi.org/10.1021/jm400619b</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400619b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400619b%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExperimental%252Band%252BStructural%252BTesting%252BModule%252Bto%252BAnalyze%252BParalogue-Specificity%252Band%252BAffinity%252Bin%252Bthe%252BHsp90%252BInhibitors%252BSeries%26aulast%3DTaldone%26aufirst%3DTony%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D26042013%26date%3D21082013%26date%3D12092013%26volume%3D56%26issue%3D17%26spage%3D6803%26epage%3D6818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sohaib  Nizami</span>, <span class="hlFld-ContribAuthor ">Kanisa  Arunasalam</span>, <span class="hlFld-ContribAuthor ">Jack  Green</span>, <span class="hlFld-ContribAuthor ">James  Cook</span>, <span class="hlFld-ContribAuthor ">Catherine B.  Lawrence</span>, <span class="hlFld-ContribAuthor ">Tryfon  Zarganes‐Tzitzikas</span>, <span class="hlFld-ContribAuthor ">John B.  Davis</span>, <span class="hlFld-ContribAuthor ">Elena  Di Daniel</span>, <span class="hlFld-ContribAuthor ">David  Brough</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of the NLRP3 inflammasome by HSP90 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Immunology</span><span> <strong>2021,</strong> <em>162 </em>
                                    (1)
                                     , 84-91. <a href="https://doi.org/10.1111/imm.13267" title="DOI URL">https://doi.org/10.1111/imm.13267</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/imm.13267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fimm.13267%26sid%3Dliteratum%253Aachs%26jtitle%3DImmunology%26atitle%3DInhibition%252Bof%252Bthe%252BNLRP3%252Binflammasome%252Bby%252BHSP90%252Binhibitors%26aulast%3DNizami%26aufirst%3DSohaib%26date%3D2021%26date%3D2020%26volume%3D162%26issue%3D1%26spage%3D84%26epage%3D91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sang Chul  Shin</span>, <span class="hlFld-ContribAuthor ">Ashraf K.  El-Damasy</span>, <span class="hlFld-ContribAuthor ">Ju Hyeon  Lee</span>, <span class="hlFld-ContribAuthor ">Seon Hee  Seo</span>, <span class="hlFld-ContribAuthor ">Ji Hyun  Kim</span>, <span class="hlFld-ContribAuthor ">Young Ho  Seo</span>, <span class="hlFld-ContribAuthor ">Yuri  Lee</span>, <span class="hlFld-ContribAuthor ">Ji Hoon  Yu</span>, <span class="hlFld-ContribAuthor ">Eun Kyoung  Bang</span>, <span class="hlFld-ContribAuthor ">Eunice EunKyeong  Kim</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (24)
                                     , 9377. <a href="https://doi.org/10.3390/ijms21249377" title="DOI URL">https://doi.org/10.3390/ijms21249377</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21249377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21249377%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DStructural%252BBasis%252Bfor%252BDesign%252Bof%252BNew%252BPurine-Based%252BInhibitors%252BTargeting%252Bthe%252BHydrophobic%252BBinding%252BPocket%252Bof%252BHsp90%26aulast%3DShin%26aufirst%3DSang%2BChul%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D24%26spage%3D9377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tony  Taldone</span>, <span class="hlFld-ContribAuthor ">Tai  Wang</span>, <span class="hlFld-ContribAuthor ">Anna  Rodina</span>, <span class="hlFld-ContribAuthor ">Naga Vara Kishore  Pillarsetty</span>, <span class="hlFld-ContribAuthor ">Chander S.  Digwal</span>, <span class="hlFld-ContribAuthor ">Sahil  Sharma</span>, <span class="hlFld-ContribAuthor ">Pengrong  Yan</span>, <span class="hlFld-ContribAuthor ">Suhasini  Joshi</span>, <span class="hlFld-ContribAuthor ">Piyusha P.  Pagare</span>, <span class="hlFld-ContribAuthor ">Alexander  Bolaender</span>, <span class="hlFld-ContribAuthor ">Gail J.  Roboz</span>, <span class="hlFld-ContribAuthor ">Monica L.  Guzman</span>, <span class="hlFld-ContribAuthor ">Gabriela  Chiosis</span>. </span><span class="cited-content_cbyCitation_article-title">A Chemical Biology Approach to the Chaperome in Cancer—HSP90 and Beyond. </span><span class="cited-content_cbyCitation_journal-name">Cold Spring Harbor Perspectives in Biology</span><span> <strong>2020,</strong> <em>12 </em>
                                    (4)
                                     , a034116. <a href="https://doi.org/10.1101/cshperspect.a034116" title="DOI URL">https://doi.org/10.1101/cshperspect.a034116</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1101/cshperspect.a034116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1101%2Fcshperspect.a034116%26sid%3Dliteratum%253Aachs%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspectives%2520in%2520Biology%26atitle%3DA%252BChemical%252BBiology%252BApproach%252Bto%252Bthe%252BChaperome%252Bin%252BCancer%2525E2%252580%252594HSP90%252Band%252BBeyond%26aulast%3DTaldone%26aufirst%3DTony%26date%3D2020%26date%3D2019%26volume%3D12%26issue%3D4%26spage%3Da034116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Liu</span>, <span class="hlFld-ContribAuthor ">Xiao-Lu  Lu</span>, <span class="hlFld-ContribAuthor ">Xian-Hua  Huang</span>, <span class="hlFld-ContribAuthor ">Wei  He</span>, <span class="hlFld-ContribAuthor ">Jing-Jing  Duan</span>, <span class="hlFld-ContribAuthor ">Jin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Complex structure of human Hsp90N and a novel small inhibitor FS5. </span><span class="cited-content_cbyCitation_journal-name">Nuclear Science and Techniques</span><span> <strong>2020,</strong> <em>31 </em>
                                    (3)
                                     <a href="https://doi.org/10.1007/s41365-020-0739-3" title="DOI URL">https://doi.org/10.1007/s41365-020-0739-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s41365-020-0739-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs41365-020-0739-3%26sid%3Dliteratum%253Aachs%26jtitle%3DNuclear%2520Science%2520and%2520Techniques%26atitle%3DComplex%252Bstructure%252Bof%252Bhuman%252BHsp90N%252Band%252Ba%252Bnovel%252Bsmall%252Binhibitor%252BFS5%26aulast%3DLiu%26aufirst%3DRui%26date%3D2020%26date%3D2020%26volume%3D31%26issue%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akhila  Mettu</span>, <span class="hlFld-ContribAuthor ">Venu  Talla</span>, <span class="hlFld-ContribAuthor ">Deepti Madanlal  Bajaj</span>, <span class="hlFld-ContribAuthor ">Naikal James Prameela  Subhashini</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and molecular docking studies of novel pyrazolyl 2‐aminopyrimidine derivatives as HSP90 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2019,</strong> <em>352 </em>
                                    (10)
                                     , 1900063. <a href="https://doi.org/10.1002/ardp.201900063" title="DOI URL">https://doi.org/10.1002/ardp.201900063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201900063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201900063%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bmolecular%252Bdocking%252Bstudies%252Bof%252Bnovel%252Bpyrazolyl%252B2%2525E2%252580%252590aminopyrimidine%252Bderivatives%252Bas%252BHSP90%252Binhibitors%26aulast%3DMettu%26aufirst%3DAkhila%26date%3D2019%26date%3D2019%26volume%3D352%26issue%3D10%26spage%3D1900063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Taner  Erdogan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, characterization, DFT and molecular docking studies for novel 1,5-diphenylpenta-1,4-dien-3-one O-benzyl oximes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Iranian Chemical Society</span><span> <strong>2019,</strong> <em>16 </em>
                                    (10)
                                     , 2243-2255. <a href="https://doi.org/10.1007/s13738-019-01697-0" title="DOI URL">https://doi.org/10.1007/s13738-019-01697-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13738-019-01697-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13738-019-01697-0%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Iranian%2520Chemical%2520Society%26atitle%3DSynthesis%25252C%252Bcharacterization%25252C%252BDFT%252Band%252Bmolecular%252Bdocking%252Bstudies%252Bfor%252Bnovel%252B1%25252C5-diphenylpenta-1%25252C4-dien-3-one%252BO-benzyl%252Boximes%26aulast%3DErdogan%26aufirst%3DTaner%26date%3D2019%26date%3D2019%26volume%3D16%26issue%3D10%26spage%3D2243%26epage%3D2255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ken  Yamada</span>, <span class="hlFld-ContribAuthor ">Yusuke  Abe</span>, <span class="hlFld-ContribAuthor ">Fumi  Nagatsugi</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of RNA Crosslinking Oligonucleotides Modified with 2‐Amino‐7‐Deaza‐7‐Propynyl‐6‐Vinylpurine. </span><span class="cited-content_cbyCitation_journal-name">Current Protocols in Nucleic Acid Chemistry</span><span> <strong>2019,</strong> <em>77 </em>
                                    (1)
                                     <a href="https://doi.org/10.1002/cpnc.79" title="DOI URL">https://doi.org/10.1002/cpnc.79</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpnc.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpnc.79%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Protocols%2520in%2520Nucleic%2520Acid%2520Chemistry%26atitle%3DSynthesis%252Bof%252BRNA%252BCrosslinking%252BOligonucleotides%252BModified%252Bwith%252B2%2525E2%252580%252590Amino%2525E2%252580%2525907%2525E2%252580%252590Deaza%2525E2%252580%2525907%2525E2%252580%252590Propynyl%2525E2%252580%2525906%2525E2%252580%252590Vinylpurine%26aulast%3DYamada%26aufirst%3DKen%26date%3D2019%26date%3D2019%26volume%3D77%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zühal  Kilic-Kurt</span>, <span class="hlFld-ContribAuthor ">Filiz  Bakar-Ates</span>, <span class="hlFld-ContribAuthor ">Yeliz  Aka</span>, <span class="hlFld-ContribAuthor ">Ozgur  Kutuk</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and in vitro apoptotic mechanism of novel pyrrolopyrimidine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>83 </em>, 511-519. <a href="https://doi.org/10.1016/j.bioorg.2018.10.060" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.10.060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.10.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.10.060%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bin%252Bvitro%252Bapoptotic%252Bmechanism%252Bof%252Bnovel%252Bpyrrolopyrimidine%252Bderivatives%26aulast%3DKilic-Kurt%26aufirst%3DZ%25C3%25BChal%26date%3D2019%26volume%3D83%26spage%3D511%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Athanasia  Warnecke</span>, <span class="hlFld-ContribAuthor ">Andreas  Kirschning</span>, <span class="hlFld-ContribAuthor ">Daniel  Landsberg</span>, <span class="hlFld-ContribAuthor ">Carsten  Zeilinger</span>. </span><span class="cited-content_cbyCitation_article-title">Hsp90: A Target for Susceptibilities and Substitutions in Biotechnological and Medicinal Application. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 387-410. <a href="https://doi.org/10.1007/978-3-030-23158-3_18" title="DOI URL">https://doi.org/10.1007/978-3-030-23158-3_18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-23158-3_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-23158-3_18%26sid%3Dliteratum%253Aachs%26atitle%3DHsp90%25253A%252BA%252BTarget%252Bfor%252BSusceptibilities%252Band%252BSubstitutions%252Bin%252BBiotechnological%252Band%252BMedicinal%252BApplication%26aulast%3DWarnecke%26aufirst%3DAthanasia%26date%3D2019%26date%3D2019%26spage%3D387%26epage%3D410%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHeat%252BShock%252BProtein%252B90%252Bin%252BHuman%252BDiseases%252Band%252BDisorders%26aulast%3DAsea%26aufirst%3DAlexzander%2BA.%2BA.%26date%3D2019%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Prathap  Somu</span>, <span class="hlFld-ContribAuthor ">Subhankar  Paul</span>. </span><span class="cited-content_cbyCitation_article-title">HSP90 and Its Inhibitors for Cancer Therapy: Use of Nano-delivery System to Improve Its Clinical Application. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 159-182. <a href="https://doi.org/10.1007/978-3-030-23158-3_8" title="DOI URL">https://doi.org/10.1007/978-3-030-23158-3_8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-23158-3_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-23158-3_8%26sid%3Dliteratum%253Aachs%26atitle%3DHSP90%252Band%252BIts%252BInhibitors%252Bfor%252BCancer%252BTherapy%25253A%252BUse%252Bof%252BNano-delivery%252BSystem%252Bto%252BImprove%252BIts%252BClinical%252BApplication%26aulast%3DSomu%26aufirst%3DPrathap%26date%3D2019%26date%3D2019%26spage%3D159%26epage%3D182%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHeat%252BShock%252BProtein%252B90%252Bin%252BHuman%252BDiseases%252Band%252BDisorders%26aulast%3DAsea%26aufirst%3DAlexzander%2BA.%2BA.%26date%3D2019%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ju-Hyeon  Lee</span>, <span class="hlFld-ContribAuthor ">Ashraf K.  El-Damasy</span>, <span class="hlFld-ContribAuthor ">Seon Hee  Seo</span>, <span class="hlFld-ContribAuthor ">Changdev G.  Gadhe</span>, <span class="hlFld-ContribAuthor ">Ae Nim  Pae</span>, <span class="hlFld-ContribAuthor ">Nakcheol  Jeong</span>, <span class="hlFld-ContribAuthor ">Soon-Sun  Hong</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (21)
                                     , 5596-5611. <a href="https://doi.org/10.1016/j.bmc.2018.10.004" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.10.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.10.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNovel%252B5%25252C6-disubstituted%252Bpyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bbroad%252Bspectrum%252Bantiproliferative%252Bagents%25253A%252BSynthesis%25252C%252Bcell%252Bbased%252Bassays%25252C%252Bkinase%252Bprofile%252Band%252Bmolecular%252Bdocking%252Bstudy%26aulast%3DLee%26aufirst%3DJu-Hyeon%26date%3D2018%26volume%3D26%26issue%3D21%26spage%3D5596%26epage%3D5611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shelly  Pathania</span>, <span class="hlFld-ContribAuthor ">Ravindra K.  Rawal</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>157 </em>, 503-526. <a href="https://doi.org/10.1016/j.ejmech.2018.08.023" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.08.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.08.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.08.023%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrrolopyrimidines%25253A%252BAn%252Bupdate%252Bon%252Brecent%252Badvancements%252Bin%252Btheir%252Bmedicinal%252Battributes%26aulast%3DPathania%26aufirst%3DShelly%26date%3D2018%26volume%3D157%26spage%3D503%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kachigere B.  Harsha</span>, <span class="hlFld-ContribAuthor ">Toreshettahally R.  Swaroop</span>, <span class="hlFld-ContribAuthor ">Rangaswamy  Roopashree</span>, <span class="hlFld-ContribAuthor ">Swamy  Jagadish</span>, <span class="hlFld-ContribAuthor ">Kanchugarakoppal S.  Rangappa</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and  in vitro  anti-proliferative studies of new 2-(arylmethylthio)-6-ethyl-7 H -pyrrolo[2,3-d]pyrimidin-4-ols. </span><span class="cited-content_cbyCitation_journal-name">Chemical Data Collections</span><span> <strong>2018,</strong> <em>15-16 </em>, 223-228. <a href="https://doi.org/10.1016/j.cdc.2018.06.004" title="DOI URL">https://doi.org/10.1016/j.cdc.2018.06.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cdc.2018.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cdc.2018.06.004%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Data%2520Collections%26atitle%3DSynthesis%252Band%252Bin%252Bvitro%252Banti-proliferative%252Bstudies%252Bof%252Bnew%252B2-%252528arylmethylthio%252529-6-ethyl-7%252BH%252B-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-ols%26aulast%3DHarsha%26aufirst%3DKachigere%2BB.%26date%3D2018%26volume%3D15-16%26spage%3D223%26epage%3D228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Len  Neckers</span>, <span class="hlFld-ContribAuthor ">Brian  Blagg</span>, <span class="hlFld-ContribAuthor ">Timothy  Haystead</span>, <span class="hlFld-ContribAuthor ">Jane B.  Trepel</span>, <span class="hlFld-ContribAuthor ">Luke  Whitesell</span>, <span class="hlFld-ContribAuthor ">Didier  Picard</span>. </span><span class="cited-content_cbyCitation_article-title">Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development. </span><span class="cited-content_cbyCitation_journal-name">Cell Stress and Chaperones</span><span> <strong>2018,</strong> <em>23 </em>
                                    (4)
                                     , 467-482. <a href="https://doi.org/10.1007/s12192-018-0877-2" title="DOI URL">https://doi.org/10.1007/s12192-018-0877-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12192-018-0877-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12192-018-0877-2%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Stress%2520and%2520Chaperones%26atitle%3DMethods%252Bto%252Bvalidate%252BHsp90%252Binhibitor%252Bspecificity%25252C%252Bto%252Bidentify%252Boff-target%252Beffects%25252C%252Band%252Bto%252Brethink%252Bapproaches%252Bfor%252Bfurther%252Bclinical%252Bdevelopment%26aulast%3DNeckers%26aufirst%3DLen%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D4%26spage%3D467%26epage%3D482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liang  Yan</span>, <span class="hlFld-ContribAuthor ">Weiming  Zhang</span>, <span class="hlFld-ContribAuthor ">Beibei  Zhang</span>, <span class="hlFld-ContribAuthor ">Chao  Xuan</span>, <span class="hlFld-ContribAuthor ">Daogang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">BIIB021: A novel inhibitor to heat shock protein 90–addicted oncology. </span><span class="cited-content_cbyCitation_journal-name">Tumor Biology</span><span> <strong>2017,</strong> <em>39 </em>
                                    (4)
                                     , 101042831769835. <a href="https://doi.org/10.1177/1010428317698355" title="DOI URL">https://doi.org/10.1177/1010428317698355</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1010428317698355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1010428317698355%26sid%3Dliteratum%253Aachs%26jtitle%3DTumor%2520Biology%26atitle%3DBIIB021%25253A%252BA%252Bnovel%252Binhibitor%252Bto%252Bheat%252Bshock%252Bprotein%252B90%2525E2%252580%252593addicted%252Boncology%26aulast%3DYan%26aufirst%3DLiang%26date%3D2017%26date%3D2017%26volume%3D39%26issue%3D4%26spage%3D101042831769835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Madeline Y.  Wong</span>, <span class="hlFld-ContribAuthor ">Andrew S.  DiChiara</span>, <span class="hlFld-ContribAuthor ">Patreece H.  Suen</span>, <span class="hlFld-ContribAuthor ">Kenny  Chen</span>, <span class="hlFld-ContribAuthor ">Ngoc-Duc  Doan</span>, <span class="hlFld-ContribAuthor ">Matthew D.  Shoulders</span>. </span><span class="cited-content_cbyCitation_article-title">Adapting Secretory Proteostasis and Function Through the Unfolded Protein Response. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 1-25. <a href="https://doi.org/10.1007/82_2017_56" title="DOI URL">https://doi.org/10.1007/82_2017_56</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/82_2017_56&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F82_2017_56%26sid%3Dliteratum%253Aachs%26atitle%3DAdapting%252BSecretory%252BProteostasis%252Band%252BFunction%252BThrough%252Bthe%252BUnfolded%252BProtein%252BResponse%26aulast%3DWong%26aufirst%3DMadeline%2BY.%26date%3D2017%26date%3D2017%26spage%3D1%26epage%3D25%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCoordinating%252BOrganismal%252BPhysiology%252BThrough%252Bthe%252BUnfolded%252BProtein%252BResponse%26aulast%3DWiseman%26aufirst%3DR.%2BLuke%26date%3D2018%26volume%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ju-Hyeon  Lee</span>, <span class="hlFld-ContribAuthor ">Sang Chul  Shin</span>, <span class="hlFld-ContribAuthor ">Seon Hee  Seo</span>, <span class="hlFld-ContribAuthor ">Young Ho  Seo</span>, <span class="hlFld-ContribAuthor ">Nakcheol  Jeong</span>, <span class="hlFld-ContribAuthor ">Chan-Wha  Kim</span>, <span class="hlFld-ContribAuthor ">Eunice EunKyeong  Kim</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3- d ]pyrimidines as potent Hsp90 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (2)
                                     , 237-241. <a href="https://doi.org/10.1016/j.bmcl.2016.11.062" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.11.062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.11.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.11.062%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bin%252Bvitro%252Bantiproliferative%252Bactivity%252Bof%252BC5-benzyl%252Bsubstituted%252B2-amino-pyrrolo%25255B2%25252C3-%252Bd%252B%25255Dpyrimidines%252Bas%252Bpotent%252BHsp90%252Binhibitors%26aulast%3DLee%26aufirst%3DJu-Hyeon%26date%3D2017%26volume%3D27%26issue%3D2%26spage%3D237%26epage%3D241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Huyan</span>, <span class="hlFld-ContribAuthor ">Qi  Li</span>, <span class="hlFld-ContribAuthor ">Dan-Dan  Dong</span>, <span class="hlFld-ContribAuthor ">Hui  Yang</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Qing-Sheng  Huang</span>, <span class="hlFld-ContribAuthor ">Da-Chuan  Yin</span>, <span class="hlFld-ContribAuthor ">Peng  Shang</span>. </span><span class="cited-content_cbyCitation_article-title">Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner. </span><span class="cited-content_cbyCitation_journal-name">Immunopharmacology and Immunotoxicology</span><span> <strong>2016,</strong> <em>38 </em>
                                    (2)
                                     , 77-86. <a href="https://doi.org/10.3109/08923973.2015.1119159" title="DOI URL">https://doi.org/10.3109/08923973.2015.1119159</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3109/08923973.2015.1119159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3109%2F08923973.2015.1119159%26sid%3Dliteratum%253Aachs%26jtitle%3DImmunopharmacology%2520and%2520Immunotoxicology%26atitle%3DHeat%252Bshock%252Bprotein%252B90%252Binhibitors%252Binduce%252Bfunctional%252Binhibition%252Bof%252Bhuman%252Bnatural%252Bkiller%252Bcells%252Bin%252Ba%252Bdose-dependent%252Bmanner%26aulast%3DHuyan%26aufirst%3DTing%26date%3D2016%26date%3D2015%26volume%3D38%26issue%3D2%26spage%3D77%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicola  Chessum</span>, <span class="hlFld-ContribAuthor ">Keith  Jones</span>, <span class="hlFld-ContribAuthor ">Elisa  Pasqua</span>, <span class="hlFld-ContribAuthor ">Michael  Tucker</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in Cancer Therapeutics. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 1-63. <a href="https://doi.org/10.1016/bs.pmch.2014.11.002" title="DOI URL">https://doi.org/10.1016/bs.pmch.2014.11.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.pmch.2014.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.pmch.2014.11.002%26sid%3Dliteratum%253Aachs%26atitle%3DRecent%252BAdvances%252Bin%252BCancer%252BTherapeutics%26aulast%3DChessum%26aufirst%3DNicola%26date%3D2015%26spage%3D1%26epage%3D63%26pub%3DElsevier%26date%3D2015%26volume%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kazuhiro  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Kazuya  Nakazawa</span>, <span class="hlFld-ContribAuthor ">Shohei  Yuba</span>, <span class="hlFld-ContribAuthor ">Hidetaka  Hiyoshi</span>, <span class="hlFld-ContribAuthor ">Kazuto  Umezu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 7-Alkyl-6-amino-7H-pyrrolo[2,3-d]pyrimidine-6-carbonitriles by the Copper-Catalyzed Reaction of 4-(Alkylamino)-5-iodopyrimidines with Propanedinitrile. </span><span class="cited-content_cbyCitation_journal-name">HETEROCYCLES</span><span> <strong>2015,</strong> <em>90 </em>
                                    (1)
                                     , 216. <a href="https://doi.org/10.3987/COM-14-S(K)5" title="DOI URL">https://doi.org/10.3987/COM-14-S(K)5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3987/COM-14-S(K)5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3987%2FCOM-14-S%28K%295%26sid%3Dliteratum%253Aachs%26jtitle%3DHETEROCYCLES%26atitle%3DSynthesis%252Bof%252B7-Alkyl-6-amino-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidine-6-carbonitriles%252Bby%252Bthe%252BCopper-Catalyzed%252BReaction%252Bof%252B4-%252528Alkylamino%252529-5-iodopyrimidines%252Bwith%252BPropanedinitrile%26aulast%3DKobayashi%26aufirst%3DKazuhiro%26date%3D2015%26volume%3D90%26issue%3D1%26spage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao-Peng  Sun</span>, <span class="hlFld-ContribAuthor ">Jian-Min  Jia</span>, <span class="hlFld-ContribAuthor ">Fen  Jiang</span>, <span class="hlFld-ContribAuthor ">Xiao-Li  Xu</span>, <span class="hlFld-ContribAuthor ">Fang  Liu</span>, <span class="hlFld-ContribAuthor ">Xiao-Ke  Guo</span>, <span class="hlFld-ContribAuthor ">Bahidja  Cherfaoui</span>, <span class="hlFld-ContribAuthor ">Hao-Ze  Huang</span>, <span class="hlFld-ContribAuthor ">Yang  Pan</span>, <span class="hlFld-ContribAuthor ">Qi-Dong  You</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>79 </em>, 399-412. <a href="https://doi.org/10.1016/j.ejmech.2014.03.061" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.03.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.03.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.03.061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Band%252Boptimization%252Bof%252Bnovel%252BHsp90%252Binhibitors%252Bwith%252Btetrahydropyrido%25255B4%25252C3-d%25255Dpyrimidines%252Bcore%252Bthrough%252Bshape-based%252Bscreening%26aulast%3DSun%26aufirst%3DHao-Peng%26date%3D2014%26volume%3D79%26spage%3D399%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tony  Taldone</span>, <span class="hlFld-ContribAuthor ">Hardik J  Patel</span>, <span class="hlFld-ContribAuthor ">Alexander  Bolaender</span>, <span class="hlFld-ContribAuthor ">Maulik R  Patel</span>, <span class="hlFld-ContribAuthor ">Gabriela  Chiosis</span>. </span><span class="cited-content_cbyCitation_article-title">Protein chaperones: a composition of matter review (2008 – 2013). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2014,</strong> <em>24 </em>
                                    (5)
                                     , 501-518. <a href="https://doi.org/10.1517/13543776.2014.887681" title="DOI URL">https://doi.org/10.1517/13543776.2014.887681</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2014.887681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2014.887681%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DProtein%252Bchaperones%25253A%252Ba%252Bcomposition%252Bof%252Bmatter%252Breview%252B%2525282008%252B%2525E2%252580%252593%252B2013%252529%26aulast%3DTaldone%26aufirst%3DTony%26date%3D2014%26date%3D2014%26volume%3D24%26issue%3D5%26spage%3D501%26epage%3D518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Li  Xu</span>, <span class="hlFld-ContribAuthor ">Hao-Peng  Sun</span>, <span class="hlFld-ContribAuthor ">Fang  Liu</span>, <span class="hlFld-ContribAuthor ">Jian-Min  Jia</span>, <span class="hlFld-ContribAuthor ">Xiao-Ke  Guo</span>, <span class="hlFld-ContribAuthor ">Yang  Pan</span>, <span class="hlFld-ContribAuthor ">Hao-Ze  Huang</span>, <span class="hlFld-ContribAuthor ">Xiao-Jin  Zhang</span>, <span class="hlFld-ContribAuthor ">Qi-Dong  You</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs as Competitive Hsp90 Inhibitors Through Shape-Based Similarity Screening. </span><span class="cited-content_cbyCitation_journal-name">Molecular Informatics</span><span> <strong>2014,</strong> <em>33 </em>
                                    (4)
                                     , 293-306. <a href="https://doi.org/10.1002/minf.201300150" title="DOI URL">https://doi.org/10.1002/minf.201300150</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/minf.201300150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fminf.201300150%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Informatics%26atitle%3DDiscovery%252Band%252BBioevaluation%252Bof%252BNovel%252BPyrazolopyrimidine%252BAnalogs%252Bas%252BCompetitive%252BHsp90%252BInhibitors%252BThrough%252BShape-Based%252BSimilarity%252BScreening%26aulast%3DXu%26aufirst%3DXiao-Li%26date%3D2014%26date%3D2014%26volume%3D33%26issue%3D4%26spage%3D293%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Swee  Sharp</span>, <span class="hlFld-ContribAuthor ">Keith  Jones</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting Cancer Dependence on Molecular Chaperones. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 239-274. <a href="https://doi.org/10.1016/B978-0-12-396521-9.00009-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-396521-9.00009-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-396521-9.00009-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-396521-9.00009-7%26sid%3Dliteratum%253Aachs%26atitle%3DExploiting%252BCancer%252BDependence%252Bon%252BMolecular%252BChaperones%26aulast%3DSharp%26aufirst%3DSwee%26date%3D2014%26spage%3D239%26epage%3D274%26pub%3DElsevier%26atitle%3DCancer%252BDrug%252BDesign%252Band%252BDiscovery%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Justin T.  Ernst</span>, <span class="hlFld-ContribAuthor ">Michael  Liu</span>, <span class="hlFld-ContribAuthor ">Harmon  Zuccola</span>, <span class="hlFld-ContribAuthor ">Timothy  Neubert</span>, <span class="hlFld-ContribAuthor ">Kevin  Beaumont</span>, <span class="hlFld-ContribAuthor ">Amy  Turnbull</span>, <span class="hlFld-ContribAuthor ">Adam  Kallel</span>, <span class="hlFld-ContribAuthor ">Bryan  Vought</span>, <span class="hlFld-ContribAuthor ">Dean  Stamos</span>. </span><span class="cited-content_cbyCitation_article-title">Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity—Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (1)
                                     , 204-208. <a href="https://doi.org/10.1016/j.bmcl.2013.11.036" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.11.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.11.036%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCorrelation%252Bbetween%252Bchemotype-dependent%252Bbinding%252Bconformations%252Bof%252BHSP90%2525CE%2525B1%25252F%2525CE%2525B2%252Band%252Bisoform%252Bselectivity%2525E2%252580%252594Implications%252Bfor%252Bthe%252Bstructure-based%252Bdesign%252Bof%252BHSP90%2525CE%2525B1%25252F%2525CE%2525B2%252Bselective%252Binhibitors%252Bfor%252Btreating%252Bneurodegenerative%252Bdiseases%26aulast%3DErnst%26aufirst%3DJustin%2BT.%26date%3D2014%26volume%3D24%26issue%3D1%26spage%3D204%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Taeho  Lee</span>, <span class="hlFld-ContribAuthor ">Young Ho  Seo</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the hydrophobic region of Hsp90’s ATP binding pocket with novel 1,3,5-triazines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (23)
                                     , 6427-6431. <a href="https://doi.org/10.1016/j.bmcl.2013.09.050" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.09.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.09.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.09.050%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DTargeting%252Bthe%252Bhydrophobic%252Bregion%252Bof%252BHsp90%2525E2%252580%252599s%252BATP%252Bbinding%252Bpocket%252Bwith%252Bnovel%252B1%25252C3%25252C5-triazines%26aulast%3DLee%26aufirst%3DTaeho%26date%3D2013%26volume%3D23%26issue%3D23%26spage%3D6427%26epage%3D6431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">JianMin  Jia</span>, <span class="hlFld-ContribAuthor ">XiaoLi  Xu</span>, <span class="hlFld-ContribAuthor ">Fang  Liu</span>, <span class="hlFld-ContribAuthor ">XiaoKe  Guo</span>, <span class="hlFld-ContribAuthor ">MingYe  Zhang</span>, <span class="hlFld-ContribAuthor ">MengChen  Lu</span>, <span class="hlFld-ContribAuthor ">LiLi  Xu</span>, <span class="hlFld-ContribAuthor ">JinLian  Wei</span>, <span class="hlFld-ContribAuthor ">Jia  Zhu</span>, <span class="hlFld-ContribAuthor ">ShengLie  Zhang</span>, <span class="hlFld-ContribAuthor ">ShengMiao  Zhang</span>, <span class="hlFld-ContribAuthor ">HaoPeng  Sun</span>, <span class="hlFld-ContribAuthor ">QiDong  You</span>, . </span><span class="cited-content_cbyCitation_article-title">Identification, Design and Bio-Evaluation of Novel Hsp90 Inhibitors by Ligand-Based Virtual Screening. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2013,</strong> <em>8 </em>
                                    (4)
                                     , e59315. <a href="https://doi.org/10.1371/journal.pone.0059315" title="DOI URL">https://doi.org/10.1371/journal.pone.0059315</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0059315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0059315%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3DIdentification%25252C%252BDesign%252Band%252BBio-Evaluation%252Bof%252BNovel%252BHsp90%252BInhibitors%252Bby%252BLigand-Based%252BVirtual%252BScreening%26aulast%3DJia%26aufirst%3DJianMin%26date%3D2013%26date%3D2013%26volume%3D8%26issue%3D4%26spage%3De59315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Hsp90 Inhibitors in Clinical Trials</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Modifications of <b>16</b> in positions Ra–Rf led to a decrease in potency, suggesting that the solvent exposed area of the molecule was pointing in the same direction as the N7 lone pair of purine <b>14</b>.</p></p></figure><figure data-id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. The X-ray structure of <b>14</b> in complex with Hsp90 shows that N7 faces a solvent exposed area (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QDD">3QDD</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preferred Synthesis of Pyrrolo[2,3-<i>d</i>]pyrimidine <b>27</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Alternative Synthesis to Pyrrolo[2,3-<i>d</i>]pyrimidine <b>27</b> and Synthesis of <b>35</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0013.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) PhB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 2 M K<sub>2</sub>CO<sub>3</sub>, 80 °C (20%); (b) HC≡C–SiMe<sub>3</sub>, Et<sub>3</sub>N, CuI, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 50 °C (25–50%), then TBAF, THF, rt (25%); (c) alkyne, Et<sub>3</sub>N, CuI, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 50 °C (25–50%), or alkyne, Et<sub>3</sub>N, CuI, 10% Pd/C, PPh<sub>3</sub>, H<sub>2</sub>O, DMA or DMSO, 75 °C (40–75%); (d) Raney Ni, H<sub>2</sub> (4.5 atm), MeOH, rt (32%).</p></p></figure><figure data-id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray structure of alcohol <b>40</b> in complex with Hsp90α (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3NMQ">3NMQ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Retention of alkyne <b>40</b> in tumors. Mice bearing N87 xenografts were administered a single dose of 6 or 12 mg/kg alkyne <b>40</b>. The concentration of alkyne <b>40</b> was measured in the serum, tumors, brain, and spleen at 1, 6, and 24 h postdose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmacodynamic effect of alkyne <b>40</b>. Mice bearing BT474 xenografts were treated with a single oral dose of 4 or 8 mg/kg alkyne <b>40</b>. Tumors were collected for Western blot analysis at 6, 24, and 48 h postdose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibition of tumor growth in the N87 gastric tumor model. Athymic mice bearing established N87 gastric tumor xenografts were treated with vehicle control, purine <b>14</b>, or alcohol <b>40</b> orally qd×5 for 4 weeks.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Tumors were measured using Vernier calipers on the indicated days, and tumor volumes are reported as mean volume ± SEM tumor for groups of eight mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Inhibition of tumor growth in the PGP overexpressing NCI295 adrenal carcinoma. Athymic mice bearing established NCI295 carcinoma were treated with vehicle control, purine <b>14</b> (120 mg/kg, po), alcohol <b>40</b> (8 mg/kg, po), or 17-AAG (60 mg/kg, ip), qd×5 for 4 weeks. Tumors were measured using Vernier calipers on the indicated days, and tumor volumes are reported as the mean volume ± SEM tumor for groups of seven mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/medium/jm-2012-00810x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Pharmacodynamic effect of <b>40</b> on Hsp70 levels in the brain, following administration of a single oral dose in B6D2F1 female mice. HSP70 levels in brain homogenates were determined by ELISA and analyzed for statistical significance using unpaired two-tailed <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-17/jm300810x/production/images/large/jm-2012-00810x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300810x&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80537" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80537" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 41 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Hsp90 molecular chaperone inhibitors: are we there yet?</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">64</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1078-0432.CCR-11-1000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=22215907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=64-76&author=L.+Neckersauthor=P.+Workman&title=Hsp90+molecular+chaperone+inhibitors%3A+are+we+there+yet%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?</span></div><div class="casAuthors">Neckers, Len; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-76</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Heat shock protein (Hsp) 90 is an ATP-dependent mol. chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-assocd. kinases and transcription factors, and it is essential for oncogenic transformation.  Originally viewed with skepticism, Hsp90 inhibitors are now being actively pursued by the pharmaceutical industry, with 17 agents having entered clin. trials.  Investigators established Hsp90's druggability using the natural products geldanamycin and radicicol, which mimic the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause potent and selective blockade of ATP binding/hydrolysis, inhibit chaperone function, deplete oncogenic clients, and show antitumor activity.  Preclin. data obtained with these natural products have heightened interest in Hsp90 as a drug target, and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has shown clin. activity (as defined by Response Evaluation Criteria in Solid Tumors) in HER2+ breast cancer.  Many optimized synthetic, small-mol. Hsp90 inhibitors from diverse chemotypes are now in clin. trials.  Here, we review the discovery and development of Hsp90 inhibitors and assess their potential.  There has been significant learning from studies of the basic biol. of Hsp90, as well as translational drug development involving this chaperone, enhanced by the use of Hsp90 inhibitors as chem. probes.  Success will likely lie in treating cancers that are addicted to particular driver oncogene products (e.g., HER2, ALK, EGFR, and BRAF) that are sensitive Hsp90 clients, as well as malignancies (esp. multiple myeloma) in which buffering of proteotoxic stress is crit. for survival.  We discuss approaches for enhancing the effectiveness of Hsp90 inhibitors and highlight new chaperone and stress-response pathway targets, including HSF1 and Hsp70.  Clin Cancer Res; 18(1); 64-76.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfICmNu1IWFbVg90H21EOLACvtfcHk0lgy173hE5yE3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D&md5=f67c3c11b5847e3866c91af2a16a63b8</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1000%26sid%3Dliteratum%253Aachs%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DHsp90%2520molecular%2520chaperone%2520inhibitors%253A%2520are%2520we%2520there%2520yet%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D64%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Massey, A. J.</span><span> </span><span class="NLM_article-title">ATPases as drug targets: insights from heat shock proteins 70 and 90</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7280</span><span class="NLM_x">–</span> <span class="NLM_lpage">7286</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100342z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosVGgsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7280-7286&author=A.+J.+Massey&title=ATPases+as+drug+targets%3A+insights+from+heat+shock+proteins+70+and+90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">ATPases as Drug Targets: Insights from Heat Shock Proteins 70 and 90</span></div><div class="casAuthors">Massey, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7280-7286</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouskN9BSeSLLVg90H21EOLACvtfcHk0lgy173hE5yE3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosVGgsrY%253D&md5=1fb082e98a0e666b2276cb7dc1e38c2a</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1021%2Fjm100342z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100342z%26sid%3Dliteratum%253Aachs%26aulast%3DMassey%26aufirst%3DA.%2BJ.%26atitle%3DATPases%2520as%2520drug%2520targets%253A%2520insights%2520from%2520heat%2520shock%2520proteins%252070%2520and%252090%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7280%26epage%3D7286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Biamonte, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van De Water, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perret, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannevin, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W.-C.</span><span> </span><span class="NLM_article-title">Heat shock protein 90: Inhibitors in clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9004708" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3-17&author=M.+A.+Biamonteauthor=R.+Van+De+Waterauthor=D.+Perretauthor=J.+W.+Arndtauthor=R.+H.+Scannevinauthor=W.-C.+Lee&title=Heat+shock+protein+90%3A+Inhibitors+in+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90: Inhibitors in Clinical Trials</span></div><div class="casAuthors">Biamonte, Marco A.; Van de Water, Ryan; Arndt, Joseph W.; Scannevin, Robert H.; Perret, Daniel; Lee, Wen-Cherng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-17</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  HSP90 is the 90 kDa member of the family and exists as two isoforms: HSP90 is an inducible form overexpressed in cancer cells, while HSP90 is the constitutive form.  Since inhibition of HSP90 can lead to the degrdn. of a large no. of oncogenic proteins, HSP90 has become a target of interest for oncol.  A major advantage of HSP90 inhibitors is that they simultaneously attack several pathways necessary for cancer development, reducing the likelihood of the tumor acquiring resistance to any single therapeutic pathway.  It has also been proposed that HSP90 occurs in an activated form in cancer cells, whereas in normal somatic cells only the latent form is found.  This has given rise to the hypothesis that HSP90 inhibitors could be designed to selectively target the activated form and thus more specifically target cancer cells, but this assertion has been challenged.  Cancer cells seem to have a higher HSP90 activity than normal cells, and oncogenes are more dependent on HSP90 than house-keeping proteins.  In cell cultures, HSP90 inhibitors kill tumor cells at concns. much lower than those required to kill normal cells.  In mice, efficacy can be obsd. at nontoxic doses, and in humans, the first signs of clin. benefit are emerging.  It remains to be verified, however, if HSP90 inhibitors will truly provide a sufficient safety margin in the clinic.  Nononcol. indications may also emerge; besides cancer, the prevalent conditions mentioned in the literature with respect to HSP90 are Parkinson's disease, Alzheimer's disease, and fungal infections.  For the time being, however, the focus is oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYseMVVt55b7Vg90H21EOLACvtfcHk0lgy173hE5yE3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ&md5=14eee1036fc22e45da13b49cc93ed845</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1021%2Fjm9004708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004708%26sid%3Dliteratum%253Aachs%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DVan%2BDe%2BWater%26aufirst%3DR.%26aulast%3DPerret%26aufirst%3DD.%26aulast%3DArndt%26aufirst%3DJ.%2BW.%26aulast%3DScannevin%26aufirst%3DR.%2BH.%26aulast%3DLee%26aufirst%3DW.-C.%26atitle%3DHeat%2520shock%2520protein%252090%253A%2520Inhibitors%2520in%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span>HSP90 Interactors. <a href="http://www.picard.ch/downloads/Hsp90interactors.pdf" class="extLink">http://www.picard.ch/downloads/Hsp90interactors.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=HSP90+Interactors.+http%3A%2F%2Fwww.picard.ch%2Fdownloads%2FHsp90interactors.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Schnur, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallaschun, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dee, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzzi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiOrio, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacci, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, M. P.</span><span> </span><span class="NLM_article-title">erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure–activity relationships</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">3813</span><span class="NLM_x">–</span> <span class="NLM_lpage">3820</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00019a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=3813-3820&author=R.+C.+Schnurauthor=M.+L.+Cormanauthor=R.+J.+Gallaschunauthor=B.+A.+Cooperauthor=M.+F.+Deeauthor=J.+L.+Dotyauthor=M.+L.+Muzziauthor=C.+I.+DiOrioauthor=E.+G.+Barbacciauthor=P.+E.+Millerauthor=V.+A.+Pollackauthor=D.+M.+Savageauthor=D.+E.+Sloanauthor=L.+R.+Pustilnikauthor=J.+D.+Moyerauthor=M.+P.+Moyer&title=erbB-2+oncogene+inhibition+by+geldanamycin+derivatives%3A+synthesis%2C+mechanism+of+action%2C+and+structure%E2%80%93activity+relationships"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm00019a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00019a011%26sid%3Dliteratum%253Aachs%26aulast%3DSchnur%26aufirst%3DR.%2BC.%26aulast%3DCorman%26aufirst%3DM.%2BL.%26aulast%3DGallaschun%26aufirst%3DR.%2BJ.%26aulast%3DCooper%26aufirst%3DB.%2BA.%26aulast%3DDee%26aufirst%3DM.%2BF.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DMuzzi%26aufirst%3DM.%2BL.%26aulast%3DDiOrio%26aufirst%3DC.%2BI.%26aulast%3DBarbacci%26aufirst%3DE.%2BG.%26aulast%3DMiller%26aufirst%3DP.%2BE.%26aulast%3DPollack%26aufirst%3DV.%2BA.%26aulast%3DSavage%26aufirst%3DD.%2BM.%26aulast%3DSloan%26aufirst%3DD.%2BE.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26atitle%3DerbB-2%2520oncogene%2520inhibition%2520by%2520geldanamycin%2520derivatives%253A%2520synthesis%252C%2520mechanism%2520of%2520action%252C%2520and%2520structure%25E2%2580%2593activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D3813%26epage%3D3820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Ge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dembski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georges, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grenier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pak, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sydor, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbits, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palombella, V. J.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of HSP90</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4606</span><span class="NLM_x">–</span> <span class="NLM_lpage">4615</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0603116" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4606-4615&author=J.+Geauthor=E.+Normantauthor=J.+R.+Porterauthor=J.+A.+Aliauthor=M.+S.+Dembskiauthor=Y.+Gaoauthor=A.+T.+Georgesauthor=L.+Grenierauthor=R.+H.+Pakauthor=J.+Pattersonauthor=J.+R.+Sydorauthor=T.+T.+Tibbitsauthor=J.+K.+Tongauthor=J.+Adamsauthor=V.+J.+Palombella&title=Design%2C+synthesis%2C+and+biological+evaluation+of+hydroquinone+derivatives+of+17-amino-17-demethoxygeldanamycin+as+potent%2C+water-soluble+inhibitors+of+HSP90"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm0603116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603116%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DDembski%26aufirst%3DM.%2BS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGeorges%26aufirst%3DA.%2BT.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DPak%26aufirst%3DR.%2BH.%26aulast%3DPatterson%26aufirst%3DJ.%26aulast%3DSydor%26aufirst%3DJ.%2BR.%26aulast%3DTibbits%26aufirst%3DT.%2BT.%26aulast%3DTong%26aufirst%3DJ.%2BK.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520hydroquinone%2520derivatives%2520of%252017-amino-17-demethoxygeldanamycin%2520as%2520potent%252C%2520water-soluble%2520inhibitors%2520of%2520HSP90%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4606%26epage%3D4615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Glaze, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormick, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaraj, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyubimov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egorin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomaszewski, J. E.</span><span> </span><span class="NLM_article-title">Dose range-finding toxicity studies of 17-DMAG</span> <span class="citation_source-journal">Proc. Am. Assoc. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">162</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=162-162&author=E.+R.+Glazeauthor=A.+C.+Smithauthor=D.+W.+Johnsonauthor=D.+L.+McCormickauthor=A.+B.+Brownauthor=B.+S.+Levinauthor=R.+Krishnarajauthor=A.+Lyubimovauthor=M.+J.+Egorinauthor=J.+E.+Tomaszewski&title=Dose+range-finding+toxicity+studies+of+17-DMAG"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGlaze%26aufirst%3DE.%2BR.%26aulast%3DSmith%26aufirst%3DA.%2BC.%26aulast%3DJohnson%26aufirst%3DD.%2BW.%26aulast%3DMcCormick%26aufirst%3DD.%2BL.%26aulast%3DBrown%26aufirst%3DA.%2BB.%26aulast%3DLevin%26aufirst%3DB.%2BS.%26aulast%3DKrishnaraj%26aufirst%3DR.%26aulast%3DLyubimov%26aufirst%3DA.%26aulast%3DEgorin%26aufirst%3DM.%2BJ.%26aulast%3DTomaszewski%26aufirst%3DJ.%2BE.%26atitle%3DDose%2520range-finding%2520toxicity%2520studies%2520of%252017-DMAG%26jtitle%3DProc.%2520Am.%2520Assoc.%2520Cancer%2520Res.%26date%3D2003%26volume%3D44%26spage%3D162%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Eiseman, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagatutta, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamburger, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covey, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egorin, M. J.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1007%2Fs00280-004-0865-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=15338192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWjt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2005&pages=21-32&author=J.+L.+Eisemanauthor=J.+Lanauthor=T.+F.+Lagatuttaauthor=D.+R.+Hamburgerauthor=E.+Josephauthor=J.+M.+Coveyauthor=M.+J.+Egorin&title=Pharmacokinetics+and+pharmacodynamics+of+17-demethoxy+17-%5B%5B%282-dimethylamino%29ethyl%5Damino%5Dgeldanamycin+%2817DMAG%2C+NSC+707545%29+in+C.B-17+SCID+mice+bearing+MDA-MB-231+human+breast+cancer+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts</span></div><div class="casAuthors">Eiseman, Julie L.; Lan, Jing; Lagattuta, Theodore F.; Hamburger, Deborah R.; Joseph, Erin; Covey, Joseph M.; Egorin, Merrill J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-32</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Purpose: 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) is a water-sol. analog of 17-(allylamino)-17-demethoxygeldanamycin (17AAG), a compd. currently in clin. trials.  These preclin. studies: (1) characterized 17DMAG concns. in plasma, normal tissues, and tumor after i.v. delivery to mice; and (2) correlated tumor and normal tissue 17DMAG concns. with alterations in heat shock protein 90 (HSP90) and selected HSP90-chaperoned proteins.  Methods: At specified times after i.v. administration of 75 mg/kg 17DMAG, SCID mice bearing s.c.  MDA-MB-231 human breast xenografts were killed and plasma and tissues were retained. 17DMAG concns. were detd. by HPLC.  Raf-1, heat shock protein 70 (HSP70), and HSP90 in tissues were detd. by Western blotting.  Results: Peak plasma 17DMAG concn. was 15.4±1.4 μg/mL.  The area under the plasma 17DMAG concn. vs. time curve was 1072 μg/mL min, corresponding to a total body clearance of 70 mL/kg/min.  Peak 17DMAG concns. in liver (118.8±5.7 μg/g), kidney (122.9±10.6 μg/g), heart (81.3±8.1 μg/g), and lung (110.6±25.4 μg/g) occurred at 5-10 min, while peak concns. in spleen (70.6±9.6 μg/g) and tumor (9.0±1.0 μg/g) occurred at 30-45 min.  At 48 h, 17DMAG was detectable in tumor but not in any normal tissue.  Raf-1 in tumors of 17DMAG-treated mice killed at 4, 7, 24 and 48 h was about 20 lower than in tumors from vehicle-treated mice.  HSP90 and HSP70 in tumors of 17DMAG-treated animals were significantly lower than in tumors of control animals at 4, 7, and 24 h.  Hepatic Raf-1 was decreased by more than 60 at all times after 17DMAG treatment; however, hepatic HSP90 was not affected.  HSP70 was undetectable in livers of vehicle-treated mice or mice killed at 2 or 4 h after 17DMAG treatment, but was detected in livers at 7, 24 and 48 h. 17DMAG did not affect renal Raf-1.  In contrast, renal HSP70 and HSP90 were decreased by more than 50 at 2 and 4 h after 17DMAG treatment.  Renal HSP70 increased approx. twofold above that in kidneys from vehicle-treated control mice at 7 and 24 h, while HSP90 relative protein concn. was no different from that in controls.  Conclusions: Plasma pharmacokinetics of 17DMAG in tumor-bearing mice were similar to those previously reported in nontumor-bearing mice. 17DMAG was distributed widely to tissues but was retained for longer in tumors than normal tissues.  Raf-1, HSP90, and HSP70 were altered to different degrees in tumors, livers, and kidneys of 17DMAG-treated animals.  These data illustrate the complex nature of the biol. responses to 17DMAG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGmcN-fv9ZSbVg90H21EOLACvtfcHk0lgJeYP3Y5YMtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWjt77J&md5=9b7cf6c82811bf0b8e93dcb52d713ba0</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1007%2Fs00280-004-0865-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-004-0865-3%26sid%3Dliteratum%253Aachs%26aulast%3DEiseman%26aufirst%3DJ.%2BL.%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DLagatutta%26aufirst%3DT.%2BF.%26aulast%3DHamburger%26aufirst%3DD.%2BR.%26aulast%3DJoseph%26aufirst%3DE.%26aulast%3DCovey%26aufirst%3DJ.%2BM.%26aulast%3DEgorin%26aufirst%3DM.%2BJ.%26atitle%3DPharmacokinetics%2520and%2520pharmacodynamics%2520of%252017-demethoxy%252017-%255B%255B%25282-dimethylamino%2529ethyl%255Damino%255Dgeldanamycin%2520%252817DMAG%252C%2520NSC%2520707545%2529%2520in%2520C.B-17%2520SCID%2520mice%2520bearing%2520MDA-MB-231%2520human%2520breast%2520cancer%2520xenografts%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2005%26volume%3D55%26spage%3D21%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span>IPI-493, a Potent, Orally Bioavailable Hsp90 Inhibitor of the Ansamycin Class. <a href="http://infi.com/pipeline-archives/IPI-493%20EORTC%202008.pdf" class="extLink">http://infi.com/pipeline-archives/IPI-493%20EORTC%202008.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=IPI-493%2C+a+Potent%2C+Orally+Bioavailable+Hsp90+Inhibitor+of+the+Ansamycin+Class.+http%3A%2F%2Finfi.com%2Fpipeline-archives%2FIPI-493%2520EORTC%25202008.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Brough, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barril, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgognoni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cansfield, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K.-M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, N. G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drysdale, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northfield, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodromou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roughley, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surgenor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walmsley, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, L.</span><span> </span><span class="NLM_article-title">4,5-Diarylisoxazole HSP90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">196</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701018h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=196-218&author=P.+A.+Broughauthor=W.+Aherneauthor=X.+Barrilauthor=J.+Borgognoniauthor=K.+Boxallauthor=J.+E.+Cansfieldauthor=K.-M.+J.+Cheungauthor=I.+Collinsauthor=N.+G.+M.+Daviesauthor=M.+J.+Drysdaleauthor=B.+Dymockauthor=S.+A.+Ecclesauthor=H.+Finchauthor=A.+Finkauthor=A.+Hayesauthor=R.+Howesauthor=R.+E.+Hubbardauthor=K.+Jamesauthor=A.+M.+Jordanauthor=A.+Lockieauthor=V.+Martinsauthor=A.+Masseyauthor=T.+P.+Matthewsauthor=E.+McDonaldauthor=C.+J.+Northfieldauthor=L.+H.+Pearlauthor=C.+Prodromouauthor=S.+Rayauthor=F.+I.+Raynaudauthor=S.+D.+Roughleyauthor=S.+Y.+Sharpauthor=A.+Surgenorauthor=D.+L.+Walmsleyauthor=P.+Webbauthor=M.+Woodauthor=P.+Workmanauthor=L.+Wright&title=4%2C5-Diarylisoxazole+HSP90+chaperone+inhibitors%3A+potential+therapeutic+agents+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm701018h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701018h%26sid%3Dliteratum%253Aachs%26aulast%3DBrough%26aufirst%3DP.%2BA.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DBorgognoni%26aufirst%3DJ.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DCansfield%26aufirst%3DJ.%2BE.%26aulast%3DCheung%26aufirst%3DK.-M.%2BJ.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DDavies%26aufirst%3DN.%2BG.%2BM.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFinch%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DLockie%26aufirst%3DA.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DNorthfield%26aufirst%3DC.%2BJ.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWalmsley%26aufirst%3DD.%2BL.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DL.%26atitle%3D4%252C5-Diarylisoxazole%2520HSP90%2520chaperone%2520inhibitors%253A%2520potential%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D196%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Woodhead, A. J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angove, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosme, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figueroa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederickson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parra, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trewartha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vimkovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolford, A. J.</span><span> </span><span class="NLM_article-title">Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-yl-methyl)-1,3-dihydroisondol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5956</span><span class="NLM_x">–</span> <span class="NLM_lpage">5969</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100060b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5956-5969&author=A.+J+Woodheadauthor=H.+Angoveauthor=M.+G.+Carrauthor=G.+Chessariauthor=M.+Congreveauthor=J.+E.+Coyleauthor=J.+Cosmeauthor=B.+Grahamauthor=P.+J.+Dayauthor=R.+Downhamauthor=L.+Fazalauthor=R.+Feltellauthor=E.+Figueroaauthor=M.+Fredericksonauthor=J.+Lewisauthor=R.+McMenaminauthor=C.+W.+Murrayauthor=M.+A.+O%E2%80%99Brienauthor=L.+Parraauthor=S.+Patelauthor=T.+Phillipsauthor=D.+C.+Reesauthor=S.+Richauthor=D.-M.+Smithauthor=G.+Trewarthaauthor=M.+Vimkovicauthor=B.+Williamsauthor=A.+J.+Woolford&title=Discovery+of+%282%2C4-dihydroxy-5-isopropylphenyl%29-%5B5-%284-methylpiperazin-1-yl-methyl%29-1%2C3-dihydroisondol-2-yl%5Dmethanone+%28AT13387%29%2C+a+novel+inhibitor+of+the+molecular+chaperone+Hsp90+by+fragment+based+drug+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm100060b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100060b%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhead%26aufirst%3DA.%2BJ%26aulast%3DAngove%26aufirst%3DH.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DCosme%26aufirst%3DJ.%26aulast%3DGraham%26aufirst%3DB.%26aulast%3DDay%26aufirst%3DP.%2BJ.%26aulast%3DDownham%26aufirst%3DR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DFeltell%26aufirst%3DR.%26aulast%3DFigueroa%26aufirst%3DE.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DParra%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DT.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.-M.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DVimkovic%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520of%2520%25282%252C4-dihydroxy-5-isopropylphenyl%2529-%255B5-%25284-methylpiperazin-1-yl-methyl%2529-1%252C3-dihydroisondol-2-yl%255Dmethanone%2520%2528AT13387%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520the%2520molecular%2520chaperone%2520Hsp90%2520by%2520fragment%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5956%26epage%3D5969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Ying, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatsuta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acquaviva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsoum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, K.</span><span> </span><span class="NLM_article-title">Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1535-7163.MCT-11-0755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=22144665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=475-484&author=W.+Yingauthor=Z.+Duauthor=L.+Sunauthor=K.+P.+Foleyauthor=D.+A.+Proiaauthor=R.+K.+Blackmanauthor=D.+Zhouauthor=T.+Inoueauthor=N.+Tatsutaauthor=J.+Sangauthor=S.+Yeauthor=J.+Acquavivaauthor=L.+S.+Ogawaauthor=Y.+Wadaauthor=J.+Barsoumauthor=K.+Koya&title=Ganetespib%2C+a+unique+triazolone-containing+Hsp90+inhibitor%2C+exhibits+potent+antitumor+activity+and+a+superior+safety+profile+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy</span></div><div class="casAuthors">Ying, Weiwen; Du, Zhenjian; Sun, Lijun; Foley, Kevin P.; Proia, David A.; Blackman, Ronald K.; Zhou, Dan; Inoue, Takayo; Tatsuta, Noriaki; Sang, Jim; Ye, Shuxia; Acquaviva, Jamie; Ogawa, Luisa Shin; Wada, Yumiko; Barsoum, James; Koya, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">475-484</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted inhibition of the mol. chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an attractive strategy for the development of novel cancer therapeutics.  Ganetespib (formerly known as STA-9090) is a unique resorcinolic triazolone inhibitor of Hsp90 that is currently in clin. trials for a no. of human cancers.  In the present study, we showed that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematol. tumor cell lines, including those that express mutated kinases that confer resistance to small-mol. tyrosine kinase inhibitors.  Ganetespib treatment rapidly induced the degrdn. of known Hsp90 client proteins, displayed superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), and exhibited sustained activity even with short exposure times.  In vivo, ganetespib showed potent antitumor efficacy in solid and hematol. xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions.  Notably, evaluation of the microregional activity of ganetespib in tumor xenografts showed that ganetespib was efficiently distributed throughout tumor tissue, including hypoxic regions >150 μm from the microvasculature, to inhibit proliferation and induce apoptosis.  Importantly, ganetespib showed no evidence of cardiac or liver toxicity.  Taken together, this preclin. activity profile indicates that ganetespib may have broad application for a variety of human malignancies, and with select mechanistic and safety advantages over other first- and second-generation Hsp90 inhibitors.  Mol Cancer Ther; 11(2); 475-84.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhzG1TPr4lbVg90H21EOLACvtfcHk0lgdNKXn77qJZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D&md5=269d41b30e5add9b9503cb43a98b0157</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0755%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DN.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DOgawa%26aufirst%3DL.%2BS.%26aulast%3DWada%26aufirst%3DY.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DKoya%26aufirst%3DK.%26atitle%3DGanetespib%252C%2520a%2520unique%2520triazolone-containing%2520Hsp90%2520inhibitor%252C%2520exhibits%2520potent%2520antitumor%2520activity%2520and%2520a%2520superior%2520safety%2520profile%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D475%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Nakashima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagaya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seike, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiotsu, Y.</span><span> </span><span class="NLM_article-title">New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2792</span><span class="NLM_x">–</span> <span class="NLM_lpage">2802</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1078-0432.CCR-09-3112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=20406843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvF2hsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2792-2802&author=T.+Nakashimaauthor=T.+Ishiiauthor=H.+Tagayaauthor=T.+Seikeauthor=H.+Nakagawaauthor=Y.+Kandaauthor=S.+Akinagaauthor=S.+Sogaauthor=Y.+Shiotsu&title=New+molecular+and+biological+mechanism+of+antitumor+activities+of+KW-2478%2C+a+novel+nonansamycin+heat+shock+protein+90+inhibitor%2C+in+multiple+myeloma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells</span></div><div class="casAuthors">Nakashima, Takayuki; Ishii, Toshihiko; Tagaya, Hisashi; Seike, Toshihiro; Nakagawa, Hiroshi; Kanda, Yutaka; Akinaga, Shiro; Soga, Shiro; Shiotsu, Yukimasa</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2792-2802</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The heat shock protein 90 (Hsp90) plays an important role in chaperoning oncogenic client proteins in multiple myeloma (MM) cells, and several Hsp90 inhibitors have shown antitumor activities both in vitro and in vivo.  However the precise mechanism of action of Hsp90 inhibitor in MM has not been fully elucidated.  Exptl. Design: The authors evaluated the antitumor activities of KW-2478, a nonansamycin Hsp90 inhibitor, in MM cells with various chromosomal translocations of Ig heavy chain (IgH) loci both in vitro and in vivo.  RESULTS: The authors' studies revealed that exposure of KW-2478 to MM cells resulted in growth inhibition and apoptosis, which were assocd. with degrdn. of well-known client proteins as well as a decrease in IgH translocation products (FGFR3, c-Maf, and cyclin D1), and FGFR3 was shown to be a new client protein of Hsp90 chaperon complex.  In addn., KW-2478 depleted the Hsp90 client Cdk9, a transcriptional kinase, and the phosphorylated 4E-BP1, a translational inhibitor.  Both inhibitory effects of KW-2478 on such transcriptional and translational pathways were shown to reduce c-Maf and cyclin D1 expression.  In NCI-H929 s.c. inoculated model, KW-2478 showed a significant suppression of tumor growth and induced the degrdn. of client proteins in tumors.  Furthermore, in a novel orthotopic MM model of i.v. inoculated OPM-2/green fluorescent protein, KW-2478 showed a significant redn. of both serum M protein and MM tumor burden in the bone marrow.  CONCLUSIONS: These results suggest that targeting such diverse pathways by KW-2478 could be a promising strategy for the treatment of MM with various cytogenetic abnormalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozKElc2AcPx7Vg90H21EOLACvtfcHk0ljMsORBe495Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvF2hsr8%253D&md5=dfe115d5696acc0a9ae62c94c24a42ec</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-3112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-3112%26sid%3Dliteratum%253Aachs%26aulast%3DNakashima%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DTagaya%26aufirst%3DH.%26aulast%3DSeike%26aufirst%3DT.%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DSoga%26aufirst%3DS.%26aulast%3DShiotsu%26aufirst%3DY.%26atitle%3DNew%2520molecular%2520and%2520biological%2520mechanism%2520of%2520antitumor%2520activities%2520of%2520KW-2478%252C%2520a%2520novel%2520nonansamycin%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%2520in%2520multiple%2520myeloma%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D2792%26epage%3D2802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Immormino, R. M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gewirth, D. T.</span><span> </span><span class="NLM_article-title">Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4953</span><span class="NLM_x">–</span> <span class="NLM_lpage">4960</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060297x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4953-4960&author=R.+M+Immorminoauthor=Y.+Kangauthor=G.+Chiosisauthor=D.+T.+Gewirth&title=Structural+and+quantum+chemical+studies+of+8-aryl-sulfanyl+adenine+class+Hsp90+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1021%2Fjm060297x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060297x%26sid%3Dliteratum%253Aachs%26aulast%3DImmormino%26aufirst%3DR.%2BM%26aulast%3DKang%26aufirst%3DY.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26atitle%3DStructural%2520and%2520quantum%2520chemical%2520studies%2520of%25208-aryl-sulfanyl%2520adenine%2520class%2520Hsp90%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4953%26epage%3D4960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Caldas-Lopes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerchietti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robles, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moulick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taldone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Stanchina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varticovski, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">8368</span><span class="NLM_x">–</span> <span class="NLM_lpage">8373</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=8368-8373&author=E.+Caldas-Lopesauthor=L.+Cerchiettiauthor=J.+H.+Ahnauthor=C.+C.+Clementauthor=A.+I.+Roblesauthor=A.+Rodinaauthor=K.+Moulickauthor=T.+Taldoneauthor=A.+Gozmanauthor=Y.+Guoauthor=N.+Wuauthor=E.+de+Stanchinaauthor=J.+Whiteauthor=S.+S.+Grossauthor=Y.+Maauthor=L.+Varticovskiauthor=A.+Melnickauthor=G.+Chiosis&title=Hsp90+inhibitor+PU-H71%2C+a+multimodal+inhibitor+of+malignancy%2C+induces+complete+responses+in+triple-negative+breast+cancer+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaldas-Lopes%26aufirst%3DE.%26aulast%3DCerchietti%26aufirst%3DL.%26aulast%3DAhn%26aufirst%3DJ.%2BH.%26aulast%3DClement%26aufirst%3DC.%2BC.%26aulast%3DRobles%26aufirst%3DA.%2BI.%26aulast%3DRodina%26aufirst%3DA.%26aulast%3DMoulick%26aufirst%3DK.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DGozman%26aufirst%3DA.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DN.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DGross%26aufirst%3DS.%2BS.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DVarticovski%26aufirst%3DL.%26aulast%3DMelnick%26aufirst%3DA.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DHsp90%2520inhibitor%2520PU-H71%252C%2520a%2520multimodal%2520inhibitor%2520of%2520malignancy%252C%2520induces%2520complete%2520responses%2520in%2520triple-negative%2520breast%2520cancer%2520models%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D8368%26epage%3D8373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Rocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">4046</span><span class="NLM_x">–</span> <span class="NLM_lpage">4057</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1078-0432.CCR-09-0152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=19509149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntlOisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=4046-4057&author=R.+Baoauthor=C.-J.+Laiauthor=H.+Quauthor=D.+Wangauthor=L.+Yinauthor=B.+Zifcakauthor=R.+Atoyanauthor=J.+Wangauthor=M.+Samsonauthor=J.+Forresterauthor=S.+Della+Roccaauthor=G.-X.+Xuauthor=X.+Taoauthor=H.-X.+Zhaiauthor=X.+Caiauthor=C.+Qian&title=CUDC-305%2C+a+novel+synthetic+HSP90+inhibitor+with+unique+pharmacologic+properties+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy</span></div><div class="casAuthors">Bao, Rudi; Lai, Cheng-Jung; Qu, Hui; Wang, Dagong; Yin, Ling; Zifcak, Brian; Atoyan, Ruzanna; Wang, Jing; Samson, Maria; Forrester, Jeffrey; Della Rocca, Steven; Xu, Guang-Xin; Tao, Xu; Zhai, Hai-Xiao; Cai, Xiong; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4046-4057</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class.  Here, we report its unique pharmacol. properties and antitumor activities in a variety of tumor types.  The potency of the compd. was analyzed by fluorescence polarization competition binding assay.  Its antiproliferative activities were assessed in 40 human cancer cell lines.  Its pharmacol. properties and antitumor activities were evaluated in a variety of tumor xenograft models.  CUDC-305 shows high affinity for HSP90α/β (IC50, ∼100 nmol/L) and HSP90 complex derived from cancer cells (IC50, 48.8 nmol/L).  It displays potent antiproliferative activity against a broad range of cancer cell lines (mean IC50, 220 nmol/L).  CUDC-305 exhibits high oral bioavailability (96.0%) and selective retention in tumor (half-life, 20.4 h) compared with normal tissues.  Furthermore, CUDC-305 can cross blood-brain barrier and reach therapeutic levels in brain tissue.  CUDC-305 exhibits dose-dependent antitumor activity in an s.c. xenograft model of U87MG glioblastoma and significantly prolongs animal survival in U87MG orthotopic model.  CUDC-305 also displays potent antitumor activity in animal models of erlotinib-resistant non-small cell lung cancer and induces tumor regression in animal models of MDA-MB-468 breast cancer and MV4-11 acute myelogenous leukemia.  Correlating with its efficacy in these various tumor models, CUDC-305 robustly inhibits multiple signaling pathways, including PI3K/AKT and RAF/MEK/ERK, and induces apoptosis.  In combination studies, CUDC-305 enhances the antitumor activity of std.-of-care agents in breast and colorectal tumor models.  CUDC-305 is a promising drug candidate for the treatment of a variety of cancers, including brain malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyxsZpWkM4MrVg90H21EOLACvtfcHk0ljMsORBe495Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntlOisL4%253D&md5=b872c7658a2fc98f263f7e6a23cb58f6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0152%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DR.%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DDella%2BRocca%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DG.-X.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-305%252C%2520a%2520novel%2520synthetic%2520HSP90%2520inhibitor%2520with%2520unique%2520pharmacologic%2520properties%2520for%2520cancer%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D4046%26epage%3D4057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span>Evaluation of the Pharmacokinetics and Efficacy of a Novel Pro-Drug of the HSP90 Inhibitor. <a href="http://www.myriadpharma.com/images/stories/product-pipeline/mpc-3100/AACR%202011/aacr-2011-abst3237-mpc-3100-prodrug-mpc-0767.pdf" class="extLink">http://www.myriadpharma.com/images/stories/product-pipeline/mpc-3100/AACR%202011/aacr-2011-abst3237-mpc-3100-prodrug-mpc-0767.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Evaluation+of+the+Pharmacokinetics+and+Efficacy+of+a+Novel+Pro-Drug+of+the+HSP90+Inhibitor.+http%3A%2F%2Fwww.myriadpharma.com%2Fimages%2Fstories%2Fproduct-pipeline%2Fmpc-3100%2FAACR%25202011%2Faacr-2011-abst3237-mpc-3100-prodrug-mpc-0767.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Fadden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steed, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barabasz, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Partridge, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubois, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freed, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silinski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barta, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ommen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spangenberg, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaves, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenks, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pronk, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verleysen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haystead, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. E.</span><span> </span><span class="NLM_article-title">Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">686</span><span class="NLM_x">–</span> <span class="NLM_lpage">694</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1016%2Fj.chembiol.2010.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=20659681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptleitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=686-694&author=P.+Faddenauthor=K.+H.+Huangauthor=J.+M.+Vealauthor=P.+M.+Steedauthor=A.+F.+Barabaszauthor=B.+Foleyauthor=M.+Huauthor=J.+M.+Partridgeauthor=J.+Riceauthor=A.+Scottauthor=L.+G.+Duboisauthor=T.+A.+Freedauthor=M.+A.+Silinskiauthor=T.+E.+Bartaauthor=P.+F.+Hughesauthor=A.+Ommenauthor=W.+Maauthor=E.+D.+Smithauthor=A.+W.+Spangenbergauthor=J.+Eavesauthor=G.+J.+Hansonauthor=L.+Hinkleyauthor=M.+Jenksauthor=M.+Lewisauthor=J.+Ottoauthor=G.+J.+Pronkauthor=K.+Verleysenauthor=T.+A.+Haysteadauthor=S.+E.+Hall&title=Application+of+chemoproteomics+to+drug+discovery%3A+identification+of+a+clinical+candidate+targeting+hsp90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Chemoproteomics to Drug Discovery: Identification of a Clinical Candidate Targeting Hsp90</span></div><div class="casAuthors">Fadden, Patrick; Huang, Kenneth H.; Veal, James M.; Steed, Paul M.; Barabasz, Amy F.; Foley, Briana; Hu, Mei; Partridge, Jeffrey M.; Rice, John; Scott, Anisa; Dubois, Laura G.; Freed, Tiffany A.; Rehder Silinski, Melanie A.; Barta, Thomas E.; Hughes, Philip F.; Ommen, Andy; Ma, Wei; Smith, Emilie D.; Woodward Spangenberg, Angela; Eaves, Jeron; Hanson, Gunnar J.; Hinkley, Lindsay; Jenks, Matthew; Lewis, Meredith; Otto, James; Pronk, Gijsbertus J.; Verleysen, Katleen; Haystead, Timothy A.; Hall, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">686-694</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: A chemoproteomics-based drug discovery strategy is presented that utilizes a highly parallel screening platform, encompassing more than 1000 targets, with a focused chem. library prior to target selection.  This chemoproteomics-based process enables a data-driven selection of both the biol. target and chem. hit after the screen is complete.  The methodol. has been exemplified for the purine binding proteome (proteins utilizing ATP, NAD, FAD).  Screening of an 8000 member library yielded over 1500 unique protein-ligand interactions, which included novel hits for the oncol. target Hsp90.  The approach, which also provides broad target selectivity information, was used to drive the identification of a potent and orally active Hsp90 inhibitor, SNX-5422, which is currently in phase 1 clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfemxEaaJVH7Vg90H21EOLACvtfcHk0lg8CyyGEcXNrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptleitL4%253D&md5=68486178a6847516af3fb5417a9b1911</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DFadden%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DK.%2BH.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DSteed%26aufirst%3DP.%2BM.%26aulast%3DBarabasz%26aufirst%3DA.%2BF.%26aulast%3DFoley%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DPartridge%26aufirst%3DJ.%2BM.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DA.%26aulast%3DDubois%26aufirst%3DL.%2BG.%26aulast%3DFreed%26aufirst%3DT.%2BA.%26aulast%3DSilinski%26aufirst%3DM.%2BA.%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DHughes%26aufirst%3DP.%2BF.%26aulast%3DOmmen%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DE.%2BD.%26aulast%3DSpangenberg%26aufirst%3DA.%2BW.%26aulast%3DEaves%26aufirst%3DJ.%26aulast%3DHanson%26aufirst%3DG.%2BJ.%26aulast%3DHinkley%26aufirst%3DL.%26aulast%3DJenks%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DJ.%26aulast%3DPronk%26aufirst%3DG.%2BJ.%26aulast%3DVerleysen%26aufirst%3DK.%26aulast%3DHaystead%26aufirst%3DT.%2BA.%26aulast%3DHall%26aufirst%3DS.%2BE.%26atitle%3DApplication%2520of%2520chemoproteomics%2520to%2520drug%2520discovery%253A%2520identification%2520of%2520a%2520clinical%2520candidate%2520targeting%2520hsp90%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D686%26epage%3D694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Kasibhatla, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biamonte, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busch, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karjian, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensintaffar, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lough, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brekken, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundgren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grecko, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timony, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ran, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansfield, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulm, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M. F.</span><span> </span><span class="NLM_article-title">Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2767</span><span class="NLM_x">–</span> <span class="NLM_lpage">2778</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050752%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2767-2778&author=S.+R.+Kasibhatlaauthor=K.+Hongauthor=M.+A.+Biamonteauthor=D.+J.+Buschauthor=P.+L.+Karjianauthor=J.+L.+Sensintaffarauthor=A.+Kamalauthor=R.+E.+Loughauthor=J.+Brekkenauthor=K.+Lundgrenauthor=R.+Greckoauthor=G.+A.+Timonyauthor=Y.+Ranauthor=R.+Mansfieldauthor=L.+C.+Fritzauthor=E.+Ulmauthor=F.+J.+Burrowsauthor=M.+F.+Boehm&title=Rationally+designed+high-affinity+2-amino-6-halopurine+heat+shock+protein+90+inhibitors+that+exhibit+potent+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm050752%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050752%252B%26sid%3Dliteratum%253Aachs%26aulast%3DKasibhatla%26aufirst%3DS.%2BR.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DBusch%26aufirst%3DD.%2BJ.%26aulast%3DKarjian%26aufirst%3DP.%2BL.%26aulast%3DSensintaffar%26aufirst%3DJ.%2BL.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DLough%26aufirst%3DR.%2BE.%26aulast%3DBrekken%26aufirst%3DJ.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DGrecko%26aufirst%3DR.%26aulast%3DTimony%26aufirst%3DG.%2BA.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DMansfield%26aufirst%3DR.%26aulast%3DFritz%26aufirst%3DL.%2BC.%26aulast%3DUlm%26aufirst%3DE.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26atitle%3DRationally%2520designed%2520high-affinity%25202-amino-6-halopurine%2520heat%2520shock%2520protein%252090%2520inhibitors%2520that%2520exhibit%2520potent%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2767%26epage%3D2778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Menezes, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taverna, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duhl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machajewski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryer, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z.</span><span> </span><span class="NLM_article-title">The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1535-7163.MCT-11-0667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=22246440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=730-739&author=D.+L.+Menezesauthor=P.+Tavernaauthor=M.+R.+Jensenauthor=T.+Abramsauthor=D.+Stuartauthor=G.+K.+Yuauthor=D.+Duhlauthor=T.+Machajewskiauthor=W.+R.+Sellersauthor=N.+K.+Pryerauthor=Z.+Gao&title=The+novel+oral+Hsp90+inhibitor+NVP-HSP990+exhibits+potent+and+broad-spectrum+antitumor+activities+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo</span></div><div class="casAuthors">Menezes, Daniel L.; Taverna, Pietro; Jensen, Michael R.; Abrams, Tinya; Stuart, Darrin; Yu, Guoying Karen; Duhl, David; Machajewski, Timothy; Sellers, William R.; Pryer, Nancy K.; Gao, Zhenhai</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A novel oral Hsp90 inhibitor, NVP-HSP990, has been developed and characterized in vitro and in vivo.  In vitro, NVP-HSP990 exhibits single digit nanomolar IC50 values on three of the Hsp90 isoforms (Hsp90α, Hsp90β, and GRP94) and 320 nanomolar IC50 value on the fourth (TRAP-1), with selectivity against unrelated enzymes, receptors, and kinases.  In c-Met amplified GTL-16 gastric tumor cells, NVP-HSP990 dissocd. the Hsp90-p23 complex, depleted client protein c-Met, and induced Hsp70.  NVP-HSP990 potently inhibited the growth of human cell lines and primary patient samples from a variety of tumor types.  In vivo, NVP-HSP990 exhibits drug-like pharmaceutical and pharmacol. properties with high oral bioavailability.  In the GTL-16 xenograft model, a single oral administration of 15 mg/kg of NVP-HSP990 induced sustained downregulation of c-Met and upregulation of Hsp70.  In repeat dosing studies, NVP-HSP990 treatment resulted in tumor growth inhibition of GTL-16 and other human tumor xenograft models driven by well-defined oncogenic Hsp90 client proteins.  On the basis of its pharmacol. profile and broad-spectrum antitumor activities, clin. trials have been initiated to evaluate NVP-HSP990 in advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4xi_VsuoE5rVg90H21EOLACvtfcHk0lg8CyyGEcXNrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKisLs%253D&md5=34994c38583b9d59d01f7a8bb8354809</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0667%26sid%3Dliteratum%253Aachs%26aulast%3DMenezes%26aufirst%3DD.%2BL.%26aulast%3DTaverna%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DStuart%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DG.%2BK.%26aulast%3DDuhl%26aufirst%3DD.%26aulast%3DMachajewski%26aufirst%3DT.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DPryer%26aufirst%3DN.%2BK.%26aulast%3DGao%26aufirst%3DZ.%26atitle%3DThe%2520novel%2520oral%2520Hsp90%2520inhibitor%2520NVP-HSP990%2520exhibits%2520potent%2520and%2520broad-spectrum%2520antitumor%2520activities%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">For another series, also from Novartis, see the following: </p></div><span class="NLM_contrib-group">Massey, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepfer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chene, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drysdale, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfaar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radimerski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruetz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweitzer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, M. R.</span><span> </span><span class="NLM_article-title">Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">906</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1535-7163.MCT-10-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=20371713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktlCqt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=906-919&author=A.+J.+Masseyauthor=J.+Schoepferauthor=P.+A.+Broughauthor=J.+Brueggenauthor=P.+Cheneauthor=M.+J.+Drysdaleauthor=U.+Pfaarauthor=T.+Radimerskiauthor=S.+Ruetzauthor=A.+Schweitzerauthor=M.+Woodauthor=C.+Garcia-Echeverriaauthor=M.+R.+Jensen&title=Preclinical+antitumor+activity+of+the+orally+available+heat+shock+protein+90+inhibitor+NVP-BEP800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800</span></div><div class="casAuthors">Massey, Andrew J.; Schoepfer, Joseph; Brough, Paul A.; Brueggen, Josef; Chene, Patrick; Drysdale, Martin J.; Pfaar, Ulrike; Radimerski, Thomas; Ruetz, Stephan; Schweitzer, Alain; Wood, Mike; Garcia-Echeverria, Carlos; Jensen, Michael Rugaard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">906-919</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a ubiquitously expressed mol. chaperone with ATPase activity involved in the conformational maturation and stability of key signaling mols. involved in cell proliferation, survival, and transformation.  Through its ability to modulate multiple pathways involved in oncogenesis, Hsp90 has generated considerable interest as a therapeutic target.  NVP-BEP800 is a novel, fully synthetic, orally bioavailable inhibitor that binds to the NH2-terminal ATP-binding pocket of Hsp90.  NVP-BEP800 showed activity against a panel of human tumor cell lines and primary human xenografts in vitro at nanomolar concns.  In A375 melanoma and BT-474 breast cancer cell lines, NVP-BEP800 induced client protein degrdn. (including ErbB2, B-RafV600E, Raf-1, and Akt) and Hsp70 induction.  Oral administration of NVP-BEP800 was well tolerated and induced robust antitumor responses in tumor xenograft models, including regression in the BT-474 breast cancer model.  In these tumor models, NVP-BEP800 modulated Hsp90 client proteins and downstream signaling pathways at doses causing antitumor activity.  NVP-BEP800 showed in vivo activity in a variety of dosing regimens covering daily to weekly schedules, potentially providing a high degree of flexibility in dose and schedule within the clin. setting.  Overall, given the mechanism of action, preclin. activity profile, tolerability, and pharmaceutical properties, NVP-BEP800 is an exciting new oral Hsp90 inhibitor warranting further development.  Mol Cancer Ther; 9(4); 906-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWkCBDzOlzZ7Vg90H21EOLACvtfcHk0liL6MK0sYRTyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktlCqt7s%253D&md5=8b52241a44d2fdd2a38aa7edaa99101c</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0055%26sid%3Dliteratum%253Aachs%26aulast%3DMassey%26aufirst%3DA.%2BJ.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DBrough%26aufirst%3DP.%2BA.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DPfaar%26aufirst%3DU.%26aulast%3DRadimerski%26aufirst%3DT.%26aulast%3DRuetz%26aufirst%3DS.%26aulast%3DSchweitzer%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520the%2520orally%2520available%2520heat%2520shock%2520protein%252090%2520inhibitor%2520NVP-BEP800%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D906%26epage%3D919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopeck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moynahan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannan, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C.</span><span> </span><span class="NLM_article-title">Hsp90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with Her-2 positive metastatic breast cancer progressing on trastuzumab</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5132</span><span class="NLM_x">–</span> <span class="NLM_lpage">5139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1078-0432.CCR-11-0072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=21558407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=5132-5139&author=S.+Modiauthor=A.+Stopeckauthor=A.+Lindenauthor=D.+Solitauthor=S.+Chandarlapatyauthor=N.+Rosenauthor=G.+D%E2%80%99Andreaauthor=M.+Dicklerauthor=M.+E.+Moynahanauthor=S.+Sugarmanauthor=W.+Maauthor=S.+Patilauthor=L.+Nortonauthor=A.+L.+Hannanauthor=C.+Hudis&title=Hsp90+inhibition+is+effective+in+breast+cancer%3A+a+phase+II+trial+of+tanespimycin+%2817-AAG%29+plus+trastuzumab+in+patients+with+Her-2+positive+metastatic+breast+cancer+progressing+on+trastuzumab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab</span></div><div class="casAuthors">Modi, Shanu; Stopeck, Alison; Linden, Hannah; Solit, David; Chandarlapaty, Sarat; Rosen, Neal; D'Andrea, Gabriella; Dickler, Maura; Moynahan, Mary E.; Sugarman, Steven; Ma, Weining; Patil, Sujata; Norton, Larry; Hannah, Alison L.; Hudis, Clifford</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5132-5139</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: HSP90 is a chaperone protein required for the stability of a variety of client proteins. 17-Demethoxygeldanamycin (17-AAG) is a natural product that binds to HSP90 and inhibits its activity, thereby inducing the degrdn. of these clients.  In preclin. studies, HER2 is one of the most sensitive known client proteins of 17-AAG.  On the basis of these data and activity in a phase I study, we conducted a phase II study of 17-AAG (tanespimycin) with trastuzumab in advanced trastuzumab-refractory HER2-pos. breast cancer.  Exptl. Design: We enrolled patients with metastatic HER2+ breast cancer whose disease had previously progressed on trastuzumab.  All patients received weekly treatment with tanespimycin at 450 mg/m2 i.v. and trastuzumab at a conventional dose.  Therapy was continued until disease progression.  The primary endpoint was response rate by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.  RESULTS: Thirty-one patients were enrolled with a median age of 53 years and a median Karnofsky performance status (KPS) of 90%.  The most common toxicities, largely grade 1, were diarrhea, fatigue, nausea, and headache.  The overall response rate was 22%, the clin. benefit rate [complete response + partial response + stable disease] was 59%, the median progression-free survival was 6 mo (95% CI: 4-9), and the median overall survival was 17 mo (95% CI: 16-28).  CONCLUSIONS: This is the first phase II study to definitively show RECIST-defined responses for 17-AAG in solid tumors.  Tanespimycin plus trastuzumab has significant anticancer activity in patients with HER2-pos., metastatic breast cancer previously progressing on trastuzumab.  Further research exploring this therapeutic interaction and the activity of HSP90 inhibitors is clearly warranted.  Clin Cancer Res; 17(15); 5132-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFgVCzhN1fHLVg90H21EOLACvtfcHk0liL6MK0sYRTyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbw%253D&md5=07d9e8e06caad7cd7abe03f9e9f7375a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0072%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DS.%26aulast%3DStopeck%26aufirst%3DA.%26aulast%3DLinden%26aufirst%3DA.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DDickler%26aufirst%3DM.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DHannan%26aufirst%3DA.%2BL.%26aulast%3DHudis%26aufirst%3DC.%26atitle%3DHsp90%2520inhibition%2520is%2520effective%2520in%2520breast%2520cancer%253A%2520a%2520phase%2520II%2520trial%2520of%2520tanespimycin%2520%252817-AAG%2529%2520plus%2520trastuzumab%2520in%2520patients%2520with%2520Her-2%2520positive%2520metastatic%2520breast%2520cancer%2520progressing%2520on%2520trastuzumab%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D5132%26epage%3D5139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Wong, K. K.; Koczywas, M.; Goldman, J. W.; Paschold, E. H.; Horn, L.; Lufkin, J. M.; Kepros, J.; Teofilici, F.; Shapiro, G.; Socinski, M. A.</span><span> </span><span class="NLM_article-title">An Open-Label Phase II Study of the Hsp90 Inhibitor Ganetespib. (STA-9090) as Monotherapy in Patients with Advanced NSCLC</span>. Presented at the ASCO Annual Meeting,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://www.syntapharma.com/Documents/Ganetespib_Phase%202%20NSCLC_Shapiro_ASCO%202011.pdf" class="extLink">http://www.syntapharma.com/Documents/Ganetespib_Phase%202%20NSCLC_Shapiro_ASCO%202011.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=K.+K.+Wong&author=M.+Koczywas&author=J.+W.+Goldman&author=E.+H.+Paschold&author=L.+Horn&author=J.+M.+Lufkin&author=J.+Kepros&author=F.+Teofilici&author=G.+Shapiro&author=M.+A.+Socinski&title=An+Open-Label+Phase+II+Study+of+the+Hsp90+Inhibitor+Ganetespib.+%28STA-9090%29+as+Monotherapy+in+Patients+with+Advanced+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DAn%2520Open-Label%2520Phase%2520II%2520Study%2520of%2520the%2520Hsp90%2520Inhibitor%2520Ganetespib.%2520%2528STA-9090%2529%2520as%2520Monotherapy%2520in%2520Patients%2520with%2520Advanced%2520NSCLC%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gettinger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senzer, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilenbaum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafeez, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayzel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borger, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natale, R.</span><span> </span><span class="NLM_article-title">Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">4953</span><span class="NLM_x">–</span> <span class="NLM_lpage">4960</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1200%2FJCO.2010.30.8338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=20940188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFCntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=4953-4960&author=L.+V.+Sequistauthor=S.+Gettingerauthor=N.+N.+Senzerauthor=R.+G.+Martinsauthor=P.+A.+J%C3%A4nneauthor=R.+Lilenbaumauthor=J.+E.+Grayauthor=A.+J.+Iafrateauthor=R.+Katayamaauthor=N.+Hafeezauthor=J.+Sweeneyauthor=J.+R.+Walkerauthor=C.+Fritzauthor=R.+W.+Rossauthor=D.+Grayzelauthor=J.+A.+Engelmanauthor=D.+R.+Borgerauthor=G.+Paezauthor=R.+Natale&title=Activity+of+IPI-504%2C+a+novel+heat-shock+protein+90+inhibitor%2C+in+patients+with+molecularly+defined+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Gettinger, Scott; Senzer, Neil N.; Martins, Renato G.; Janne, Pasi A.; Lilenbaum, Rogerio; Gray, Jhanelle E.; Iafrate, A. John; Katayama, Ryohei; Hafeez, Nafeeza; Sweeney, Jennifer; Walker, John R.; Fritz, Christian; Ross, Robert W.; Grayzel, David; Engelman, Jeffrey A.; Borger, Darrell R.; Paez, Guillermo; Natale, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4953-4960</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: IPI-504 is a novel, water-sol., potent inhibitor of heat-shock protein 90 (Hsp90).  Its potential anticancer activity has been validated in preclin. in vitro and in vivo models.  We studied the activity of IPI-504 after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced, molecularly defined non-small-cell lung cancer (NSCLC).  Patients and Methods: Patients with advanced NSCLC, prior treatment with EGFR TKIs, and tumor tissue available for mol. genotyping were enrolled in this prospective, nonrandomized, multicenter, phase II study of IPI-504 monotherapy.  The primary outcome was objective response rate (ORR).  Secondary aims included safety, progression-free survival (PFS), and anal. of activity by mol. subtypes.  Results: Seventy-six patients were enrolled between Dec. 2007 and May 2009 from 10 United States cancer centers.  An ORR of 7% (five of 76) was obsd. in the overall study population, 10% (four of 40) in patients who were EGFR wild-type, and 4% (one of 28) in those with EGFR mutations.  Although both EGFR groups were below the target ORR of 20%, among the three patients with an ALK gene rearrangement, two had partial responses and the third had prolonged stable disease (7.2 mo, 24% redn. in tumor size).  The most common adverse events included grades 1 and 2 fatigue, nausea, and diarrhea.  Grade 3 or higher liver function abnormalities were obsd. in nine patients (11.8%).  Conclusion: IPI-504 has clin. activity in patients with NSCLC, particularly among patients with ALK rearrangements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyleDQqYi1qLVg90H21EOLACvtfcHk0lheUmxNm5TnIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFCntA%253D%253D&md5=accaddc9ab9e334d40d513a70fbcd9ed</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.30.8338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.30.8338%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DGettinger%26aufirst%3DS.%26aulast%3DSenzer%26aufirst%3DN.%2BN.%26aulast%3DMartins%26aufirst%3DR.%2BG.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DLilenbaum%26aufirst%3DR.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DHafeez%26aufirst%3DN.%26aulast%3DSweeney%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DFritz%26aufirst%3DC.%26aulast%3DRoss%26aufirst%3DR.%2BW.%26aulast%3DGrayzel%26aufirst%3DD.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DBorger%26aufirst%3DD.%2BR.%26aulast%3DPaez%26aufirst%3DG.%26aulast%3DNatale%26aufirst%3DR.%26atitle%3DActivity%2520of%2520IPI-504%252C%2520a%2520novel%2520heat-shock%2520protein%252090%2520inhibitor%252C%2520in%2520patients%2520with%2520molecularly%2520defined%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D4953%26epage%3D4960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">7535</span><span class="NLM_x">–</span> <span class="NLM_lpage">7540</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebiauthor=V.+M.+Riveraauthor=W.+C.+Shakespeareauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Therapeutic+strategies+to+overcome+crizotinib+resistance+in+non-small+cell+lung+cancers+harboring+the+fusion+oncogene+EML4-ALK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520strategies%2520to%2520overcome%2520crizotinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancers%2520harboring%2520the%2520fusion%2520oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D7535%26epage%3D7540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Richardson, P G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanan-Khan, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonial, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">153</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="NLM_x">–</span> <span class="NLM_lpage">740</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1111%2Fj.1365-2141.2011.08664.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=21534941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslajtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2011&pages=729-740&author=P+G.+Richardsonauthor=A.+A.+Chanan-Khanauthor=S.+Lonialauthor=A.+Y.+Krishnanauthor=M.+P.+Carrollauthor=M.+Alsinaauthor=M.+Albitarauthor=D.+Bermanauthor=M.+Messinaauthor=K.+C.+Anderson&title=Tanespimycin+and+bortezomib+combination+treatment+in+patients+with+relapsed+or+relapsed+and+refractory+multiple+myeloma%3A+results+of+a+phase+1%2F2+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study</span></div><div class="casAuthors">Richardson, Paul G.; Chanan-Khan, Asher A.; Lonial, Sagar; Krishnan, Amrita Y.; Carroll, Michael P.; Alsina, Melissa; Albitar, Maher; Berman, David; Messina, Marianne; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">729-740</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">This open-label, dose escalation, multicentre phase 1/2 trial was undertaken to det. the safety and tolerability of the heat shock protein 90 (HSP90) inhibitor tanespimycin (100-340 mg/m2) + bortezomib (0.7-1.3 mg/m2) given on days 1, 4, 8 and 11 in each 21-d cycle.  Phase 2 expansion occurred at the highest tested dose of tanespimycin at 340 mg/m2 and bortezomib at 1.3 mg/m2.  Seventy-two patients (median age, 60 years) with relapsed or relapsed and refractory multiple myeloma (MM) were enrolled; 63 patients (89%) completed the study.  Tanespimycin in combination with bortezomib was well tolerated; few patients experienced significant neutropenia, constipation and anorexia (<10%), and no patients developed severe peripheral neuropathy.  Among 67 efficacy-evaluable patients, there were 2 (3%) complete responses and 8 (12%) partial responses, for an objective response rate (ORR) of 27%, including 8 (12%) minimal responses.  Response rates were highest among bortezomib-naive patients and proved durable in all patient subgroups, including those with bortezomib-refractory disease.  Pharmacodynamic analyses indicated that tanespimycin plus bortezomib effectively inhibited the proteasome, as evidenced by decreased 20S proteasome activity, and inhibited HSP90, as reflected by increased HSP70 expression.  The results of this study support addnl. studies of this combination approach in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw1MlwVkziIrVg90H21EOLACvtfcHk0lheUmxNm5TnIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslajtrY%253D&md5=c1d4ac3b4758b8830cf2b192979e3961</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2011.08664.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2011.08664.x%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP%2BG.%26aulast%3DChanan-Khan%26aufirst%3DA.%2BA.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DKrishnan%26aufirst%3DA.%2BY.%26aulast%3DCarroll%26aufirst%3DM.%2BP.%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DBerman%26aufirst%3DD.%26aulast%3DMessina%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DTanespimycin%2520and%2520bortezomib%2520combination%2520treatment%2520in%2520patients%2520with%2520relapsed%2520or%2520relapsed%2520and%2520refractory%2520multiple%2520myeloma%253A%2520results%2520of%2520a%2520phase%25201%252F2%2520study%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2011%26volume%3D153%26spage%3D729%26epage%3D740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laubach, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonial, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanan-Khan, A. A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1111%2Fj.1365-2141.2010.08360.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=21219297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtVOntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2011&pages=367-379&author=P.+G.+Richardsonauthor=C.+S.+Mitsiadesauthor=J.+P.+Laubachauthor=S.+Lonialauthor=A.+A+Chanan-Khanauthor=K.+C.+Anderson&title=Inhibition+of+heat+shock+protein+90+%28HSP90%29+as+a+therapeutic+strategy+for+the+treatment+of+myeloma+and+other+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers</span></div><div class="casAuthors">Richardson, Paul G.; Mitsiades, Constantine S.; Laubach, Jacob P.; Lonial, Sagar; Chanan-Khan, Asher A.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">367-379</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Heat shock protein 90 (HSP90) is a mol. chaperone that is induced in response to cellular stress and stabilizes client proteins involved in cell cycle control and proliferative/anti-apoptotic signalling.  HSP90 is overexpressed in a range of cancers, and may contribute to tumor cell survival by stabilizing aberrant signalling proteins and by interfering with apoptosis.  Tanespimycin, an HSP90 inhibitor, reduces tumor cell survival in vitro.  In multiple myeloma (MM), HSP90 inhibition affects multiple client proteins that contribute to tumor cell survival, including the IGF1 receptor and the IL-6 receptor, and elements of the PI3/Akt, STAT3, and MAPK signalling pathways.  HSP90 inhibition also abrogates the protective effect of bone marrow stromal cells and inhibits angiogenesis and osteoclastogenesis.  Tanespimycin acts synergistically with the proteasome inhibitor bortezomib in MM cells and tumor explants, possibly reducing their ability to resist bortezomib-induced stress to the endoplasmic reticulum.  The combination of tanespimycin and bortezomib has demonstrated significant and durable responses with acceptable toxicity in a phase I/II study in patients with relapsed and relapsed/refractory MM.  HSP90 inhibition is a promising strategy in MM esp. in combination with bortezomib; addnl. studies will further evaluate optimal dosings of candidate drugs and schedules, as well as confirm efficacy in comparative phase III trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9tsEVNXnwwrVg90H21EOLACvtfcHk0lheUmxNm5TnIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtVOntr4%253D&md5=2ec48571564edbf6ec2bcab69baf01a2</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2010.08360.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2010.08360.x%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DChanan-Khan%26aufirst%3DA.%2BA%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DInhibition%2520of%2520heat%2520shock%2520protein%252090%2520%2528HSP90%2529%2520as%2520a%2520therapeutic%2520strategy%2520for%2520the%2520treatment%2520of%2520myeloma%2520and%2520other%2520cancers%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2011%26volume%3D152%26spage%3D367%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Yin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundgren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shores, C. G.</span><span> </span><span class="NLM_article-title">BIIB021, a novel Hsp90 inhibitor, sensitized head and neck squamous cell carcinoma to radiotherapy</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">1216</span><span class="NLM_x">–</span> <span class="NLM_lpage">1225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=19662650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFCr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=1216-1225&author=Z.+Yinauthor=H.+Zhangauthor=K.+Lundgrenauthor=L.+Wilsonauthor=F.+Burrowsauthor=C.+G.+Shores&title=BIIB021%2C+a+novel+Hsp90+inhibitor%2C+sensitized+head+and+neck+squamous+cell+carcinoma+to+radiotherapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy</span></div><div class="casAuthors">Yin, Xiaoying; Zhang, Hong; Lundgren, Karen; Wilson, Lynn; Burrows, Francis; Shores, Carol G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1216-1225</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a mol. chaperone that promotes the conformational maturation of numerous client proteins, many of which play crit. roles in tumor cell growth and survival.  The ansamycin-based Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) is currently in Phase III clin. testing.  However, 17-AAG is difficult to formulate and assocd. with dose-limited toxicity issues.  A fully synthetic and bioavailable Hsp90 inhibitor, BIIB021, was evaluated for antitumor activity in a variety of head and neck squamous cell carcinoma (HNSCC) cell lines and HNSCC xenograft models, either as a single agent or in combination with fractionated radiation and the results were compared with that of 17-AAG.  BIIB021 showed strong antitumor activity, comparable with, and in certain instances, superior to 17-AAG.  BIIB021 enhanced the in vitro radiosensitivity of HNSCCA cell lines with a corresponding redn. in the expression of key radioresponsive proteins, increased apoptotic cells and enhance G2 arrest.  In xenograft studies, BIIB021 exhibited a strong antitumor effect outperforming 17-AAG, either as a single agent and or in combination with radiation, thereby improved the efficacy of radiation.  These results suggest that this synthetic and bioavailable Hsp90 inhibitor affects multiple pathways involved in tumor development and progression in the HNSCC setting and may represent a better strategy for the treatment of HNSCC patients, either as a monotherapy or a radiosensitizer.  Furthermore, it also demonstrates the benefits of using preclin. models of chemosensitization to radiotherapy to explore clin. relevant radiation dosing schemes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOA3e86hmal7Vg90H21EOLACvtfcHk0lhYmUGZwdU7Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFCr&md5=e06436d60f7a79e43d68ec1064d1f6fd</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DL.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DShores%26aufirst%3DC.%2BG.%26atitle%3DBIIB021%252C%2520a%2520novel%2520Hsp90%2520inhibitor%252C%2520sensitized%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%2520to%2520radiotherapy%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2010%26volume%3D126%26spage%3D1216%26epage%3D1225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Infante, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brega, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Hoff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, R.</span><span> </span><span class="NLM_article-title">Phase 1 dose escalation study of the oral heat shock protein 90 (Hsp90) inhibitor PF-04929113/SNX-5422 (PF-113) and its associated ocular toxicity</span> <span class="citation_source-journal">EJC Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1016%2FS1359-6349%2810%2972082-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=119&author=J.+Infanteauthor=G.+Weissauthor=S.+Jonesauthor=R.+Tibesauthor=J.+Bendellauthor=N.+Bregaauthor=V.+Tortiauthor=D.+Von+Hoffauthor=H.+Burrisauthor=R.+Ramanathan&title=Phase+1+dose+escalation+study+of+the+oral+heat+shock+protein+90+%28Hsp90%29+inhibitor+PF-04929113%2FSNX-5422+%28PF-113%29+and+its+associated+ocular+toxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS1359-6349%2810%2972082-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6349%252810%252972082-6%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DTibes%26aufirst%3DR.%26aulast%3DBendell%26aufirst%3DJ.%26aulast%3DBrega%26aufirst%3DN.%26aulast%3DTorti%26aufirst%3DV.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26aulast%3DBurris%26aufirst%3DH.%26aulast%3DRamanathan%26aufirst%3DR.%26atitle%3DPhase%25201%2520dose%2520escalation%2520study%2520of%2520the%2520oral%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitor%2520PF-04929113%252FSNX-5422%2520%2528PF-113%2529%2520and%2520its%2520associated%2520ocular%2520toxicity%26jtitle%3DEJC%2520Suppl.%26date%3D2010%26volume%3D8%26spage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, K. H.; Eaves, J.; Veal, J.; Barta, T.; Lifeng, G.; Hinkley, L.; Hanson, G.</span><span> </span><span class="NLM_article-title">Tetrahydroindolone and Tetrahydroindazolone Derivatives</span>, WO 2006/091963,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=K.+H.+Huang&author=J.+Eaves&author=J.+Veal&author=T.+Barta&author=G.+Lifeng&author=L.+Hinkley&author=G.+Hanson&title=Tetrahydroindolone+and+Tetrahydroindazolone+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DK.%2BH.%26atitle%3DTetrahydroindolone%2520and%2520Tetrahydroindazolone%2520Derivatives%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Huang, K. H.; Eaves, J.; Veal, J.; Hall, S. E.; Barta, T. E.; Hanson, G. J.</span><span> </span><span class="NLM_article-title">Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives</span>. US 2007/0207984,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=K.+H.+Huang&author=J.+Eaves&author=J.+Veal&author=S.+E.+Hall&author=T.+E.+Barta&author=G.+J.+Hanson&title=Cyclohexylamino+Benzene%2C+Pyridine%2C+and+Pyridazine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DK.%2BH.%26atitle%3DCyclohexylamino%2520Benzene%252C%2520Pyridine%252C%2520and%2520Pyridazine%2520Derivatives%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Lundgren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brekken, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huser, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timple, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busch, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neely, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensintaffar, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenzie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannevin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, F. J.</span><span> </span><span class="NLM_article-title">BIIB021, an orally available, fully synthetic small molecule inhibitor of the heat shock protein HSP90</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">921</span><span class="NLM_x">–</span> <span class="NLM_lpage">929</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1158%2F1535-7163.MCT-08-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=19372565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1amt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=921-929&author=K.+Lundgrenauthor=H.+Zhangauthor=J.+Brekkenauthor=N.+Huserauthor=R.+E.+Powellauthor=N.+Timpleauthor=D.+J.+Buschauthor=L.+Neelyauthor=J.+L.+Sensintaffarauthor=Y.-C.+Yangauthor=A.+McKenzieauthor=J.+Friedmanauthor=R.+Scannevinauthor=A.+Kamalauthor=K.+Hongauthor=S.+R.+Kasibhatlaauthor=M.+F.+Boehmauthor=F.+J.+Burrows&title=BIIB021%2C+an+orally+available%2C+fully+synthetic+small+molecule+inhibitor+of+the+heat+shock+protein+HSP90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90</span></div><div class="casAuthors">Lundgren, Karen; Zhang, Hong; Brekken, John; Huser, Nanni; Powell, Rachel E.; Timple, Noel; Busch, David J.; Neely, Laura; Sensintaffar, John L.; Yang, Yong-ching; McKenzie, Andres; Friedman, Jessica; Scannevin, Robert; Kamal, Adeela; Hong, Kevin; Kasibhatla, Srinivas R.; Boehm, Marcus F.; Burrows, Francis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">921-929</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inhibition of heat shock protein 90 (Hsp90) results in the degrdn. of oncoproteins that drive malignant progression, inducing cell death, making Hsp90 a target of substantial interest for cancer therapy.  BIIB021 is a novel, fully synthetic inhibitor of Hsp90 that binds competitively with geldanamycin in the ATP-binding pocket of Hsp90.  In tumor cells, BIIB021 induced the degrdn. of Hsp90 client proteins including HER-2, AKT, and Raf-1 and up-regulated expression of the heat shock proteins Hsp70 and Hsp27.  BIIB021 treatment resulted in growth inhibition and cell death in cell lines from a variety of tumor types at nanomolar concns.  Oral administration of BIIB021 led to the degrdn. of Hsp90 client proteins measured in tumor tissue and resulted in the inhibition of tumor growth in several human tumor xenograft models.  Studies to investigate the antitumor effects of BIIB021 showed activity on both daily and intermittent dosing schedules, providing dose schedule flexibility for clin. studies.  Assays measuring the HER-2 protein in tumor tissue and the HER-2 extracellular domain in plasma were used to show interdiction of the Hsp90 pathway and utility as potential biomarkers in clin. trials for BIIB021.  Together, these data show that BIIB021 is a promising new oral inhibitor of Hsp90 with antitumor activity in preclin. models.[Mol Cancer Ther 2009;8(4):921-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSbI2RYG4aF7Vg90H21EOLACvtfcHk0ljGkB-45K9OFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1amt74%253D&md5=271e2311ab807bc74b2ac66b81e514e1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0758%26sid%3Dliteratum%253Aachs%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBrekken%26aufirst%3DJ.%26aulast%3DHuser%26aufirst%3DN.%26aulast%3DPowell%26aufirst%3DR.%2BE.%26aulast%3DTimple%26aufirst%3DN.%26aulast%3DBusch%26aufirst%3DD.%2BJ.%26aulast%3DNeely%26aufirst%3DL.%26aulast%3DSensintaffar%26aufirst%3DJ.%2BL.%26aulast%3DYang%26aufirst%3DY.-C.%26aulast%3DMcKenzie%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DJ.%26aulast%3DScannevin%26aufirst%3DR.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DKasibhatla%26aufirst%3DS.%2BR.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26atitle%3DBIIB021%252C%2520an%2520orally%2520available%252C%2520fully%2520synthetic%2520small%2520molecule%2520inhibitor%2520of%2520the%2520heat%2520shock%2520protein%2520HSP90%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D921%26epage%3D929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Miller, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravikumar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suh, J.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerwin, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertus, J. D.</span><span> </span><span class="NLM_article-title">Structure-based and characterization of novel platforms for ricin and shiga toxin inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm010186s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=90-98&author=D.+J.+Millerauthor=K.+Ravikumarauthor=H.+Shenauthor=J.-K.+Suhauthor=S.+M.+Kerwinauthor=J.+D.+Robertus&title=Structure-based+and+characterization+of+novel+platforms+for+ricin+and+shiga+toxin+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm010186s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010186s%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DD.%2BJ.%26aulast%3DRavikumar%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSuh%26aufirst%3DJ.-K.%26aulast%3DKerwin%26aufirst%3DS.%2BM.%26aulast%3DRobertus%26aufirst%3DJ.%2BD.%26atitle%3DStructure-based%2520and%2520characterization%2520of%2520novel%2520platforms%2520for%2520ricin%2520and%2520shiga%2520toxin%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D90%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Taylor, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhnt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinzel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grindey, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barredo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jannatipour, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, R. G.</span><span> </span><span class="NLM_article-title">A dideazatetrahydrofolate analog lacking a chiral center at C-6: <i>N</i>-[4-[2-(2-amino-3,4-dihydro-4-oxo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-5yl)ethyl[benzoyl]-<span class="smallcaps smallerCapital">l</span>-glutamic acid is an inhibitor of thymidylate synthase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">4450</span><span class="NLM_x">–</span> <span class="NLM_lpage">4454</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00101a023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=4450-4454&author=E.+C.+Taylorauthor=D.+Kuhntauthor=C.+Shihauthor=S.+M.+Rinzelauthor=G.+B.+Grindeyauthor=J.+Barredoauthor=M.+Jannatipourauthor=R.+G.+Moran&title=A+dideazatetrahydrofolate+analog+lacking+a+chiral+center+at+C-6%3A+N-%5B4-%5B2-%282-amino-3%2C4-dihydro-4-oxo-7H-pyrrolo%5B2%2C3-d%5Dpyrimidin-5yl%29ethyl%5Bbenzoyl%5D-l-glutamic+acid+is+an+inhibitor+of+thymidylate+synthase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm00101a023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00101a023%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DE.%2BC.%26aulast%3DKuhnt%26aufirst%3DD.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DRinzel%26aufirst%3DS.%2BM.%26aulast%3DGrindey%26aufirst%3DG.%2BB.%26aulast%3DBarredo%26aufirst%3DJ.%26aulast%3DJannatipour%26aufirst%3DM.%26aulast%3DMoran%26aufirst%3DR.%2BG.%26atitle%3DA%2520dideazatetrahydrofolate%2520analog%2520lacking%2520a%2520chiral%2520center%2520at%2520C-6%253A%2520N-%255B4-%255B2-%25282-amino-3%252C4-dihydro-4-oxo-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-5yl%2529ethyl%255Bbenzoyl%255D-l-glutamic%2520acid%2520is%2520an%2520inhibitor%2520of%2520thymidylate%2520synthase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D4450%26epage%3D4454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisliuk, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haile, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobrero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuire, J. J.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological activities of classical <i>N</i>-{4-[2-(2-amino-4-ethylpyrrolo[2,3-<i>d</i>]pyrimidin-5-yl)ethyl]benzoyl}-<span class="smallcaps smallerCapital">l</span>-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase as potential antitumor agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0203534" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=591-600&author=A.+Gangjeeauthor=J.+Yuauthor=R.+L.+Kisliukauthor=W.+H.+Haileauthor=G.+Sobreroauthor=J.+J.+McGuire&title=Design%2C+synthesis%2C+and+biological+activities+of+classical+N-%7B4-%5B2-%282-amino-4-ethylpyrrolo%5B2%2C3-d%5Dpyrimidin-5-yl%29ethyl%5Dbenzoyl%7D-l-glutamic+acid+and+its+6-methyl+derivative+as+potential+dual+inhibitors+of+thymidylate+synthase+and+dihydrofolate+reductase+as+potential+antitumor+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0203534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0203534%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26aulast%3DHaile%26aufirst%3DW.%2BH.%26aulast%3DSobrero%26aufirst%3DG.%26aulast%3DMcGuire%26aufirst%3DJ.%2BJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520activities%2520of%2520classical%2520N-%257B4-%255B2-%25282-amino-4-ethylpyrrolo%255B2%252C3-d%255Dpyrimidin-5-yl%2529ethyl%255Dbenzoyl%257D-l-glutamic%2520acid%2520and%2520its%25206-methyl%2520derivative%2520as%2520potential%2520dual%2520inhibitors%2520of%2520thymidylate%2520synthase%2520and%2520dihydrofolate%2520reductase%2520as%2520potential%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D591%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Shih, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gossett, L. S.</span><span> </span><span class="NLM_article-title">The synthesis of <i>N</i>-{2-amino-4-substituted [(pyrrolo[2,3-<i>d</i>]pyrimidin-5-yl)ethyl]benzoyl}-<span class="smallcaps smallerCapital">l</span>-glutamic acids as antineoplastic agents</span> <span class="citation_source-journal">Heterocycles</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">825</span><span class="NLM_x">–</span> <span class="NLM_lpage">841</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1993&pages=825-841&author=C.+Shihauthor=L.+S.+Gossett&title=The+synthesis+of+N-%7B2-amino-4-substituted+%5B%28pyrrolo%5B2%2C3-d%5Dpyrimidin-5-yl%29ethyl%5Dbenzoyl%7D-l-glutamic+acids+as+antineoplastic+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShih%26aufirst%3DC.%26aulast%3DGossett%26aufirst%3DL.%2BS.%26atitle%3DThe%2520synthesis%2520of%2520N-%257B2-amino-4-substituted%2520%255B%2528pyrrolo%255B2%252C3-d%255Dpyrimidin-5-yl%2529ethyl%255Dbenzoyl%257D-l-glutamic%2520acids%2520as%2520antineoplastic%2520agents%26jtitle%3DHeterocycles%26date%3D1993%26volume%3D35%26spage%3D825%26epage%3D841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Seela, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span> </span><span class="NLM_article-title">Regioselective syntheses of 7-halogenated 7-deazapurine nucleosides related to 2-amino-7-deaza-2′-deoxyadenosine and 7-deaza-2′-deoxyisoguanosine</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_fpage">1203</span><span class="NLM_x">–</span> <span class="NLM_lpage">1210</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1055%2Fs-2004-822382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltFCqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=1203-1210&author=F.+Seelaauthor=X.+Peng&title=Regioselective+syntheses+of+7-halogenated+7-deazapurine+nucleosides+related+to+2-amino-7-deaza-2%E2%80%B2-deoxyadenosine+and+7-deaza-2%E2%80%B2-deoxyisoguanosine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective syntheses of 7-halogenated 7-deazapurine nucleosides related to 2-amino-7-deaza-2'-deoxyadenosine and 7-deaza-2'-deoxyisoguanosine</span></div><div class="casAuthors">Seela, Frank; Peng, Xiaohua</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1203-1210</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">The syntheses of 7-halogenated derivs. of 2-amino-7-deaza-2'-deoxyadenosine as well as 7-bromo and 7-chloro-7-deaza-2'-deoxyisoguanosines are described.  Nucleobase anion glycosylation was employed for the convergent nucleoside synthesis.  The regioselective 7-halogenation was performed either on the nucleoside precursor or on the nucleobase.  Two bromo substituents were introduced in the 7- and 8-position when the unprotected 2-amino nucleoside 9 was used.  Conformational anal. of the sugar moiety of nucleosides was performed on the basis of vicinal 1H, 1H NMR coupling consts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2GYJJcH-6ibVg90H21EOLACvtfcHk0lhkdDz5cq88xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltFCqsLs%253D&md5=0441eb21091a9e2c0e9565c3d944ea30</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1055%2Fs-2004-822382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2004-822382%26sid%3Dliteratum%253Aachs%26aulast%3DSeela%26aufirst%3DF.%26aulast%3DPeng%26aufirst%3DX.%26atitle%3DRegioselective%2520syntheses%2520of%25207-halogenated%25207-deazapurine%2520nucleosides%2520related%2520to%25202-amino-7-deaza-2%25E2%2580%25B2-deoxyadenosine%2520and%25207-deaza-2%25E2%2580%25B2-deoxyisoguanosine%26jtitle%3DSynthesis%26date%3D2004%26spage%3D1203%26epage%3D1210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Barnett, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobierski, M. E.</span><span> </span><span class="NLM_article-title">A convenient method for regioselective C-5 halogenation of 4(3<i>H</i>)-oxo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidines</span> <span class="citation_source-journal">J. Heterocycl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1181</span><span class="NLM_x">–</span> <span class="NLM_lpage">1183</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1994&pages=1181-1183&author=C.+J.+Barnettauthor=M.+E.+Kobierski&title=A+convenient+method+for+regioselective+C-5+halogenation+of+4%283H%29-oxo-7H-pyrrolo%5B2%2C3-d%5Dpyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarnett%26aufirst%3DC.%2BJ.%26aulast%3DKobierski%26aufirst%3DM.%2BE.%26atitle%3DA%2520convenient%2520method%2520for%2520regioselective%2520C-5%2520halogenation%2520of%25204%25283H%2529-oxo-7H-pyrrolo%255B2%252C3-d%255Dpyrimidines%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1994%26volume%3D31%26spage%3D1181%26epage%3D1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Tu, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huebener, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dettner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francke, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McErlean, C. S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitching, W.</span><span> </span><span class="NLM_article-title">Synthesis and stereochemistry of insect derived spiroacetals with branched carbon skeletons</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1956</span><span class="NLM_x">–</span> <span class="NLM_lpage">1978</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1055%2Fs-2000-8232" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=1956-1978&author=Y.+Q.+Tuauthor=A.+Huebenerauthor=H.+Zhangauthor=C.+J.+Mooreauthor=M.+T.+Fletcherauthor=P.+Hayesauthor=K.+Dettnerauthor=W.+Franckeauthor=C.+S.+P.+McErleanauthor=W.+Kitching&title=Synthesis+and+stereochemistry+of+insect+derived+spiroacetals+with+branched+carbon+skeletons"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1055%2Fs-2000-8232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2000-8232%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DY.%2BQ.%26aulast%3DHuebener%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMoore%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DM.%2BT.%26aulast%3DHayes%26aufirst%3DP.%26aulast%3DDettner%26aufirst%3DK.%26aulast%3DFrancke%26aufirst%3DW.%26aulast%3DMcErlean%26aufirst%3DC.%2BS.%2BP.%26aulast%3DKitching%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520stereochemistry%2520of%2520insect%2520derived%2520spiroacetals%2520with%2520branched%2520carbon%2520skeletons%26jtitle%3DSynthesis%26date%3D2000%26volume%3D13%26spage%3D1956%26epage%3D1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="note"><p class="first last">The sterically bulky <i>gem</i>-dimethyl group of <b>40</b> was designed to maximize the metabolic stability of <b>40</b> by simultaneously hindering any potential phase I metabolism at the adjacent propargylic position and any potential phase II metabolism of the OH group. This may be a reason for the improved pharmacokinetic properties.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Yun, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harning, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giza, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabah, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchetti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biamonte, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundgren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kehry, M. R.</span><span> </span><span class="NLM_article-title">EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">186</span><span class="NLM_x">, </span> <span class="NLM_fpage">563</span><span class="NLM_x">–</span> <span class="NLM_lpage">575</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2011&pages=563-575&author=T.+J.+Yunauthor=E.+K.+Harningauthor=K.+Gizaauthor=D.+Rabahauthor=P.+Liauthor=J.+W.+Arndtauthor=D.+Luchettiauthor=M.+A.+Biamonteauthor=J.+Shiauthor=K.+Lundgrenauthor=A.+Manningauthor=M.+R.+Kehry&title=EC144%2C+a+synthetic+inhibitor+of+heat+shock+protein+90%2C+blocks+innate+and+adaptive+immune+responses+in+models+of+inflammation+and+autoimmunity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DT.%2BJ.%26aulast%3DHarning%26aufirst%3DE.%2BK.%26aulast%3DGiza%26aufirst%3DK.%26aulast%3DRabah%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DArndt%26aufirst%3DJ.%2BW.%26aulast%3DLuchetti%26aufirst%3DD.%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DManning%26aufirst%3DA.%26aulast%3DKehry%26aufirst%3DM.%2BR.%26atitle%3DEC144%252C%2520a%2520synthetic%2520inhibitor%2520of%2520heat%2520shock%2520protein%252090%252C%2520blocks%2520innate%2520and%2520adaptive%2520immune%2520responses%2520in%2520models%2520of%2520inflammation%2520and%2520autoimmunity%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D186%26spage%3D563%26epage%3D575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="note"><p class="first last">Compounds <b>14</b> and <b>40</b> were dosed in 0.1 N HCl for the xenograft models.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blower, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadée, W.</span><span> </span><span class="NLM_article-title">Chemogenomic analysis indentifies geldanamycins as substrated and inhibitors of ABCB1</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1702</span><span class="NLM_x">–</span> <span class="NLM_lpage">1712</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=1702-1712&author=Y.+Huangauthor=P.+E.+Blowerauthor=R.+Liuauthor=Z.+Daiauthor=A.+N.+Phamauthor=H.+Moonauthor=J.+Fangauthor=W.+Sad%C3%A9e&title=Chemogenomic+analysis+indentifies+geldanamycins+as+substrated+and+inhibitors+of+ABCB1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DBlower%26aufirst%3DP.%2BE.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DDai%26aufirst%3DZ.%26aulast%3DPham%26aufirst%3DA.%2BN.%26aulast%3DMoon%26aufirst%3DH.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DSad%25C3%25A9e%26aufirst%3DW.%26atitle%3DChemogenomic%2520analysis%2520indentifies%2520geldanamycins%2520as%2520substrated%2520and%2520inhibitors%2520of%2520ABCB1%26jtitle%3DPharm.%2520Res.%26date%3D2007%26volume%3D9%26spage%3D1702%26epage%3D1712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neely, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timple, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, F.</span><span> </span><span class="NLM_article-title">BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">1226</span><span class="NLM_x">–</span> <span class="NLM_lpage">1234</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2009&pages=1226-1234&author=H.+Zhangauthor=L.+Neelyauthor=Y.-C.+Yangauthor=N.+Timpleauthor=F.+Burrows&title=BIIB021%2C+a+synthetic+Hsp90+inhibitor%2C+has+broad+application+against+tumors+with+acquired+multidrug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DNeely%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DY.-C.%26aulast%3DTimple%26aufirst%3DN.%26aulast%3DBurrows%26aufirst%3DF.%26atitle%3DBIIB021%252C%2520a%2520synthetic%2520Hsp90%2520inhibitor%252C%2520has%2520broad%2520application%2520against%2520tumors%2520with%2520acquired%2520multidrug%2520resistance%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2009%26volume%3D126%26spage%3D1226%26epage%3D1234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Luo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Heat shock protein 90: translation from cancer to Alzheimer’s disease treatment?</span> <span class="citation_source-journal">BMC Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">S7</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=S7&issue=Suppl.+2&author=W.+Luoauthor=A.+Rodinaauthor=G.+Chiosis&title=Heat+shock+protein+90%3A+translation+from+cancer+to+Alzheimer%E2%80%99s+disease+treatment%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DRodina%26aufirst%3DA.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DHeat%2520shock%2520protein%252090%253A%2520translation%2520from%2520cancer%2520to%2520Alzheimer%25E2%2580%2599s%2520disease%2520treatment%253F%26jtitle%3DBMC%2520Neurosci.%26date%3D2008%26volume%3D9%26issue%3DSuppl.%25202%26spage%3DS7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Luo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dou, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chip, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moulick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greengard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">9511</span><span class="NLM_x">–</span> <span class="NLM_lpage">9516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1073%2Fpnas.0701055104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=17517623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtlGqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=9511-9516&author=W.+Luoauthor=F.+Douauthor=A.+Rodinaauthor=S.+Chipauthor=J.+Kimauthor=Q.+Zhaoauthor=K.+Moulickauthor=J.+Aguirreauthor=N.+Wuauthor=P.+Greengardauthor=G.+Chiosis&title=Roles+of+heat-shock+protein+90+in+maintaining+and+facilitating+the+neurodegenerative+phenotype+in+tauopathies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies</span></div><div class="casAuthors">Luo, Wenjie; Dou, Fei; Rodina, Anna; Chip, Sophorn; Kim, Joungnam; Zhao, Qi; Moulick, Kamalika; Aguirre, Julia; Wu, Nian; Greengard, Paul; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9511-9516</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Neurodegeneration, a result of multiple dysregulatory events, is a lengthy multistep process manifested by accrual of mutant variants and abnormal expression, posttranslational modification, and processing of certain proteins.  Accumulation of these dysregulated processes requires a mechanism that maintains their functional stability and allows the evolution of the neurodegenerative phenotype.  In malignant cells, the capacity to buffer transformation has been attributed to heat-shock protein 90 (Hsp90).  Although normal proteins seem to require limited assistance from the chaperone, their aberrant counterparts seem to be highly dependent on Hsp90.  Whereas enhanced Hsp90 affinity for mutated or functionally deregulated client proteins has been obsd. for several oncoproteins, it is unknown whether Hsp90 plays a similar role for neuronal proteins and thus maintains and facilitates the transformed phenotype in neurodegenerative diseases.  Tauopathies are neurodegenerative diseases characterized by aberrant phosphorylation and/or expression of Tau protein, leading to a time-dependent accumulation of Tau aggregates and subsequent neuronal death.  Here, we show that the stability of p35, a neuronal protein that activates cyclin-dependent protein kinase 5 through complex formation leading to aberrant Tau phosphorylation, and that of mutant but not WT Tau protein is maintained in tauopathies by Hsp90.  Inhibition of Hsp90 in cellular and mouse models of tauopathies leads to a redn. of the pathogenic activity of these proteins and results in elimination of aggregated Tau.  The results identify important roles played by Hsp90 in maintaining and facilitating the degenerative phenotype in these diseases and provide a common principle governing cancer and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcCkJP_DiSK7Vg90H21EOLACvtfcHk0ljpw4wErc4ZrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtlGqsr4%253D&md5=232a72b98067db9340561258ebb6fcb8</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0701055104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0701055104%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DDou%26aufirst%3DF.%26aulast%3DRodina%26aufirst%3DA.%26aulast%3DChip%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DMoulick%26aufirst%3DK.%26aulast%3DAguirre%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DN.%26aulast%3DGreengard%26aufirst%3DP.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DRoles%2520of%2520heat-shock%2520protein%252090%2520in%2520maintaining%2520and%2520facilitating%2520the%2520neurodegenerative%2520phenotype%2520in%2520tauopathies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D9511%26epage%3D9516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Dickey, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunmore, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrucelli, L.</span><span> </span><span class="NLM_article-title">HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=753-755&author=C.+A.+Dickeyauthor=J.+Dunmoreauthor=B.+Luauthor=J.-W.+Wangauthor=W.+C.+Leeauthor=A.+Kamalauthor=F.+Burrowsauthor=C.+Eckmanauthor=M.+Huttonauthor=L.+Petrucelli&title=HSP+induction+mediates+selective+clearance+of+tau+phosphorylated+at+proline-directed+Ser%2FThr+sites+but+not+KXGS+%28MARK%29+sites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDickey%26aufirst%3DC.%2BA.%26aulast%3DDunmore%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DJ.-W.%26aulast%3DLee%26aufirst%3DW.%2BC.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DEckman%26aufirst%3DC.%26aulast%3DHutton%26aufirst%3DM.%26aulast%3DPetrucelli%26aufirst%3DL.%26atitle%3DHSP%2520induction%2520mediates%2520selective%2520clearance%2520of%2520tau%2520phosphorylated%2520at%2520proline-directed%2520Ser%252FThr%2520sites%2520but%2520not%2520KXGS%2520%2528MARK%2529%2520sites%26jtitle%3DFASEB%2520J.%26date%3D2006%26volume%3D20%26spage%3D753%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Dickey, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckman, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrucelli, L.</span><span> </span><span class="NLM_article-title">Development of a high throughput drug screening assay for the detection of changes in tau levels—proof of concept with HSP90 inhibitors</span> <span class="citation_source-journal">Curr. Alzheimer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.2174%2F1567205053585927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=15974923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltVant7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=231-238&author=C.+A.+Dickeyauthor=J.+Eriksenauthor=A.+Kamalauthor=F.+Burrowsauthor=S.+Kasibhatlaauthor=C.+B.+Eckmanauthor=M.+Huttonauthor=L.+Petrucelli&title=Development+of+a+high+throughput+drug+screening+assay+for+the+detection+of+changes+in+tau+levels%E2%80%94proof+of+concept+with+HSP90+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a high throughput drug screening assay for the detection of changes in Tau levels - proof of concept with HSP90 inhibitors</span></div><div class="casAuthors">Dickey, Chad A.; Eriksen, Jason; Kamal, Adeela; Burrows, Francis; Kasibhatla, Srinivas; Eckman, Christopher B.; Hutton, Mike; Petrucelli, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">231-238</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Therapeutic development for Alzheimer's disease has largely focused on the removal of beta amyloid because of its suggested role in the primary agent in initiating the disease process.  However, with the recent discovery of mutations that result as pathol. buildup of tau in the absence of amyloid pathol., tau is beginning to be recognized as a potential target for drug discovery.  We have developed a high-throughput drug screening method that allows for direct intracellular quantitation of tau protein species, enabling the fast, reliable detection of these changes.  We have identified a family of small, blood brain barrier penetrant heat shock protein 90 inhibitors that significantly reduce tau protein levels in vitro.  Western blot anal. demonstrated a clear inverse correlation between the tau levels and the increase in HSP27, HSP40 and HSP90.  Modifications to this assay will further allow the specific anal. of pathol. relevant species.  Using this assay, we have demonstrated that a class of HSP90 inhibitors is able to significantly lower intracellular tau levels most likely through induction of a heat shock response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8QafNfAabPLVg90H21EOLACvtfcHk0lhG59cNX8MM5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltVant7g%253D&md5=419ce21f9d5c342c266a58fbd804d7a8</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2174%2F1567205053585927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567205053585927%26sid%3Dliteratum%253Aachs%26aulast%3DDickey%26aufirst%3DC.%2BA.%26aulast%3DEriksen%26aufirst%3DJ.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DEckman%26aufirst%3DC.%2BB.%26aulast%3DHutton%26aufirst%3DM.%26aulast%3DPetrucelli%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520a%2520high%2520throughput%2520drug%2520screening%2520assay%2520for%2520the%2520detection%2520of%2520changes%2520in%2520tau%2520levels%25E2%2580%2594proof%2520of%2520concept%2520with%2520HSP90%2520inhibitors%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2005%26volume%3D2%26spage%3D231%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Salminen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojala, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaarniranta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiltunen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soininen, H.</span><span> </span><span class="NLM_article-title">Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer’s disease</span> <span class="citation_source-journal">Prog. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm300810x&amp;key=10.1016%2Fj.pneurobio.2010.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm300810x&amp;key=21056617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm300810x&amp;key=1%3ACAS%3A280%3ADC%252BC3M7mvFSitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2011&pages=99-110&author=A.+Salminenauthor=J.+Ojalaauthor=K.+Kaarnirantaauthor=M.+Hiltunenauthor=H.+Soininen&title=Hsp90+regulates+tau+pathology+through+co-chaperone+complexes+in+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease</span></div><div class="casAuthors">Salminen Antero; Ojala Johanna; Kaarniranta Kai; Hiltunen Mikko; Soininen Hilkka</div><div class="citationInfo"><span class="NLM_cas:title">Progress in neurobiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-110</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's disease is a tauopathy which involves the deposition of microtubule-associated tau proteins into neurofibrillary tangles.  Post-translational modifications, in particular site-specific phosphorylations, affect the conformation of tau protein which is an intrinsically disordered protein.  These structural changes significantly increase the affinity of tau protein for certain molecular chaperones.  Hsp90 is a major cellular chaperone which assembles large complexes with a variety of co-chaperones.  The main function of Hsp90 complexes is to maintain protein quality control and assist in protein degradation via proteasomal and autophagic-lysosomal pathways.  Tau protein is a client protein for these Hsp90 complexes.  If the tau protein is in an abnormal or modified form, then it can trigger the recruitment of CHIP protein, a co-chaperone with E3 activity, to the complex which induces the ubiquitination of tau protein and activates its downstream degradation processes.  Large immunophilins, FKBP51 and FKBP52 are also co-chaperones of Hsp90-tau complexes.  These proteins contain peptidylprolyl cis/trans isomerase activity which catalyzes phosphorylation-dependent rotation in pSer/Thr-Pro peptide bond.  The proline switch in the tau conformation triggers dephosphorylation of Ser/Thr residues phosphorylated, e.g. by two well-known tau kinases Cdk5 and GSK-3β.  Binding of PP5 protein phosphatase to Hsp90 complex, can also dephosphorylate tau protein.  Subsequently, dephosphorylated tau protein can be shuttled back to the microtubules.  It seems that high-affinity binding of abnormal tau to Hsp90 complexes may have some counteracting effects on the aggregation process, since Hsp90 inhibitors can ameliorate the aggregation process in several neurodegenerative diseases.  We will review the role of Hsp90 chaperone network in the regulation of tau biology and pathology in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIGys_IlOfaRe4jJGKT5N0fW6udTcc2eaeatxUCw15YLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7mvFSitw%253D%253D&md5=92c5535c5b5bc12c8c0807ea338310d4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2010.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2010.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DSalminen%26aufirst%3DA.%26aulast%3DOjala%26aufirst%3DJ.%26aulast%3DKaarniranta%26aufirst%3DK.%26aulast%3DHiltunen%26aufirst%3DM.%26aulast%3DSoininen%26aufirst%3DH.%26atitle%3DHsp90%2520regulates%2520tau%2520pathology%2520through%2520co-chaperone%2520complexes%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DProg.%2520Neurobiol.%26date%3D2011%26volume%3D93%26spage%3D99%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QDD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QDD','PDB','3QDD'); return false;">PDB: 3QDD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3NMQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3NMQ','PDB','3NMQ'); return false;">PDB: 3NMQ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i18"><a href="/doi/suppl/10.1021/jm300810x">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_62817"></div></div></div></div></div><hr /></hr><p class="last">Preparation of iodide <b>27</b> and of Hsp90 inhibitors <b>35</b>–<b>41</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300810x/suppl_file/jm300810x_si_001.pdf">jm300810x_si_001.pdf (730.65 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm300810x&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-17%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm300810x" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm300810x" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b0a388c332521","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
